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DENDRITIC CELLS AND T CELLS 
 
The immune system continuously guards the body for invading pathogens, like bacteria and 
viruses. This complicated defense system comprises many different cells, which orchestrate 
to protect us against these microorganisms. The first line of defense, also called innate 
immunity, is regulated by macrophages, Natural Killer cells (NK cells), monocytes, and 
Dendritic Cells (DCs), which interact with pathogens in a non-specific manner. Although both 
NK cells and DCs are players in the innate immune response, their bi-directional cross-talk 
results in their involvement in the specific immune response (Moretta, 2002). This second 
line of defense, the specific recognition of antigens is controlled by cells of the adaptive 
immune system, which includes T and B cells. After their development in the thymus and 
bone marrow respectively, naïve T cells and B cells circulate via the blood through peripheral 
lymphoid organs, where they encounter antigens, which are presented by the sentinels of 
the immune system, the DCs (Butcher & Picker, 1996; Banchereau & Steinman, 1998). DCs 
and their precursors are continuously produced from hematopoietic stem cells within the 
bone marrow (Liu, 2001; Shortman & Liu, 2002). From in vitro studies it became clear that 
human hematopoietic stem cells can differentiate in two different DC precursors, one from 
myeloid origin and the other from lymphoid origin (Fig. 1). The myeloid precursor further 
differentiates into Langerhans cells (LCs), Interstitial DCs, and myeloid DCs (MDCs). The 
lymphoid precursor most likely differentiates in plasmacytoid DCs (PDCs)(Spits et al., 2000). 
After antigen encounter all distinct DC subtypes mature. The functional plasticity among the 
different DC subsets, which depends on cytokine and antigen exposure, hampers the 
definition of distinct functions to the different DC lineages. 
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Figure 1. Proposed model for DC subsets. 
 
Although many DC subsets can be generated in vitro, their relation with in vivo existing DCs 
still remains unclear. Studies using a transendothelial trafficking model point at monocytes, 
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especially the CD16+ subclass, as precursors of DCs (Randolph et al., 1998a; Randolph et al., 
2002). This is supported by an in vivo study, in which subcutaneously injected fluorescent 
microspheres are phagocytosed by monocytes, which subsequently migrate into the T cell 
areas of draining lymph nodes and express DC-specific markers (Randolph et al., 1999). In 
the blood, three DC populations can be distinguished by specific blood DC markers, two of 
myeloid origin and one of lymphoid origin (Dzionek et al., 2000; Grabbe et al., 2000). The 
most commonly used DCs in vitro are derived from monocytes by culture in IL-4 and GM-CSF 
(Romani et al., 1994; Sallusto & Lanzavecchia, 1994). Their maturation can be induced by 
several inflammatory mediators, like LPS or a combination of TNFα, IL-1β, PGE2, and IL-6 
(Jonuleit et al., 1997). 
DCs and their precursors enter the blood, transmigrate through the endothelium lining the 
blood vessel and populate the peripheral tissues. Here, DCs reside in an immature state and 
patrol for foreign antigens. Immature DCs are very efficient in antigen capture and can use 
either macropinocytosis, phagocytosis, or receptor-mediated endocytosis via Fcγ-receptors, 
toll-like receptors (TLRs), or lectins (Banchereau et al., 2000; Figdor et al., 2002; Gordon, 
2002). Upon antigen uptake, DCs process the antigen into peptides, mature, and migrate 
through afferent lymph vessels into the T-cell areas of lymphoid organs to present the 
peptides and stimulate naïve T cells (Steinman, 1991; Banchereau & Steinman, 1998; De 
Vries et al., 2003). Mature DCs are well equipped to present antigens; they express high 
levels of MHC class I and II molecules as well as the costimulatory molecules CD80 and 
CD86 and can be recognized by the expression of the maturation marker CD83. 
Endogenous, cytosolic proteins processed to peptides by DCs are presented in MHC class I 
molecules to CD8+, cytotoxic T cells, whereas exogenous derived peptides are presented in 
MHC class II molecules to CD4+, helper T cells. CD4+ T cells comprise Th1 cells and Th2 
cells. Th1 cells are induced upon IL-12 production by DCs and can provide help to other T 
cells, like CD8+ cells, whereas Th2 cells need IL-4 and can stimulate the production of 
antibodies by B cells. MDC and PDC stimulate in a cytokine-independent way the polarization 
of T cells to Th1 cells and Th2 cells, respectively (Rissoan et al., 1999). Recently, it became 
clear that DCs are flexible in their ability to direct T cell polarization (Boonstra et al., 2003). 
The plasticity of the DCs to direct Th1 or Th2 cell development is not directly linked to the 
DC subtype but is determined by the antigen dose, the maturation of the DCs, and the 
stimulation of DCs by pathogen-derived products. In general, high antigen doses stimulate 
Th1 cells, whereas low antigen doses induce Th2 cells. 
Upon antigen recognition, T cells proliferate, differentiate into effector cells, and migrate 
from the lymph nodes via the blood to the side of inflammation, to provide help by 
regulating other cells or to attack pathogens (Fig. 2). Some of these T cells survive for a long 
period of time and become memory T cells. Based on their migratory capacity two subtypes 
of memory T cells can be distinguished; effector memory cells, which migrate to peripheral 
tissues, and central memory cells, which traffick to secondary lymphoid organs. After a 
second antigen challenge, central memory cells can stimulate DCs, provide help to B cells, 
and generate new effector cells (Sallusto et al., 1999a). 
To induce an immune response, DCs and T cells must migrate between peripheral tissues 
and the lymphoid organs. During this migration process, both DCs and T cells have multiple 
dynamic adhesive contacts with their environment. They interact with extracellular matrix 
(ECM) molecules in peripheral tissues and endothelium. The migration process is organ-
specific and orchestrated by an intimate interplay between chemokines, chemokine 
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receptors, proteases and adhesion molecules, and establishes multiple attachments and 
detachments. The C-type lectin and integrin family of adhesion molecules are the main 
players involved in these contacts. 
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Figure 2. Migration of DCs and T cells. Hematopoietic stem cells differentiate in progenitor cells (1), which 
migrate via blood to peripheral tissues (2) or to the thymus (3) to differentiate into DCs and T cells. DCs and their 
precursors migrate from the blood into the peripheral tissue (2) and patrol as immature DCs for antigens. Upon 
antigen uptake (4), immature DCs process antigen, mature (5) and migrate via lymph vessels to the T cell area of 
the draining lymph node to stimulate naïve T cells (6). Progenitor cells that migrate from the bone marrow to the 
thymus undergo selection and become T cells (7). T cells migrate from thymus via High Endothelial Venules 
(HEV) into the lymph node (8) and subsequently also migrate into the T cell areas (9). After activation of T cells 
by DCs, T cells migrate via the blood vessel to the peripheral tissue (10) to exert their function (11). 
 
 
C-TYPE LECTINS 
 
In contrast to most cell adhesion molecules that establish protein-protein interactions, lectins 
bind sugars using carbohydrate recognition domains. One group of lectins are the C-type 
lectins, which bind their ligands in a calcium-dependent manner. The ligands are composed 
of a scaffold protein, or carrier molecule, which are modified by certain carbohydrates. The 
glycosylation of the ligand determines whether the ligand will interact with the receptor. 
Several subtypes of C-type lectins can be distinguished, like selectins and type I and type II 
lectins. Type I lectins have the N terminus outside the cell, whereas this terminus is pointing 
into the cytoplasm in type II lectins. Lectins are expressed on several cell types, including 
leukocytes and endothelial cells. They are involved in cell migration, in antigen uptake by 
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DCs, and in the interaction between DCs and T cells (Vestweber & Blanks, 1999; Geijtenbeek 
et al., 2000c; Ariizumi et al., 2000a; Geijtenbeek et al., 2000a; Figdor et al., 2002). 
 
 
Table 1. Overview of C-type lectins, integrins, and their binding partners expressed on leukocytes and 
endothelium. 
 
C-type Lectins Ligands 
 
  Selectins  
  E-selectin (CD62E) ESL-1, PSGL-1, sLex, sLea 
  P-selectin (CD62P) PSGL-1, sLex, sLea, CD24 
  L-selectin (CD62L) 
 
CD34, GlyCAM, MAdCAM, E-selectin 
  Type I receptors  
  MMR 
 
sLex 
  Type II receptors  
  DC-SIGN ICAM-2, ICAM-3, gp120, Ebola virus, SIV, CMV, hepatitis C virus, Leishmania 
amastigotes, Mycobacterium tuberculosis, Helicobacter pylori, Leishmania 
mexicana, Schistosoma mansoni, Candida Albicans, Lex neoglycoconjugates 
 
Integrins 
 
 
  β1 integrins  
  α1β1 (CD49a/CD29, VLA-1) Coll, LM 
  α2β1 (CD49b/CD29, VLA-2) Coll, LM, E-cadherin 
  α3β1 (CD49c /CD29, VLA-3) FN, LM, Coll, TSP-1 
  α4β1 (CD49d, VLA-4) FN, VCAM-1, α4 
  α5β1 (CD49e /CD29, VLA-5) FN 
  α6β1 (CD49f /CD29, VLA-6) LM 
  α9β1 
 
LM, VCAM-1, tenasin-C 
  β2 integrins  
  αLβ2 (CD11a /CD18, LFA-1) ICAM-1, -2, -3, -4, -5, JAM-1 
  αMβ2 (CD11b /CD18, Mac-1) ICAM-1, -2, -4, uPAR, LPS, fibrinogen, C3bi, CD23, X, heparin and other 
soluble factors 
  αXβ2 (CD11c /CD18, p150,95) fibrinogen, C3bi, CD23, X, LPS, and other soluble factors 
  αDβ2 (CD11d /CD18) 
 
ICAM-3, VCAM-1 
  β3 integrins  
  αvβ3 
 
PECAM-1 (CD31), VN, fibrinogen 
  β7 integrins  
  α4β7 FN, MAdCAM-1, VCAM-1, α4 
  αEβ7 (CD103) E-cadherin 
 
Lectins consist of 2 to 9 repeats of complement regulatory protein ( ), an epidermal growth factor domain ( ), 
followed by a lectin domain (  ). Integrins are heterodimeric receptors that contain a non-covalently linked α and 
β domain. Abbreviations used: ESL-1, E-selectin ligand-1; PSGL-1, P-selectin glycoprotein ligand-1; sLex, sialyl 
lewis x; sLea, sialyl lewis a; GlyCAM, glycosylation-dependent cell adhesion molecule; MAdCAM, mucosal 
addressin cell adhesion molecule; MMR, macrophage mannose receptor; ICAM, intercellular adhesion molecule; 
DC-SIGN, DC-specific ICAM-3 grabbing non-integrin; SIV, simian immunodeficiency virus; CMV, cytomegalovirus; 
VLA, very late antigen; Coll, collagen; LM, laminin; FN, fibronectin; TSP-1, thrombospondin-1; VCAM-1, vascular 
cell adhesion molecule 1; LFA-1, leukocyte function-associated antigen-1; JAM-1, junctional adhesion molecule 1; 
uPAR, urokinase-type plasminogen activator receptor; LPS, lipopolysaccharide; C3bi, complement factor C3bi; X, 
factor X; PECAM-1, platelet-endothelial cell adhesion molecule-1; VN, vitronectin. 
 
 
Selectins comprise L-, E-, and P-selectins (Vestweber & Blanks, 1999)(table 1). Whereas L-
selectin is expressed on leukocytes, E-, and P-selectins are expressed by endothelial cells. 
Ligands for selectins include CD34, glycosylation-dependent cell adhesion molecule (GlyCAM-
1), mucosal addressin cell adhesion molecule (MAdCAM-1), P-selectin glycoprotein ligand-1 
(PSGL-1), E-selectin ligand-1 (ESL-1), and sialyl Lewis x (sLex). Selectins mediate rolling 
interactions between leukocytes and endothelium, which is the first step before adhesion and 
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subsequent migration of these leukocytes into the underlying tissue or lymph node 
(Springer, 1994). The relevance of the selectins in leukocyte homing is demonstrated in 
selectin-deficient mice, which have an increased susceptibility to bacterial infections (Tedder 
et al., 1995; Frenette & Wagner, 1997). 
Both type I and type II C-type lectins are expressed on DCs and LCs. The macrophage 
mannose receptor (MMR) and DEC-205 belong to the C-type I lectins and are involved in 
internalization of antigens (Sallusto et al., 1995; Jiang et al., 1995). MMR also mediates 
rolling interactions by binding to sLex structures on endothelial cells (Leteux et al., 2000). 
Other receptors involved in antigen uptake are the C-type II lectins, Dectin 2 and DC-SIGN 
(DC-Specific ICAM-3 Grabbing Non-integrin) (Ariizumi et al., 2000b; Geijtenbeek et al., 
2000a). 
DC-SIGN mediates cellular interactions by binding to ICAM-2, ICAM-3, and Lex 
neoglycoconjugates, which are non-sialylated (Geijtenbeek et al., 2000a; Geijtenbeek et al., 
2000c; Appelmelk et al., 2003)(table 1). Next to its function as an adhesion receptor, DC-
SIGN binds to viral and non-viral pathogens, like HIV (Geijtenbeek et al., 2000b), SIV 
(Pohlmann et al., 2001), Ebola virus (Alvarez et al., 2002; Simmons et al., 2003), 
cytomegalovirus (Halary et al., 2002), hepatitis C virus (Lozach et al., 2003), dengue virus 
(Navarro-Sanchez et al., 2003), Leishmania amastigotes (Colmenares et al., 2002), 
Mycobacterium tuberculosis (Appelmelk et al., 2003; Tailleux et al., 2003), Helicobacter 
pylori, Leishmania mexicana, Schistosoma mansoni (Appelmelk et al., 2003), and Candida 
Albicans (Cambi et al., 2003). Moreover, DC-SIGN internalizes antigen for presentation to T 
cells and is an efficient DC-specific Ag receptor (Engering et al., 2002b). In vivo, DC-SIGN is 
present on DCs in blood, in T cell areas of lymph nodes, tonsil, spleen, in dermis, and in 
mucosal tissues (Geijtenbeek et al., 2000a; Soilleux et al., 2002; Engering et al., 2002a). 
Alveolar macrophages in the lung, specialized antigen-presenting cells, like Hofbauer cells in 
the placenta, and decidual macrophages also express DC-SIGN (Lee et al., 2001; 
Geijtenbeek et al., 2001; Soilleux et al., 2001; Soilleux et al., 2002; Kämmerer et al., 2003). 
Furthermore, DC-SIGN expressing cells are found in atherosclerotic plaques (Soilleux et al., 
2002), in synovium of rheumatoid arthritis patients (van Lent et al., 2003), and the colonic 
mucosa of patients with Crohn's disease (te Velde et al., 2003). In mouse, five homologues 
of DC-SIGN are cloned, and only one is highly expressed on DCs (Park et al., 2001). Murine 
DC-SIGN, designated as mSIGNR1, is specifically expressed by medullary and subcapsular 
macrophages in lymph nodes (Geijtenbeek et al., 2002). 
 
 
INTEGRINS 
 
To date, the integrin family of glycoproteins comprises nineteen different integrin α-subunits 
and 8 different β-subunits that form at least 25 αβ heterodimers (Hynes, 1992; Humphries, 
2000). Based on shared β-subunits, eight subfamilies of integrins can be distinguished within 
the integrin family. The combination of an α-subunit with a β-subunit determines the binding 
specificity. 
The β1 integrins are expressed on a wide variety of cell types, including hematopoietic cells, 
and mainly mediate interactions between cells and the ECM, such as collagen (Hemler, 
1990), laminin (Mercurio, 1995; Taooka et al., 1999), and fibronectin (Hemler, 1990; 
Petruzzelli et al., 1999)(table 1). Some β1 integrins also mediate interactions between cells, 
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like α2β1 and α4β1. α2β1 interacts with the adhesion molecule E-cadherin (Whittard et al., 
2002), expressed on epithelium, and α4β1 also binds to α4 and VCAM-1 (vascular cell 
adhesion molecule 1), presented by endothelial cells (Altevogt et al., 1995). 
The β2 and β7 integrins are leukocyte-specific integrins, which mediate cell-cell interactions. 
The β2 integrin family comprehends four molecules, αLβ2, αMβ2, αXβ2, and αDβ2 (table 1). 
The main ligands of these molecules, αXβ2 excluded, are the InterCellular Adhesion 
Molecules (ICAM), which are members of the Ig superfamily. To date, five ICAMs have been 
identified. αLβ2 binds to all five ICAMs, whereas αMβ2 binds to ICAM-1, -2, and -4 (Marlin & 
Springer, 1987; Staunton et al., 1989; Diamond et al., 1991; Fawcett et al., 1992; Tian et 
al., 1997; Kotovuori et al., 1999; Hermand et al., 2000). αDβ2 is a receptor for ICAM-3, but 
can also interact with VCAM-1 (Van der Vieren et al., 1995; Van der Vieren et al., 1999). 
Integrins can exist in both an inactive as well as an active conformation on many cell types 
and need to be activated to exert their function (Hynes, 1992). Upon activation integrins 
change their conformation or cluster at the cell surface. This process is termed ‘inside-out’ 
signaling (Lub et al., 1995). By this mechanism they regulate their binding to different 
ligands (van Kooyk & Figdor, 2000). Integrin activation can be induced by other cell surface 
receptors, like CD3 (van Kooyk et al., 1989), phorbol esters that activate PKC (Rothlein & 
Springer, 1986; Danilov & Juliano, 1989; Shimizu et al., 1990), G protein coupled signaling 
(e.g. via chemokines)(Constantin et al., 2000; Grabovsky et al. 2000), or by particular 
activating antibodies (O'Toole et al., 1990; van Kooyk et al., 1991; Robinson et al., 1992; 
van de Wiel-van Kemenade et al., 1992; Arroyo et al., 1992; Andrew et al., 1993; Landis et 
al., 1994). The intracellular signaling induced by these activation mechanisms regulate 
clustering of integrins and subsequent adhesion strengthening (Stewart et al., 1998). 
Moreover, integrin-mediated adhesion requires the presence of divalent cations, like Ca2+, 
Mg2+, and Mn2+ (Gailit & Ruoslahti, 1988; Dransfield et al., 1992). Activated αLβ2 expresses 
a Ca2+-dependent epitope, recognized by the NKI-L16 antibody (Keizer et al., 1988), and a 
Mn2+-dependent epitope, recognized by the M24 antibody (Dransfield et al., 1992; Kamata et 
al., 2002). The presence of the Ca2+-dependent epitope on αLβ2 corresponds with a 
clustered status of αLβ2 and enables ligand binding (van Kooyk et al., 1994; Binnerts & van 
Kooyk, 1999). Upon ligand binding or cross-linking of integrins, they induce ‘outside-in’ 
signals, such as increased levels of intracellular calcium and pH, phosphorylation of PLC, and 
costimulatory signals, which lead to biological responses, like cell spreading and migration 
(Wacholtz et al., 1989; Figdor et al., 1990; Van Seventer et al., 1990; Hynes, 1992; Van 
Seventer et al., 1992; Kanner et al., 1993). 
The functional importance of integrin families in the immune system has been illustrated by 
β2-/- mice and by genetic defects in integrin subunits that abolish integrin-mediated 
adhesive functions in vivo (Scharffetter-Kochanek et al., 1998). This is best illustrated in 
patients suffering from Leukocyte Adhesion Deficiency (LAD), which have lost expression of 
β2 molecules due to deletions or mutations in this subunit (Anderson & Springer, 1987). 
LAD-patients die at a very young age of recurrent bacterial infections, because of impaired 
leukocyte adhesive functions. 
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CHEMOKINES 
 
Chemokines are small secreted chemotactic cytokines, which signal through seven-fold 
membrane spanning G-protein-coupled receptors. Four families of chemokines can be 
distinguished based on cysteine motifs which connect the N-terminal loop to the more 
structured core of the molecule (C, CC, CXC, and CX3C). There is a large diversity in signaling 
since one chemokine can interact with more receptors and one receptor can bind distinct 
chemokines. Several chemokine receptors are expressed on DCs and T cells (table 2). 
Chemokines are involved in leukocyte trafficking by regulating integrin-dependent adhesion 
of leukocytes to endothelium, are specialized in tissue-specific homing of T cells, and are 
involved in microenvironmental segregation of lymphocyte subsets in lymphoid organs. An 
overview of chemokine receptors expressed by monocytes, DCs, and T cells is presented in 
Table 2. 
DCs and T cells have to pass the endothelium to enter peripheral tissues. Endothelial cells 
produce chemokines or transfer chemokines that are produced by other cells from the 
abluminal part to the lumen of the blood vessel to display them to leukocytes (Sallusto et al., 
2000). Some chemokines will be immobilized via heparan sulfate-binding domains to 
glycosaminoglycans expressed on endothelium (Gale & McColl, 1999). Upon encountering 
chemokines, integrins expressed on rolling leukocytes will be activated resulting in an 
integrin-mediated arrest of the leukocytes to the vessel wall. For instance, CCL19 (MIP-
3β/ELC), CCL20 (MIP-3α/LARC), CCL21 (6C-kine/SLC), and CXCL12 (SDF-1α/β) rapidly 
enhance the adhesion of T cells to endothelium under flow conditions (Campbell et al., 1998; 
Grabovsky et al., 2000; Constantin et al., 2000). Moreover, apical endothelial chemokines in 
combination with shear stress promote transendothelial migration of lymphocytes (Cinamon 
et al., 2001). 
 
 
Table 2. Overview of chemokine receptors expressed by monocytes, DCs, and T cells.  
 
chemokine 
receptor 
chemokine Expression of chemokine receptor 
 
CCR1 CCL3, CCL5, CCL7, CCL8, 
CCL13-16, CCL23 
monocyte, immature DC, PDC, Th1, Tem 
CCR2 CCL2, CCL7, CCL8, CCL13 monocyte, immature DC, MDC, PDC, Th1, Th2 
CCR3 CCL5, CCL7, CCL8, CCL11, 
CCL13, CCL15, CCL24, CCL26 
MDC, PDC, Th2, Tem 
CCR4 CCL17, CCL22 mature DC, MDC, PDC, Th2, semi-naïve T, Tcm, 
Tem 
CCR5 CCL3-5, CCL8, CCL14 monocyte, immature DC, MDC, PDC, Th1, Tem 
CCR6 CCL20 immature DC, memory/activated T, Tcm, Tem 
CCR7 CCL19, CCL21 mature DC, MDC, PDC, mature MDC, mature PDC, 
naïve T, semi-naïve T, Tcm 
CXCR1 CXCL8 monocyte, immature DC, MDC, PDC 
CXCR2 CXCL1-3, CXCL5-8 MDC, PDC 
CXCR3 CXCL9-11 MDC, PDC, Tem, Tcm 
CXCR4 CXCL12 monocyte, mature DC, MDC, PDC, naïve T 
CXCR5 CXCL13 Th1, Th2 
unknown CCL18 naïve T 
 
Abbreviations used: PDC, plasmacytoid DC; MDC, myeloid DC; Th1, T helper 1 cells; Th2, T helper 2 cells; Tcm, 
central memory T cells; Tem, effector memory T cells. 
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Currently, no data are available about chemokine-induced arrest of DCs. However, the arrest 
of monocytes, which are DC-precursors, is mediated via CXCR1 and CCR2 (Gerszten et al., 
1999). The recruitment of immature DCs into inflamed tissue is mediated by CXCR1, CCR1, 
CCR2, and CCR5. During DC maturation these receptors are downmodulated, whereas 
CXCR4, CCR4, and especially CCR7 are upregulated. Hence, mature DCs become responsive 
to CCL19 and CCL21, which are produced by lymphatic endothelium and interdigitating DCs, 
respectively (Sallusto et al., 2000). This maturation-induced expression of CCR7 is also 
observed for MDCs and PDCs (Penna et al., 2001; Penna et al., 2002; de la Rosa et al., 
2003). The pivotal role for CCR7 in DC migration to lymph nodes is demonstrated in CCR7 
knock out mice, which show a defect in DC migration from the skin to the lymph nodes 
(Forster et al., 1999). 
Homing of naïve T cells to peripheral lymph nodes is also mediated by CCL19 and CCL21, 
which bind to CCR7 (Campbell et al., 1998). Upon stimulation of T cells with antigen, CCR7 is 
downregulated and both CXCR5, and CCR4 are upregulated to make T cells more sensitive to 
chemokines produced in the B cell areas. Central memory T cells express CCR4, CCR6, and 
CXCR3, whereas effector memory T cells in addition to these receptors also express CCR1, 
CCR3, and CCR5 (Sallusto & Lanzavecchia, 2000). 
DCs produce chemokines, some of which are induced upon maturation (Sallusto et al., 
1999b; Vissers et al., 2001). The regulated expression of chemokines by DCs indicates that 
upon stimulation DCs first attrack immature DCs and other inflammatory cells, whereas at 
later stages they produce CCL18 (DC-CK1, PARC) and CXCL12 to recruit T cells into lymphoid 
organs to facilitate T cell activation (Adema et al., 1997). The expression of chemokines by 
blood DCs as well as Langerhans cells resembles the expression by monocyte-derived DCs 
(Vissers et al., 2001). 
 
 
MULTI-STEP MIGRATION MODEL 
 
To extravasate into (inflamed) tissues, (precursor) DCs and T cells first tether to 
endothelium, roll along the endothelial cell lining, adhere, and subsequently transmigrate 
through the endothelium into the underlying tissue (Fig. 3)(Butcher, 1991; Springer, 1994). 
This multi-step process requires sequential engagement of adhesion and signaling receptors. 
Though adhesion molecules have distinct expression patterns on different type of endothelial 
cells, they all mediate transendothelial migration of T cells and DCs, but use different ligand 
and receptor combinations. Whereas lectins are mainly involved in rolling interactions, 
integrins play a role in each event in this multi-step cascade (Fig. 3). 
 
Rolling 
The initial rolling step is mediated by selectins (E-, P-, and L-selectin) and their ligands, α4 
integrins, and CD44 (Alon et al., 1995; Berlin et al., 1995; DeGrendele et al., 1996; Chen et 
al., 1999; Robert et al., 1999). αLβ2 can also mediate rolling when transfected in 
erythroleukemic K562 cells (Sigal et al., 2000; Shimaoka et al., 2002). However αLβ2-
mediated rolling is cell type-dependent, since wild type αLβ2 in subsets of peripheral blood 
lymphocytes and Jurkat cells is unable to initiate rolling on ICAM-1 (Sigal et al., 2000). Most 
likely, this difference in rolling capacity of αLβ2 depends on the restriction in αLβ2-mediated 
adhesion strengthening, which is cell-type dependent (Sigal et al., 2000). 
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In vivo rolling depends on selectins and selectin-mediated rolling is more efficient than 
integrin-dependent rolling (Gaboury & Kubes, 1994; Lawrence et al., 1995). The 
extravasation of DCs depends on fucosylated ligands of endothelial selectins, however, is not 
mediated by PSGL-1 (Robert et al., 1999; Pendl et al., 2002). DC-SIGN is also implicated in 
rolling interactions as was shown in an in vitro study in DC-SIGN-transfected erythroleukemic 
K562 cells (Geijtenbeek et al., 2000c). This may imply that DCs use this molecule to roll on 
endothelium. During the tethering step, T cells and DCs will be exposed to stimuli causing 
activation-dependent firm adhesion. 
 
1 2 3
 
  Leukocyte 
 
blood vessel 
1 tethering/rolling L-selectin Sialyated sugars, CD34, MAdCAM-1, Glycam-1, 
(E-selectin) 
  sLex, sLea, PSGL-1 E-selectin, P-selectin 
  α4β1 VCAM-1 
  α4β7 MAdCAM-1, VCAM-1 
  αLβ2 ICAM-1 
  DC-SIGN ICAM-2 
  CD44 hyaluronan 
2 arrest/adhesion αLβ2 ICAM-1, ICAM-2 
  αMβ2 ICAM-1, ICAM-2 
  α4β1 VCAM-1 
  α4β7 MAdCAM-1, VCAM-1 
  αvβ3 CD31 
  CD31 CD31 
  ? VAP-1 
3 transmigration αLβ2 ICAM-1, ICAM-2, JAM-1 
  JAM-2? JAM-2 
  αMβ2 ICAM-1, ICAM-2 
  α4β1 VCAM-1 
  CD31 CD31 
  CD99 CD99 
 
Figure 3. Multi-step migration model. To extravasate into tissue, DCs and T cells tether and roll on endothelium 
(1), arrest and adhere (2), and finally transmigrate through the endothelial layer (3). Multiple adhesion receptors 
are involved in these different steps, among them the integrins and lectins. Molecules implicated in each step are 
depicted below the graph. 
 
 
Arrest and adhesion 
The transition from rolling to adhesion is characterized by the activation of integrins, in 
particular αLβ2 and α4β1. Both, L-selectin and α4β7 are required for engagement of αLβ2 
with its ligand (Bargatze et al., 1995). In contrast, L-selectin-mediated rolling is not 
mandatory for the adhesion of α4 integrins (Berlin et al., 1995). The importance of integrin 
activation is clearly demonstrated in experiments in which they locked the ligand binding 
domain (I domain) of αLβ2 in a closed or an open conformation, resulting in low or high 
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affinity for its ligand, respectively. Whereas wild type I-domain and wild type αLβ2 mediate 
rolling, the locked open form is involved in firm adhesion (Salas et al., 2002). In other 
studies with non-stimulated Jurkat cells, α4β1 also supported rolling and spontaneous arrest 
on VCAM-1, whereas a reduced α4β1 affinity failed to mediate spontaneous arrest after 
tethering to or during rolling on VCAM-1 (Chen et al., 1999). Thus, high affinity integrin 
receptors are pivotal in inducing arrest of rolling cells under flow. 
Integrin activation can be accomplished by signaling via chemokines presented on 
endothelium or via ligand signaling and takes place in fractions of seconds (Grabovsky et al., 
2002). Immobilized chemokines can induce integrin-mediated capture of lymphocytes and 
arrest, but can also interfere with a subsecond stabilization of selectin tethers which are 
necessary for persistent rolling (Campbell et al., 1998; Grabovsky et al., 2000; Constantin et 
al., 2000; Grabovsky et al., 2002). Cross talk between integrins also induces activation of 
one of these integrins. For example, the activation status of α4β1 and subsequent ligation to 
VCAM-1 regulates the α4β1- and αLβ2-mediated adhesion and migration (Chan et al., 2000; 
May et al., 2000; Rose et al., 2001). On the contrary, adhesion of human T cells to ICAM-1 
via αLβ2 decreases the adhesion mediated via α4β1 to VCAM-1 and fibronectin, however, 
has less effect on α5β1-mediated binding (Porter & Hogg, 1997). This latter cross talk might 
be important for the transition of adherent to more migratory cells. Another example that 
adhesion molecules can induce integrin activation is the adhesion initiated by CD44 binding 
inducing α4β1-mediated firm adhesion and subsequent transmigration of activated T cells 
(Siegelman et al., 2000). 
Integrins involved in adhesion of leukocytes to endothelium are α4β1, α4β7 (Bargatze et al., 
1995), αMβ2 (Smith et al., 1989), and αLβ2 (Bargatze et al., 1995). The binding of T cells to 
resting endothelium is mainly mediated by αLβ2/ICAM-1 interactions. In contrast, adhesion 
to activated endothelium is partially accomplished via α4β1/VCAM-1 interactions 
(Oppenheimer-Marks et al., 1991). α4β1-mediated adhesion to endothelium only occurs 
when αLβ2 is not present or inactive (Wysocki & Issekutz, 1992; van Kooyk et al., 1993). 
The adhesion of DCs, monocyte-derived as well as blood DCs, to resting endothelium is 
mediated by DC-SIGN, β2 integrins, αLβ2 and αMβ2, whereas DC-SIGN, β2 integrins, and 
α4β1 are involved in the adhesion of DCs to activated endothelium (Brown et al., 1997; 
D'Amico et al., 1998; Bianchi et al., 2000; Geijtenbeek et al., 2000c). 
 
Diapedesis 
To extravasate into the underlying tissue, leukocytes have to transit from the firmly adherent 
state into a more migratory phenotype. As discussed above, this can be established by cross 
talk of αLβ2 to α4β1, resulting in a diminished adhesion to VCAM-1 (Porter & Hogg, 1997). 
The binding of αLβ2 and α4β1 to their endothelial and ECM counterparts can induce 
migration (Hauzenberger et al., 1997). Moreover, subsequent internalization of VCAM-1 by 
the endothelium would facilitate de-adhesion of lymphocytes (Ricard et al., 1998). 
The final diapedesis requires αLβ2 binding to ICAM-1, ICAM-2, and JAM-1 (Butcher, 1991; 
Springer, 1994; Ostermann et al., 2002), α4β1 binding to VCAM-1, homo- and heterotypic 
CD31 aggregation, possibly homo- or heterotypic JAM-2 interactions (Johnson-Leger et al., 
2002; JAM-2 has also been named JAM-3 by other groups) and homotypic CD99 interactions 
(Schenkel et al., 2002). αLβ2/ICAM interactions are prominent over α4β1/VCAM-1 
interactions (Roth et al., 1995). The major role of αLβ2 in this process is illustrated in LAD 
Introduction 
21 
clones, which have lost expression of β2 molecules and migrate significantly less through an 
endothelial monolayer than control clones (Kavanaugh et al., 1991). In addition, monocyte-
derived DCs from LAD-1 patients showed an abnormal morphology and an impaired 
transendothelial migration, indicating that β2 integrins are involved in migration of DCs 
(Fiorini et al., 2002). In transmigration of DCs through a microvascular endothelial 
monolayer DC-SIGN also plays a role (Geijtenbeek et al., 2000c). 
The sequence of steps in this final part of the transmigration process is not clear. αLβ2/JAM-
1 interactions might act in concert with, prior to, or after CD31/CD31 ligation. However, 
CD99 is involved at the end of transmigration, just before this process is completed 
(Aurrand-Lions et al., 2002). The diapedesis of DCs is, in contrast to the adhesion process, 
not only dependent on αLβ2, but also on CD31 ligation (D'Amico et al., 1998). The reverse 
transmigration of DCs involves other proteins, like p-glycoprotein and tissue factor (Randolph 
et al., 2002) and is mediated via the lipid transporter multidrug resistance protein 1 (MDR-1) 
and the LTC4 transporter multidrug resistance associated protein 1 (MRP1) (Randolph et al., 
1998b; Robbiani et al., 2000). LTC4, a cysteinyl leukotriene (cysLT) is a key mediator of DC 
chemotaxis and lymphatic migration by triggering CCL19-dependent migration of DCs to 
lymph nodes. 
 
Infiltration into tissue 
After passing the endothelial monolayer and underlying basement membrane, DCs and T 
cells enter the tissue and interact mainly via β1 integrin receptors with the ECM. 
Transmigrated T cells possess lower expression levels of α4β1 and αLβ2, resulting in a 
decreased adhesion to VCAM-1 and ICAM-1, respectively. In addition, the adhesion of 
transmigrated T cells to ECM molecules, like fibronectin, collagen type I and IV was 
increased (Romanic et al., 1997). The expression of α4β1 is lost when T cells migrate more 
deeply into the tissue, as was shown on brain sections of experimental autoimmune 
encephalomyelitis mice (Romanic et al., 1997). 
 
 
T CELL AND DC INTERACTIONS WITH ECM 
 
During inflammation, cells produce inflammatory mediators, like cytokines and chemokines, 
which bind to the ECM and create a haptotactic gradient of chemoattractant (Schor et al., 
2000). In this way, the immune response is restricted to inflammatory regions. T cells exhibit 
a haptotactic (a directed response of cells in a gradient of adhesion) and chemotactic 
migration to laminin, fibronectin and collagen type IV (Hauzenberger et al., 1995). However, 
two-photon imaging studies question the role of chemokine gradients within T cells areas, 
because T cells appear to migrate independent paths and do migrate in a random manner 
(Miller et al., 2002). 
Both T cells and DCs bind to the ECM via β1 integrins. Several integrins can bind to the same 
ECM structure (table 1). For instance, both α4β1 and α5β1 are receptors for fibronectin. 
Dependent on cell type and the process (adhesion or migration) both α4β1 and α5β1 or one 
of these integrins are involved in the interaction (Hauzenberger et al., 1994; D'Amico et al., 
1998; Bianchi et al., 2000; De Vries et al., 2003). The induction of T cell migration to ECM 
molecules requires signaling via either α4β1 or αLβ2 (Hauzenberger et al., 1995). 
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In vivo, ECM molecules are arranged in matrices. To mimic the in vivo situation, three-
dimensional matrix models have been developed (Friedl et al., 1993). The matrix forces the 
cells to adapt their morphology or degrade the ECM components by proteolytic enzymes 
(Friedl & Brocker, 2000). Indeed, the migration of T cells and DCs in collagen type I matrices 
is determined by the adaptation of the cell shape of the cells, and is β1 integrin-independent 
(Friedl et al., 1998; Friedl & Brocker, 2000). Nevertheless, the migration of CD4+ T cells was 
diminished by increased adhesion induced by β1 integrin-activating antibodies (Friedl et al., 
1998). Migration via non-specific low affinity interactions of T cells with either charged or 
uncharged residues of the matrix can not be excluded (Friedl & Brocker, 2000). T cells and 
DCs form short-lived transient interactions with collagen without remodeling the matrix 
(Friedl et al., 1998). The matrix structure might therefore play a redundant role in T cell and 
DC migration (Friedl & Brocker, 2000). Although in vitro studies in collagen matrix models 
resemble DC-T cell interactions as determined by two photon imaging of T cells in lymph 
nodes in vivo, mean migration velocities of these T cells are less when investigated in 
collagen matrix models (Friedl et al., 1994; Miller et al., 2002). 
 
 
ROLE OF INTEGRINS AND LECTINS IN MIGRATION OF T CELL AND DC SUBSETS 
 
T cell subsets 
Naïve T cells recirculate between the blood and the secondary lymphoid tissues. Upon 
encountering antigen, they loose the capability to home to lymph nodes and enter peripheral 
tissues (Hamann & Jablonski-Westrich, 1993). Activated and memory T cells have a higher 
potential to enter inflamed tissue than do naïve T cells. This might be due to the higher 
expression of adhesion molecules on activated and memory T cells when compared to naïve 
T cells (Hemler, 1990; Shimizu et al., 1990; Shimizu et al., 1991; Hamann & Jablonski-
Westrich, 1993; Picker et al., 1993). Within the memory population adhesion molecule 
expression is different. Whereas high levels of L-selectin are expressed by naïve and CCR7+ 
central memory T cells, CCR7- effector memory T cells have lower amounts of L-selectin at 
their surface, but express higher levels of β1 and β2 integrins, as well as homing receptors 
as CLA (Sallusto et al., 1999a). 
A less distinct difference in migratory properties was demonstrated between CD4+ and CD8+ 
T cells. In vitro studies in collagen lattices showed that a significant percentage of CD8+ cells 
slowed down with time, whereas CD4+ cells had a more sustained migratory capacity for up 
to 12 h (Friedl et al., 1994). CD8+ T cells have different expression levels of adhesion 
molecules than CD4+ T cells. As example, αM, αX, and α4 are preferentially expressed on 
CD8+ cells, whereas L-selectin is preferentially expressed on CD4+ cells. Although the 
expression of αL is similar on both CD4+ and CD8+ cells, the mean fluorescence intensity is 
higher on CD8+ cells, as holds true for αM (Cavers et al., 2002). 
Within the CD4+ cells, Th1 cells express higher levels of β2 integrins than Th2 cells, while the 
expression of β1 is comparable (Clissi et al., 2000). However, some α chains linked to β1 
integrins are differentially expressed (Colantonio et al., 1999; Clissi et al., 2000). The 
adhesion of Th1 cells seems, in contrast to Th2 cells, chemokine sensitive. In this way, Th1 
and Th2 cells may differ in their adhesive response following chemokine stimulation (Clissi et 
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al., 2000). This indicates that besides integrin expression, also other factors such as 
chemokines and activating signals regulate the extravasation of T cell subsets. 
 
DC subsets 
The adhesion and migration of DCs critically depends on their maturation state. Though both 
immature and mature DCs bind to fibronectin, binding and in particular cell spreading of 
immature DCs is much stronger than for mature DCs (Brand et al., 1998; De Vries et al., 
2003). In addition, immature, but not mature DCs adhere to immobilized E- and P-selectin 
under static and flow conditions (Pendl et al., 2002). Migration studies with immature and 
mature murine DCs showed enhanced migration of DCs upon maturation (Gunzer et al., 
2000). 
The origin of the DCs also determines their migratory properties. For instance, murine DCs 
derived from spleen have a higher initial migratory capacity than DCs isolated from the 
epidermis (Gunzer et al., 2000). MDCs are also more motile cells than PDCs (de la Rosa et 
al., 2003). 
Adhesion molecules are differentially expressed on the distinct DC subsets. As described 
above for T cells, adhesion molecule expression is related to the migration pathway. 
Epidermal LCs express the skin-homing molecule CLA and the laminin receptor α6. Dermal 
DCs lack the expression of CLA, and lymph node DCs have no α6 expression (Price et al., 
1997; Strunk et al., 1997; Ebner et al., 1998). Another example is the upregulated 
expression of αLβ2 on LCs upon their migration to lymph nodes (Anjuere et al., 1999). 
 
 
SCOPE OF THIS THESIS 
 
Nowadays DCs are used as cell-based vaccines in anti-tumor therapy. DCs are loaded with 
tumor-antigen, tumor lysates, are fused with tumor cells or transduced with tumor-derived 
RNA or viral vectors. The migration of DCs from the injection depot to the draining lymph 
node is essential to stimulate T cells to induce an effective immune response. The 
subsequent migration of these T cells to the tumor is a prerequisite to eradicate tumor cells. 
The aim of this thesis is to investigate the role of (novel) adhesion molecules in DC and T 
cell migration. 
Several migration systems exist to study leukocyte migration. Whereas some of these 
systems, like transwell and Boyden assays only provide information about a population of 
cells, more sophisticated migration assays are coupled to time-lapse video systems to 
monitor the migratory behavior of individual cells. The cell recognition in these latter systems 
is based on contrast differences between cells and the substratum or on a priori morphology 
criteria. In chapter 2, we describe an Automated Cell Track System (ACTS) to quantify and 
track migration of multiple cells. The focus of the algorithm is only directed to the detection 
of the cell centroids in the successive images. As migrating cells continuously change their 
shape during their movement, the algorithm should be robust to the changing morphology. 
We used this system to investigate the migration of T cells as well as immature and mature 
DCs (chapters 2 and 3). Interestingly, a substantial difference in adhesion and migration 
between immature and mature DCs was demonstrated, which can be attributed to a 
difference in the activation status of the β1 integrin (chapter 4). 
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Recently, a novel DC-specific C-type II lectin, DC-SIGN was described which binds ICAM-3 
(Geijtenbeek et al., 2000a) and gp120 playing a role in HIV-biology (Geijtenbeek et al., 
2000b). Since ICAM-2 and ICAM-3 have a high homology and lectins are involved in rolling 
interactions, we examined whether ICAM-2/DC-SIGN interactions are involved in DC 
migration (chapter 5). We demonstrate that DC-SIGN binds ICAM-2 and mediates rolling 
interactions. 
Mature DCs are very well equipped to stimulate T cells. MHC class I, MHC class II as well as 
the costimulatory molecules CD80 and CD86 are highly expressed on mature DCs. Moreover, 
mature DCs are characterized by the expression of the maturation marker CD83. The 
selective expression and upregulation of CD83 on mature DCs suggest a functional role of 
CD83 in immune responses. Indeed, circumstantial evidence for a biological role of CD83 is 
shown in literature. Virus-infected DCs express less CD83 and displayed a reduced capacity 
to initiate T cell proliferation (Kruse et al., 2000b; Jenne et al., 2000). In addition, human 
sera contain low levels of soluble CD83. In chapter 6, we used CD83-Fc to investigate the 
direct function of CD83. Interestingly, CD83-Fc binds to both immature and mature DCs and 
has a functional role in DC biology by regulating DC-mediated immune responses. 
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ABSTRACT 
 
Design of automated image processing systems to determine migration characteristics of 
individual cells is not trivial. Every test sample requires separate recording and the analysis 
of individual cell tracks in two- or three-dimensional migration systems by time-lapse 
microscopy is extremely laborious. Here, we describe a new Automated Cell Track System 
(ACTS). In addition to contrast differences, which are used by existing analysis systems, the 
ACTS algorithms recognize cells on the basis of morphological similarities in successive 
images and adapt to the continuous shape changes of individual cells during migration. The 
system facilitates simultaneous analysis of multiple cells and the measurement of multiple 
wells in one single experiment.  
We validated the system studying HSB-2 T cell migration in standard 96-well microtiter 
plates coated with ICAM-1-Fc protein or control CD14-Fc protein. Migration of HSB-2 T cells 
on ICAM-1-Fc is LFA-1-mediated and both the number and the speed of migrating cells 
depend on the ICAM-1-Fc concentration.  
We show that automated analysis of the migration data yields similar results as manual 
analysis, but in a fraction of the time. We conclude that this system is extremely well suited 
to precisely monitor the migratory behavior of individual cells. The analysis of multiple wells 
in parallel makes this set-up appropriate in high throughput screening in which multiple 
components are simultaneously tested for their effect on cell migration. 
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INTRODUCTION 
 
Cell migration is essential in many immunological processes, such as inflammation, 
responses against tumors and viruses, and leukocyte homing. During these processes, 
dynamic interactions occur between cells and their environment, including other cells and 
extracellular matrix molecules (Huttenlocher et al., 1995). Several well-established methods, 
such as the Transwell and Boyden assays, are used to study these interactions during 
migration (Wilkinson, 1982). In these assays, micropore filters are either coated with 
extracellular matrix molecules, cells, or other proteins of interest and the adhesion, as well 
as factors inducing migration, can be investigated. The migration is defined as the 
percentage of cells passing the filter. However, information about cell spreading, speed, or 
the migratory capacity of individual cells cannot be obtained from such assays (Wilkinson, 
1982).  
Therefore, two-dimensional and three-dimensional assays coupled to time-lapse video 
systems have been developed to monitor the migratory behavior of individual cells or of a 
population of cells in time (Thurston et al., 1988; Friedl et al., 1993; Niggemann et al., 1997; 
Soll et al., 2000; Demou & McIntire, 2002). Cells are either detected by light or fluorescence 
microscopy (Soll, 1988; Chon et al., 1997; Chon et al., 1998). These migration assays permit 
evaluation of the dynamics of the cells, such as distance of migration, migration speed, 
direction, and duration of migration. First, cells were tracked manually but more recently, 
automatic tracking programs have been generated to investigate their motility (Poole et al., 
1988; Bergman & Zygourakis, 1999; Demou & McIntire, 2002). Cell recognition is based on 
contrast differences between cells and the substratum or a priori morphology criteria and the 
focus of the software is directed to feature extraction of relevant cells (Soll, 1988; Wu et al., 
1995; De Hauwer et al., 1999; Hoppe et al., 1999). 
In this report, we describe an Automated Cell Track System (ACTS) to quantify and track 
migration of multiple cells. The focus of the algorithm is directed to the detection of the cell 
centroids in the successive images. As migrating cells continuously change their shape during 
their movement, the algorithm should be robust to the changing morphology. Furthermore, 
multiple samples can be evaluated in this system by repetitive and simultaneously scanning 
multi-well plates, which is less time-consuming and will be more reproducible than systems 
in which every sample requires separate recordings in sequential experiments. 
Using this tracking system, we studied the motility of HSB-2 T cells on ICAM-1-Fc 
(Intercellular Cell Adhesion Molecule-1-Fc chimera). HSB-2 T cells express the cell adhesion 
molecule LFA-1 (Leukocyte Function associated Antigen-1), which plays a pivotal role in 
adhesion as well as in migration processes. LFA-1 is a β2 integrin, which binds ICAM-1 
(Marlin & Springer, 1987) with high affinity. Other ligands of LFA-1 are ICAM-2 (Dustin et al., 
1986) and ICAM-3 (de Fougerolles et al., 1993). For maximal binding, LFA-1 must be 
activated, which involves a conformational change of the molecule, leading to an increase of 
affinity and/or avidity for its ligands (Binnerts & van Kooyk, 1999).  
We demonstrate that this ACTS is well suited to automatically track individual HSB-2 T cells 
migrating on ICAM-1-Fc in multiple wells. 
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MATERIAL AND METHODS 
 
mAbs and Chemicals 
Monoclonal antibodies reactive against different adhesion molecules were used: SPV-L7 (IgG1) (Keizer 
et al., 1985), NKI-L15 (IgG2a) (Keizer et al., 1985), and NKI-L16 (IgG2a) (Keizer et al., 1988); a β2 
blocking antibody AZN-L19 (IgG1) (Geijtenbeek et al., 2000c), and the activating antibody KIM185 
(IgG1) against the β chain of LFA-1 (Andrew et al., 1993); KIM 225 (IgG1) against the α-chain of 
Mac-1 was a kind gift of Dr. M. Robinson (Celltech, Berkshire, UK); REK-1 (IgG1) reactive with ICAM-1 
(Binnerts et al., 1994). Other chemicals used were: deoxyglucose (50 mM, Sigma Chemical Co, St. 
Louis, MO), sodium azide (10 mM; Merck, Hohenbrunn, Germany) to deprive cells of energy, 
cytochalasin D (5 mg/ml, Sigma Chemical Co., St. Louis, MO) to disrupt integrin-cytoskeletal 
interactions, poly-L-lysine (Sigma Chemical Co., St. Louis, MO), and formaldehyde (3%; MERCK, 
Hohenbrunn, Germany). 
 
Cells 
The human T cell line HSB-2 (ATCC) was cultured in Iscove’s medium (Gibco, Life Technologies ltd., 
Paisley, Scotland), containing 5% FCS and 1% Antibiotics/antimycotics (containing 100 U/ml penicillin, 
100 mg/ml streptomycin, 0.25 mg/ml amphotericin B) (Gibco, Life Technologies ltd., Paisley, 
Scotland). 
 
Immunofluorescence 
Cells (50 x 103) were incubated with 2-5 µg/ml mAb (25 µl/well) in PBA (PBS containing 0.5% bovine 
serum albumin and 0.01% NaN3) for 30 min at 4°C. After one wash step with cold PBA, cells were 
incubated with 25 µl FITC-labeled goat anti-mouse secondary antibodies (Zymed, San Francisco, CA; 
1/50 dilution in PBA) for 30 min at 4°C. Subsequently, cells were washed and diluted in 100 µl PBA. 
Fluorescence was measured using a FACScan® (Becton and Dickinson & Co., Oxnard, Ca). 
 
Adhesion Assay 
96-well flat bottom Maxisorp plates (Nunc., Roskilde, Denmark) were coated with 50 µl goat anti-
human Fc antibodies (Jackson Immunoresearch Laboratories, Inc., Westgrove, PA) at a concentration 
of 4 µg/ml in TSM (150 mM NaCl, 10 mM Tris/HCL, 2 mM MgCl2, 1 mM CaCl2, pH 8.0) for 60 min at 
37°C, followed by blocking of the plate with 100 µl TSM/1%BSA. Subsequently, wells were coated 
with ICAM-1-Fc or CD14-Fc containing supernatant at the indicated concentrations O/N at 4°C as 
described previously (Binnerts et al., 1996). Cells (7 x 106/ml) were fluorescently labeled with Calcein-
AM (25 µg/ml; Molecular probes, Eugene, OR) for 30 min at 37°C and subsequently incubated 
(20,000-40,000/well) in the absence or presence of mAb, or stimulating or blocking agents on ICAM-
1-Fc coated plates for 45 min at 37°C. Non-adherent cells were removed by gently washing steps with 
warm 0.5% BSA in TSM. Adherent cells were lysed with 100 µl lysis buffer (50mM Tris, 0.1% SDS) 
and their fluorescence (Calcein-AM) was quantified using the cytofluorometer (Perseptive Biosystems). 
Results are expressed as the mean percentage of adhesion of triplicate wells. 
 
Migration assay 
96-well flat bottom Maxisorp plates (Nunc., Roskilde, Denmark) were coated with ICAM-1-Fc or CD14-
Fc as described in the adhesion assay or with poly-L-lysine. Cells (8 x 104/ml) were pre-incubated with 
either 5 µg/ml stimulating mAb, 80 µg/ml blocking antibodies, a combination of deoxyglucose (50 
mM) and NaN3 (10 mM), or with cytochalasin D (5 µg/ml) for 10 min at RT. Per well, 4,000 cells (50 
µl) including the antibodies or reagents were added, resulting in 20 to 30 cells per image. Mineral oil 
(30 µl, Sigma Chemical Co., St. Louis, MO) was pipetted on top of the medium to prevent pH changes 
and evaporation of the medium. The coated plate with cells was placed on the microscope table and 
the experiment was started when the temperature of the medium in the control well had reached 
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37°C to start the experiment at physiological temperature, since LFA-1 binding critically depends on a 
physiological temperature (Figdor et al., 1990), and to allow cells to settle to the bottom of the well. 
This was, in general, within 20 min. In the case of Poly-L-lysine coating, HSB-2 T cells (4,000/well) 
were seeded for 45 min, washed with PBS and fixed with 3.7% formaldehyde to validate hysteresis of 
the system. 
 
Automated cell track system 
The ACTS is depicted in Fig. 1A. A Zeiss (Thornwood, NY) Axiovert 35M inverted microscope equipped 
with the 10x/0.3 Ph1 bright phase contrast objective was connected to a 512 x 512 video camera 
(HCS MX5, DIFA, Breda, The Netherlands). Signals were digitized with Scion CG-7 or Pixel Pipeline 
frame grabbers in a Macintosh workstation (G4 or Quadra 800) (Boezeman et al., 1997). The 
microscope was installed in a 37°C incubator to perform the experiments at physiologic temperatures. 
The wells of a 96-well plate were positioned in X, Y, and Z directions with an EK8b MTP scanning table 
(Marzhauser, Wetzlar, Germany) manually controlled by the operator or by the serial interface of the 
Macintosh computer during the experiment. The cycling moving table scanned a series of wells and 
sampled each well in parallel at a sample rate 1/30 Hz during at least 20 min. The images of each well 
were stored and linked to generate a movie. 
 
Algorithm 
The cells to be tracked were marked by the operator. A series of initial cell centroids  
{(x,y)grav,i , i=1,N} was selected by pointing to the cell centers in the very first frame I0 with typically 
N=8. The centroid (x,y)grav was calculated over all pixel values in the template: 
 
xgrav = Σ(Ij.xj) / Σ(Ij),  ygrav = Σ(Ij.yj) / Σ(Ij) 
  
The 32*32 pixel environment of each selected cell in the first frame I0 initialized also the cell specific 
masks Ki. The algorithm then cycled through all successive frames Ij, j =1,J with three distinguished 
steps in each loop. First, the correlation function Ui,j of mask Ki with the next frame j was calculated 
(Parker, 1997)(Russ, 1998) 
 
Ui,j = Ij • Ki 
 
The position of the cell in the next frame was the weighted maximum of correlation function: 
 
(x,y)i,j = max {g(x i-1,yj-1,τ), Ui,j}  
 
The weight function g(x,y,τ) benefits nearby maxima and prevents selection of a cell with similar 
morphology in the next frame. The scaling parameter τ is tuned with respect to sample frequency and 
cell speed. Lastly, the mask Ki was updated from the environment of the cell centroids in the new 
frame. 
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Figure 1. Schematic overview of the Automated Cell Track System (ACTS) and image, track analysis. (A) A 96-
well plate is fixed onto an inverted microscope, which is connected to a video camera and coupled to a computer. 
The X, Y, and Z positions of the microscope table are regulated by a x, y, z stage controller. (B) Time-lapse 
recorded images of HSB-2 T cells. HSB-2 T cells (4,000/well) were seeded in an ICAM-1-Fc coated 96-well plate 
and monitored by the microscope every 30 s. Subsequently, the motility of the cells was analyzed with the 
tracking system. The images monitored at 0, 5, 10, 15, and 20 min are shown. (C) Traversed paths of the cells 
tracked in B. X and Y positions of the cells at each image are linked to generate the motility lines. Each square 
represents an individual cell at its starting position. 
 
 
Data Analysis and Statistics 
The tracked (x,y)i,j coordinates were visualized in time (Fig. 1B) with the most nearby pixels. 
Parameters, such as distance, speed, and direction were directly calculated from these coordinates, 
not from round-off pixel positions. Speed was calculated as the traversed path divided by the tracking 
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time. The traversed path of each individual cell was plotted in a graph as is shown in Fig. 1C. Cells 
that passed the image borders within the first 10 minutes of the experiment or which underwent cell 
division were excluded from the analysis. 
Non parametric Kruskal-Wallis and Mann-Whitney tests were used to compare the reproducibility and 
specificity of different groups. Pearson correlation was applied to analyze the correlation between 
manual and automated tracking of the cells. Furthermore, Student’s t-test was used to compare 
migration data from different experiments. 
 
 
RESULTS 
 
Adhesion molecule expression and adhesion profile of HSB-2 T cells 
Cell migration is based on transient adhesive interactions both between cells and between 
cells and the extracellular matrix. Since β2 integrins are known to mediate leukocyte 
migration, we examined the β2 integrin expression of HSB-2 T cells and the adhesive 
properties mediated by these molecules, as a model. Flow cytometric analysis showed that 
HSB-2 T cells express high levels of the integrin β2 chain and the associated integrin unit αL 
(Leukocyte Function associated Antigen 1, LFA-1), but lack the expression of αM and αX 
(Mac-1 and p150,95 respectively) (Fig. 2A). Furthermore, LFA-1 is in an active state on these 
cells, since NKI-L16, an antibody reactive against the Ca2+ activation epitope, is expressed. 
HSB-2 T cells spontaneously bind to ICAM-1-Fc coated plates (Fig. 2B), but not to CD14-Fc 
coated plates, which were used as controls (data not shown). The LFA-1-activating antibody 
KIM185, which causes a conformational change in LFA-1 (Andrew et al., 1993), enhanced 
the adhesion of HSB-2 T cells to ICAM-1-Fc (Fig. 2B). It is important to realize that adhesion 
depends not only on the activation state of LFA-1, but also on integrin avidity and integrin 
distribution on the cell surface (Huttenlocher et al., 1996; van Kooyk & Figdor, 2000). 
Adhesion to ICAM-1-Fc could be inhibited by blocking anti-LFA-1 antibodies, again indicating 
that adhesion of HSB-2 T cells to ICAM-1-Fc is LFA-1-mediated. 
 
Effect of hysteresis 
To evaluate the precision of the movement of the microscope stage, we plated HSB-2 T cells 
on poly-L-lysine, fixed the cells and measured the positions of the cells during continuously 
cycling and during stasis of the microscope stage (data not shown). In contrast to stasis 
conditions, cycling of the microscope stage induced a small mechanical jitter. 
In addition, living cells change their morphology in successive images, which implies that the 
track dot placed within the cell at the start of the analysis moves continuously. This leads to 
false positives, cells that were identified as migrating, but instead, were non-migrating 
(cellular jitter). This phenomenon is illustrated in Fig. 3A and 3B, in which a non-migrating 
cell due to cellular jitter received an apparent motility by automated analysis. To reduce 
cellular jitter in our analysis we defined threshold distances, i.e. the distance the cell has to 
overcome in four subsequent frames (four 30 s intervals = 2 min in total). The x, y positions 
of a cell in frame Ij were included in the analysis when the displacement from frame Ij to 
frame Ij+4 exceeded the minimal distance d. The reduction in cellular jitter was analyzed for 
increasing d values (d = 2, 4, or 6 µm) (Fig. 3B and 3D). Using these thresholds, motility of 
both visually scored migrating as well as non-migrating HSB-2 T cells coated on ICAM-1-Fc 
was determined (Fig. 3E and F). The cellular jitter was almost completely reduced by a d 
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value of 6 µm (Fig. 3E). This validation algorithm of x,y positions was applied to each cell in 
each frame in all migration experiments performed. 
Next, we determined the percentage of migrating cells (in four experiments) using the track 
results (a migrating cell was defined as motility > 0.5 µm/min, based on results in Fig. 3E) 
and compared these percentages with visually scored migrating cells (Fig. 3G). Similar 
results (non-significant difference by Student’s t-test) were observed, indicating that the 
track data discriminate very well between migrating and non-migrating cells, given the 
correction for cellular jitter. 
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Figure 2. β2 integrin expression on HSB-2 T cells and LFA-1-mediated adhesion to ICAM-1-Fc. (A) Expression of 
β2 integrins on HSB-2 T cells by flow cytometry. HSB-2 T cells were stained for LFA-1 (NKI-L15), activation 
epitope of LFA-1 (NKI-L16), Mac-1 (KIM225), p150,95 (SHCL3), and β2 chain (NKI-L19). Open histograms 
represent the isotype controls, shaded histograms are the indicated antibodies. (B) Adhesion of HSB-2 T cells to 
ICAM-1-Fc. Activated HSB-2 T cells were incubated in wells coated with 50 ng/ml ICAM-1-Fc protein in the 
absence or presence of the LFA-1-activating antibody KIM185 (5µg/ml) and in the absence or presence of the 
LFA-1-blocking antibody NKI-L15 (10 µg/ml). Results are expressed as the mean % of adhesion of triplicate wells 
± SD. Data are representative of three experiments. 
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Figure 3. Correction of motility of migrating and non-migrating cells. Illustration of a non-migrating (A) and a 
migrating (C) cell. Each overlay represents the position of the cell in a next frame. x, y positions and tracks during 
migration of the non-migrating (B) and migrating (D) cell. As illustrated, due to cellular jitter the automated track 
system falsely assigns distances to non-migrating cells (B). We introduced threshold distances (2, 4, and 6 µm) to 
distinguish migrating cells from cellular jitter (B and D). HSB-2 T cells were seeded on either 50 ng/ml ICAM-1-Fc 
or CD14-Fc (control coating). The wells were monitored every 30 s for a period of 20 min. Subsequently, cells 
were tracked and threshold distances were included to discriminate between migrating cells and non-migrating 
cells. As limits, 0, 2, 4, and 6 µm of displacement in 2 min were investigated. (E) Average motility of visually 
scored non-migrating and migrating cells at threshold levels of 0, 2, 4, and 6 µm. Motility is indicated in µm/min 
± SEM. F. Speed of individual cells. Each square represents the speed of a cell after inclusion of the different 
threshold distances. G. Percentage of migrating cells determined visually and automatically (Motility < 0.5 
µm/min is scored as non-migrating (decided on basis of speed in Fig. 3E). The mean ± SEM of four experiments 
is shown (Student’s t-test, n.s.). 
 
 
Validation of the tracking system 
The automated tracking system was validated by comparison of the computer-assisted 
analysis with manual analysis of 20 cells by a blinded and a non-blinded observer. No 
significant differences were found between both observers (data not shown). Automated 
analysis has an advantage over manual analysis, since computer-assisted tracking is much 
less time-consuming (at least 10 times faster than manual analysis). Fig. 4 illustrates the 
excellent correlation (r = 0.98) between both analyses over a wide range of migration 
distances. 
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Reproducibility and specificity of the migration 
HSB-2 T cells were used to investigate the reproducibility of our ACTS. The number of HSB-2 
T cells that migrated on ICAM-1-Fc was measured in four separate wells. CD14-Fc was used 
as a control coating. As is depicted in Fig. 5A, cells were motile on ICAM-1-Fc (40±6% 
migrating cells), whereas on CD14-Fc they were considerably less motile (13±2% migrating 
cells, Mann Whitney U test p<0.006).  
The software also permitted calculation of the speed of migrating cells. As is depicted in Fig. 
5B, the average speed of the cells in four wells coated with ICAM-1-Fc was similar, i.e. 
Figure 4. Comparison of migration distances of cells 
measured by manual as well as by automated 
tracking analysis. HSB-2 T cells were seeded on 50 
ng/ml ICAM-1-Fc. The wells were monitored every 
30 sec for a period of 20 min and subsequently 
tracked by manual and automated analysis. 
Distances are indicated in µm. 
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4.0±0.5 µm/min, 5.2±0.8 µm/min, 5.0±0.8 µm/min, 4.7±0.6 µm/min (non-significant, 
Kruskal Wallis). Differences in speed observed between individual cells reflect slower and 
faster moving cells. Taken together these results show that data obtained with this novel 
migration and tracking system are highly reproducible. 
Substrate-ligand interactions together with an active cell metabolism and an intact 
cytoskeleton are a prerequisite for migration (Huttenlocher et al., 1996). As HSB-2 T cells 
were motile on ICAM-1-Fc but not so on CD14-Fc, we studied the locomotion of HSB-2 T 
cells on ICAM-1-Fc in the presence of NaN3 and deoxyglucose, and in the presence of 
cytochalasin D (Fig. 5C). In both cases, the motility of the cells was abolished, indicating that 
the locomotive behavior depended on metabolic energy and cytoskeletal rearrangements. 
Moreover, blocking antibodies against ICAM-1 (REK-1) and the β2 chain (NKI-L19) 
completely disrupted the motility on ICAM-1-Fc. Taken together, motility of HSB-2 T cells on 
ICAM-1-Fc is LFA-1-specific and depends on an intact cytoskeleton and an active cell 
metabolism. 
 
Adhesion and migration are ligand concentration dependent 
Both the integrin-mediated adhesion and the migration of cells on a substratum depend on 
ligand levels, integrin levels, integrin-ligand binding affinities, and integrin avidity 
(Huttenlocher et al., 1996; Palecek et al., 1997; van Kooyk & Figdor, 2000). To investigate 
the role of ligand concentration and integrin activity on HSB-2 T cell adhesion and migration, 
we studied both processes using 5, 50, and 500 ng/ml ICAM-1-Fc in the presence and 
absence of the LFA-1-activating antibody KIM185. 
The adhesion of HSB-2 T cells was enhanced at increasing concentrations of ICAM-1-Fc and 
could be completely blocked by NKI-L15, demonstrating the specificity of the interaction. 
Furthermore, activation of LFA-1 by KIM185 antibodies enhanced cellular adhesion at a 
ligand concentration of 50 ng/ml, but no further increase of adhesion was observed at a 
concentration of 500 ng/ml ICAM-1-Fc (Fig. 6A), indicating that maximal adhesion was 
already reached at this extremely high ligand concentration.  
The number of migrating HSB-2 T cells also depended on ICAM-1-Fc concentrations (Fig. 
6B). At 50 ng/ml and 500 ng/ml ICAM-1-Fc, activation of LFA-1 by KIM185 completely 
blocked migration. The specificity of the interaction was confirmed using blocking antibodies. 
In contrast to the adhesion to ICAM-1-Fc that could not be further induced by KIM185 at 500 
ng/ml (Fig. 6A), migration was further reduced as depicted in Fig. 6B. These apparent 
differences can be explained by the fact that the plate adhesion assay provides only a rough 
indication of adhesive strength (it measures only strong adhesion due to stringent washing), 
whereas the migration assay provides information on all cells including weakly adherent 
cells. 
In addition, the speed of migrating cells at different ICAM-1-Fc concentrations was measured 
(Fig. 6C). The results showed that the speed of migrating cells was dependent on the ligand 
concentrations, exhibiting maximum levels at 50 ng/ml ICAM-1-Fc.  
From these findings, we conclude that LFA-1-mediated adhesion as well as migration of HSB-
2 T cells on ICAM-1-Fc depends on both the activation state of LFA-1 and the concentration 
of substrate coated. 
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Figure 5. Reproducibility and specificity of the migration system. HSB-2 T cells in medium were seeded in four 
wells coated with either 50 ng/ml ICAM-1-Fc or CD14-Fc (control coating) (A and B), or with 30 ng/ml ICAM-1-Fc 
(C). The wells were monitored every 30 s for a period of 20 min (A and B) or 40 min (C). (A) Percentage of 
migrating cells on ICAM-1-Fc and CD14-Fc. The mean percentage of cells that migrate ± SEM in four different 
wells is presented. Data are representative of three experiments. (B) Average speed (in µm/min) of individual 
cells in four ICAM-1-Fc coated wells and overall average speed (-) in µm/min. Data are representative of three 
experiments. (C) Cell tracks of HSB-2 T cells in the absence or presence of NaN3 and deoxyglucose, cytochalasin 
D, or a combination of ICAM-1-blocking (REK-1) and β2 chain-blocking (NKI-L19) antibodies. Each square 
represents an individual cell at its starting position. Data are representative of two experiments. 
 
Chapter 2 
40 
 
A
*
*mediumNKI-L15
KIM185 + NKI-L15
KIM185
100
80
60
40
20
0
control 5 50 500
ng/ml ICAM-1-Fc
%
 a
dh
es
io
n
C
0
2
4
6
8
10
sp
ee
d 
(µ
m
/m
in
)
5 50 500
ng/ml ICAM-1-Fc
B
medium
KIM185
KIM185 + L19 + REK-1
L19 + REK-1
100
80
60
40
20
0
control 5 50 500
ng/ml ICAM-1-Fc
%
 m
ig
ra
tin
g 
ce
lls
  
 
 
 
 
Figure 6. Adhesion and 
migration of HSB-2 T cells to 
different concentrations of 
ICAM-1-Fc. (A) Adhesion of 
HSB-2 T cells to ICAM-1-Fc. 
HSB-2 T cells were incubated 
on wells coated with a range 
of ICAM-1-Fc protein or with 
50 ng/ml CD14-Fc as a 
control coating, in the 
absence or presence of the 
LFA-1-activating antibody 
KIM185 (5 µg/ml) and in the 
absence or presence of the 
LFA-1-blocking antibody NKI-
L15 (10 µg/ml). Results are 
expressed as the mean % 
adhesion of triplicate wells ± 
SD. Data are representatives 
of three experiments (* 
p<0.05 in Mann Whitney U 
test). (B) Migration of HSB-2 
T cells on ICAM-1-Fc. HSB-2 T 
cells were incubated on wells 
coated with a range of ICAM-
1-Fc protein or with 50 ng/ml 
CD14-Fc (control coating), in 
the absence or presence of 
the LFA-1-activating antibody 
KIM185 (5 µg/ml) or with a 
combination of the ICAM-1-
blocking antibody REK-1 (80 
µg/ml) and the β2 chain-
blocking antibody NKI-L19 
(80 µg/ml). The wells were 
monitored every 30 s for a 
period of 20 min. Results are 
expressed as the % of 
migrating cells. Data are 
representatives of three 
experiments. (C) Average 
speed of migrating HSB-2 T 
cells on 5, 50, and 500 ng/ml 
ICAM-1-Fc. Speed of 
individual cells as well as the 
average speed (-) in µm/min 
is depicted. Data are 
representative of three 
experiments. 
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DISCUSSION 
 
Several methods have been developed to study the migration of cells. Besides methods that 
only provide information on the number of migrating cells, such as the Boyden chamber and 
Transwell assay (Wilkinson, 1982), systems have been developed to study the migratory 
behavior of individual cells (Friedl et al., 1993). Most of the techniques for automated cell 
tracking applied so far use contrast differences or fluorescent markers and a priori 
morphology criteria to recognize cells. Moreover, extraction of relevant cells is the main 
focus of the software of these systems (Soll, 1988; Wu et al., 1995; Chon et al., 1997; 
Hoppe et al., 1999; Demou & McIntire, 2002). However, when the interface between cells 
and their environment is of low contrast or when two cells of equal contrast approach, the 
cells cannot be distinguished from each other and manual analysis is preferred. By contrast, 
the analysis performed in our system is based on the highly dynamic morphological 
alterations during cell migration (this is of particular relevance for lymphocytes, as shown in 
this report, but also for highly motile cells such as dendritic cells, as shown in the paper by 
(De Vries et al., 2003)). 
Typically 20 to 30 cells were recorded from each well. This sample size is representative for 
the population as shown by the high reproducibility of measurements in four subsequent 
wells. A further advantage of this newly designed imaging system is the possibility of 
performing multiple experiments under various experimental conditions in one series of 
recordings using only one set-up. In addition, the images are directly digitized into the 
workstation. Accordingly, our system is independent of the quality of videotapes and enables 
analysis without previously converting the data. Therefore, this multiple well migration 
system significantly reduces the workload (more than 10-fold reduction).  
The accuracy of the tracking analysis is highly dependent on the speed of the cells and the 
density of the cell suspension. Our system records multiple wells in parallel by motion of the 
microscope table, which limits the sample rate. However, the sampling rate might be too low 
for fast migrating cells, since these cells have a large displacement per image. Hence, tracing 
of fast migrating cells will be more difficult and cells will easily be lost during analysis. 
Therefore, we reduced the time interval between individual images to 30 s in our 
experiments. Another feature of fast moving cells is that they induce a border problem, as 
they migrate out of the recorded area. As a consequence the tracking dot loses the cell near 
the edge of the image, which frequently results in jumping up and down along the recording 
border. Evidently, this results in incorrect migration data. Therefore, the software is designed 
such that it aborts tracking of a cell when it comes within a distance of 3 µm from the 
boundary. 
As discussed above, the density of the cell suspension also affects cell tracking accuracy, the 
higher the cell concentration, the more difficult the tracking analysis. We found a density 
below 4,000 cells per well a satisfactory concentration to track the cells. In some cases, for 
instance when two approaching cells have highly similar morphology and contrast, the 
tracking system was not always able to discriminate between those cells. Although such 
events will not influence the overall results, the system allows the operator to interrupt the 
analysis to manually position the track dot back onto the cell after which the automated 
analysis can proceed. 
Both the cycling of the microscope stage and the dynamics of the cells induced jitter in 
successive images of the same well. As a consequence cells scored as non-migrating 
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appeared to have an apparent speed between of 2.8±0.2 µm/min (see Fig. 3). Visual 
inspection of the time-lapse movies revealed that in most instances background speed 
resulted from a shift of the dot within the borders of the cell. Since the dot represents one 
pixel (1.52 µm) and the HSB-2 T cells have a diameter of approximately 10 µm this can lead 
to significant ‘movement’ of a cell. Therefore we defined migrating cells as cells exceeding a 
displacement of at least 6 µm in 2 min, since this threshold clearly reduced the speed of the 
non-migrating cells to background levels of nearly 0 µm/min.  
Cell migration is a dynamic adhesive process, in which cells form new interactions with the 
substrate at their leading edge and detach from the substrate at the rear of the cell 
(Huttenlocher et al., 1995). These adhesive forces can either be strong or weak, depending 
on the cell and substratum type. When the interaction is very weak or absent, as 
investigated with the plate adhesion assay, a synchrone flow of cells in the wells can be 
detected, despite the regulated temperature of the incubation chamber. A likely explanation 
for the flow of weak binders is the remaining liquid convection. Addition of mineral oil on top 
of the medium prevented not only pH changes but also evaporation of the medium thereby 
reducing this phenomenon. The direction of the movement of the stage was not correlated 
with the direction of the flow of the cells (data not shown), indicating that mechanical 
movement of the microscope stage did not contribute to this non-specific movement of non-, 
or weakly- binding cells. 
To test the applicability and accuracy of this new migration system, we used the T cell line 
HSB-2 to study its adhesive and migratory capacities on ICAM-1-Fc. Since LFA-1 on HSB-2 T 
cells is already partially activated, the cells spontaneously bind to ICAM-1-Fc (Figdor et al., 
1990; van Kooyk et al., 1994). However, further activation of LFA-1 with the LFA-1-activating 
antibody KIM185 results in an even higher percentage of bound HSB-2 T cells (Robinson et 
al., 1992; Andrew et al., 1993; Lub et al., 1997).  
Here, we demonstrate that HSB-2 T cells migrate on ICAM-1-Fc. This migration is LFA-1 
specific, since blocking antibodies against LFA-1 and ICAM-1 could inhibit the motility to 
background levels. Moreover, activation of LFA-1 with KIM185 affected the migratory 
behavior of HSB-2 T cells on both 50 and 500 ng/ml ICAM-1-Fc. These data are in 
accordance with previous studies showing that CD2 activation (Carpen et al., 1991), T Cell 
Receptor stimulation (Dustin et al., 1997) and activation via PMA induce the activation state 
of LFA-1, and result in reduced motility of leukocytes on ICAM-1-Fc. KIM185 did not enhance 
the adhesion at 500 ng/ml ICAM-1-Fc, but migration was clearly affected. It should be 
stressed that the plate adhesion assay and the migration assay are completely different 
tests. In the adhesion assay a stringent washing step is applied which removes all non-
adherent cells. It therefore only gives a rough indication of the adhesive strength of cells. In 
contrast, in the migration assay all cells are present because no washing forces are applied. 
Hence, it is highly likely that weakly binding cells are the ones that are, because of their 
limited adhesion, highly motile (in the adhesion assay these cells will, because of their low 
adhesion be washed away). In the migration assay these cells will stop migrating when 
activated with KIM185 and stick firmly, thus explaining the apparently different results 
between the adhesion and migration assays. This difference is also observed for control 
conditions (CD14-Fc), in which weakly binding cells might account for the background level 
of migration, i.e. 10-15% of the cells. 
We showed that motility of HSB-2 T cells was clearly dependent on the concentration of 
ICAM-1-Fc. The proportion of migrating cells reached a maximum at 50 ng/ml. At lower 
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ligand concentrations, adhesion strength was too low to generate traction for migration. At 
higher concentrations the adhesive forces became too strong, resulting in immobile cells 
(DiMilla et al., 1991). These results are in line with the observations of Palecek and 
colleagues, who also showed this biphasic pattern of migration for the integrins α5β1 and 
αIIbβ3 on fibronectin and fibrinogen respectively (Palecek et al., 1997). Furthermore, they 
showed that the migration speed of cells depends on several variables, including ligand 
levels, receptor density, and receptor-ligand binding affinities (Palecek et al., 1997). 
Likewise, the mean speed of the HSB-2 T cells also depended on the ICAM-1-Fc 
concentration.  
In conclusion, the ACTS we describe is well suited to study cell migration. The advantage 
over previously described methods is the automated track analysis based on contrast 
differences as well as on the actual cell morphology, and the simultaneous measurement of 
multiple wells in one single experiment. Therefore, this novel method will be useful to rapidly 
study the effects of multiple factors (ligands, chemokines, cytokines) influencing the 
migration of different cell types. 
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ABSTRACT 
 
Dendritic cells are the professional antigen-presenting cells of the immune system. To induce 
an effective immune response, these cells should not only express high levels of MHC and 
costimulatory molecules but also migrate into the lymph nodes to interact with naïve T cells. 
Here, we demonstrate that in vitro-generated mature, but not immature dendritic cells, 
efficiently migrate into the T-cell areas of lymph nodes of melanoma patients. This difference 
is confirmed by in vitro studies, in which immature dendritic cells are strongly adherent, 
whereas mature dendritic cells remain highly motile. Our present findings demonstrate that 
the ability of dendritic cells to mount a proper immune response correlates with their ability 
to migrate both in vitro and in vivo.  
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INTRODUCTION 
 
The Dendritic Cell (DC) is a specialized antigen-presenting cell that can induce de novo 
antitumor responses in patients (Hsu et al., 1996; Nestle et al., 1998; Thurner et al., 1999). 
Tissue-resident immature DCs take up antigen, followed by a complex maturation and 
activation process that is characterized by an up-regulation of antigen-presenting MHC 
molecules and costimulatory molecules, as well as a switch in their adhesion- and 
chemokine- receptor repertoire (Sallusto et al., 1998; Mellman & Steinman, 2001). Although 
this process is only partially understood, it has become clear that these phenotypical changes 
allow DCs to migrate from peripheral tissues to the lymph nodes, in which they present 
processed antigens to resting T cells (Saeki et al., 1999).  
Recent studies in cancer patients, in which the efficacy of in vitro-generated DC vaccines are 
evaluated, show that mature DCs, but not immature DCs, induce an effective antitumor 
response (Jonuleit et al., 2001; Dhodapkar et al., 2001). The incapacity of immature DCs to 
induce an immune response is at least in part because of a low expression of antigen 
presenting- and costimulatory- molecules. In addition, monocyte-derived immature DCs lack 
CCR7, required for migration into the T cell areas of lymph nodes (Takayama et al., 2001; 
Parlato et al., 2001). Hence, immature DC generated in vitro may not colocalize and interact 
with naïve T cells in the lymph nodes, a prerequisite for the induction of an effective immune 
response.  
Animal studies have provided direct evidence that DCs injected subcutaneously, but not 
intravenously, preferentially migrate to the draining lymph nodes to induce a measurable 
antitumor effect (Eggert et al., 1999). Similarly, administration of radiolabeled DCs in 
humans demonstrates that the tissue distribution depends on the route of administration. 
DCs injected intravenously accumulate in the spleen and liver, whereas DC injected 
subcutaneously or intradermally migrate to the draining lymph nodes (Mackensen et al., 
1999; Morse et al., 1999). 
Studies in which DCs are directly injected intralymphatically show that DCs localize in the 
draining lymph node (Mackensen et al., 1999), but do not inform whether the injected DCs 
reach the T-cell areas of the lymphoid organs. Here we compare the migratory capacity of 
DC vaccines in vitro, by measuring morphology and speed of individual cells, with the 
behavior of these cells in vivo. By radiolabeling of the DCs, we investigate the effects not 
only of the maturation state but also the route of administration on DC migration in vivo. Our 
findings demonstrate that the migration of DCs is highly dependent on their maturation state 
and suggest that injection of monocyte-derived mature DCs is superior to the injection of 
immature DC preparations. 
 
 
MATERIALS AND METHODS 
 
Antibodies and immunostaining 
The following mAbs were used: anti-HLA class I (W6/32), anti-HLA DR/DP (Q5/13), anti-CD80 (all 
Becton Dickinson, Mountain View, California), anti-CD83 (Beckman Coulter, Mijdrecht, The 
Netherlands), anti-CD86 and anti-CCR5 (both Pharmingen, San Diego, CA), anti-CCR7, AZN-D1 against 
DC-SIGN, HP2/1 against α4, SAM-1 against α5, AZN-L19 against β2 integrins, and AIIB2 against β1 
integrins (Developmental Studies Hybridoma Bank, Iowa City, IA). 
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Preparation of DC 
DCs were generated from peripheral blood mononuclear cells (PBMCs) as described previously 
(Thurner et al., 1999; De Vries et al., 2002). After leukapheresis, PBMCs were used for the generation 
of monocyte-conditioned medium (MCM), and plastic-adherent monocytes were cultured in X-VIVO 15 
medium (BioWhittaker, Walkersville, MD) supplemented with 2% pooled human serum (Bloodbank 
Rivierenland, Nijmegen, The Netherlands), IL-4 (500 U/ml), and granulocyte macrophage colony 
stimulating factor (GM-CSF, 800 U/ml; both from Schering-Plough, International, Kenilworth, NJ) 
(Thurner et al., 1999). After the addition of KLH (10 µg/ml) on day 3-4, immature DCs were harvested 
on day 6-7.  
Mature DCs were cultured as immature DCs. Autologous MCM with prostaglandin E2 (PGE2, 10 µg/ml; 
Pharmacia & Upjohn, Puurs, Belgium) and 10 ng/ml recombinant TNF-α (kindly provided by Dr. Adolf, 
Bender, Vienna, Austria) were added on day 7 (30%, v/v). Mature DCs were harvested on day 9.  
 
Adhesion and migration assay 
Flat-bottom plates (96-well; Costar, Corning, NY) were coated with 20 µg/ml fibronectin (Roche, 
Mannheim, Germany) and blocked with 0.01% gelatin (Sigma Chemical Co., St. Louis, MO). DCs (7 x 
106/ml) were labeled with Calcein-AM (25 µg/ml; Molecular probes, Eugene, OR) for 30 min at 37°C, 
either untreated or preincubated (10 min, room temperature) with blocking mAb (10 µg/ml), and 
seeded on fibronectin-coated plates (20,000-40,000/well) for 45 min at 37°C. Non-adherent cells were 
removed by gently washing steps with warm 0.5% BSA (Boeringher Mannheim, Germany) in TSM 
(150 mM NaCl, 10 mM Tris/HCL, 2 mM MgCl2, 1 mM CaCl2, pH 8.0). Adherent cells were lysed with 
100 µl of lysisbuffer (50mM Tris, 0.1% SDS) and fluorescence was quantified using the 
cytofluorometer (PerSeptive Biosystems). Results were expressed as the mean percentage of adhesion 
of triplicate wells. 
We used our previously established migration assay to study migration of DCs. Four thousand DCs (40 
µl) per well were seeded on fibronectin-coated plates, resulting in 100 cells per image. DCs were 
recorded for up to 100 min, after which, migration tracks of individual DCs were analyzed. The speed 
is defined as the traversed path during the entire experiment divided by the imaging time. 
 
Patients 
Melanoma patients, participating in an ongoing protocol in which the in vivo immune responses of a 
DC vaccine are studied (KUN 99-150) were included in this study. Eligibility criteria included stage 
III/IV melanoma, planned radical lymphadenectomy for lymph node metastases, HLA-A2.1 phenotype, 
melanoma expressing gp100 and tyrosinase, and written informed consent. The local regulatory 
committee approved the study. Twenty-four to 48 h before surgery, eligible patients received a single 
injection of the 111In-labeled DCs (10x106, 200 µl saline) either intradermally in the proximity, or 
intranodally directly into a lymph node of the lymph node region that was to be resected. Intranodal 
injections were performed under ultrasound guidance.  
At the same time, patients also received the DC vaccine (DCs pulsed with peptides gp100:154-162, 
gp100:280-288, and tyrosinase:369-377) intradermally or intranodally at a clinically tumor-free lymph 
node region. This was repeated for a total of four injections every 2 weeks.  
After the DC vaccinations, a delayed type hypersensitivity (DTH) reaction was performed. Briefly, DCs 
(5 x 105 in 0.2 ml), either loaded with KLH and/or peptide or unloaded, were injected on the back by 
using a 25-gauge needle and a 1 ml syringe. The DTH was characterized by swelling, erythema, and 
induration. The diameter (in millimeters) of edema and induration was measured after 48 h. 
 
Proliferative response to KLH 
Cellular responses against the protein KLH were measured in a proliferation assay. Briefly, per well of 
a 96-well tissue culture microplate, 1x105 PBMC, isolated from blood samples taken after one DC 
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vaccination, were plated either in the presence of KLH or without. After 4 days of culture, 1 µCi/well 
of tritiated thymidine was added, and incorporation of tritiated thymidine was measured in a beta-
counter. 
 
111[In]oxinate labeling, administration and autoradiography 
Immature and mature DCs were labeled with 111indium oxinate (Mallinckrodt Medical, Petten, The 
Netherlands) in 0.1 M Tris-HCl (pH 7.0) for 15 min at room temperature as described previously 
(Eggert et al., 1999; De Vries et al., 2002). Scintigraphic images of the depot and corresponding 
lymph node basin were acquired with a gamma camera, 24 or 48 h after injection. After the last 
imaging session, the lymph node basin was resected. The radioactive lymph nodes in the resected 
specimen were identified and counted in a gamma counter in combination with injection standards. 
The fraction of 111In-labeled DCs that migrated from the injection depot was determined as a measure 
of their migratory capacity in vivo. Radioactive lymph nodes were embedded in paraffin. Sections (4-
µm) were dipped in LM1 photographic emulsion (Amersham, Buck, United Kingdom) and exposed for 
2-3 weeks at 4°C. After exposure, the sections were developed and poststained with haematoxylin 
and eosin. 
 
 
RESULTS 
 
Characterization and potency of immature versus mature DCs when used as 
vaccines 
Immature and mature DC populations exhibited their respective characteristic phenotype and 
morphology (Fig. 1A). Expression of adhesion molecules, both β1 and β2 integrins, slightly 
decreased after maturation (Fig. 1B, and data not shown). CCR5 was expressed by ~40% of 
the immature DCs but was absent on mature DCs (Fig. 1B). Conversely, immature DCs 
lacked expression of the homing receptor CCR7, whereas this molecule was present on 
~80% of the mature DCs (Fig. 1B). We tested both immature and mature DCs for their 
capacity to induce a “de novo” immune response in vivo. In an ongoing study, melanoma 
patients received vaccinations either with immature (n=9) or mature (n=10) KLH-loaded 
DCs. We observed that only mature DCs, already after a single vaccination, induced a 
proliferative response against KLH in the peripheral blood of these patients (Fig. 1C). 
Moreover, DTH reactivity towards KLH-loaded DCs was observed after vaccination with 
mature DCs in all patients tested (n=9), whereas none of the patients (n=7) vaccinated with 
KLH-loaded immature DCs showed any DTH. 
 
Adhesive and migratory properties of DCs to fibronectin 
To examine whether differences in adhesive and migratory behavior between immature and 
mature DCs contribute to their efficacy as a vaccine, we investigated their capacity to bind to 
the extracellular matrix protein fibronectin. Although both types of DCs bind to fibronectin, 
binding and, in particular, cell spreading of immature DCs was much stronger than of mature 
DCs (Fig. 2A and B). DC adhesion could be blocked completely by antibodies against β1 
integrins but was only partially inhibited by β2 integrin blocking antibodies (Fig. 2C).  
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Adhesion of immature DC to fibronectin was mediated through α5β1 because blocking α5, 
but not α4, antibodies inhibited this type of adhesion (Fig. 2D). 
Consistent with the enhanced spreading of immature DCs on fibronectin (Fig. 2A), virtually 
none of these cells migrated when followed in time-lapse cinematography (Fig. 2E and 
G). Although cell membranes of immature DCs were highly dynamic, and expanding, 
contracting, and changing shape continuously, no migration was observed. In contrast, 
mature DCs were highly motile on fibronectin (Fig. 2F and G), using their dendrites to 
continuously attach and detach from the substrate. As a consequence, the speed of mature 
DCs was 10 times higher than of immature DCs, 5.0 µm/min versus 0.5 µm/min (Fig. 2 H, 
Mann Whitney U test, P<0.0001). 
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Figure 1. Characterization of immature and mature DCs. DCs were stained with mAbs against antigen-
presentation molecules, costimulatory molecules, and DC-specific molecules (A), and adhesion molecules and 
chemokine receptors (B), and were measured by flow cytometry. Grey lines, isotype-matched controls; dark 
overlays, the markers as indicated underneath the histograms. Mature but not immature KLH-loaded DCs can 
induce an immune response in vivo after a single vaccination. (C) proliferative response against KLH in the PBMCs 
of the vaccinated patients was used as a readout: closed bars, without KLH; open bars, with KLH. The data from 
1 of the 9 patients vaccinated with immature DCs and from 1 of the 10 patients vaccinated with mature DCs are 
shown. 
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Figure 2. Adhesion, spreading, and migration of DCs to fibronectin. Morphology of DCs on fibronectin-coated 
wells (A, immature DCs; B, mature DCs). Adhesion in the absence or presence of blocking antibodies against β1, 
β2 integrins (C), and α4, α5 integrins (D); closed bars, immature DCs; open bars, mature DCs. Results are 
expressed as the mean percentage of adhesion of triplicate wells. Data are representatives of three 
experiments. (E and F) different lines, migration paths of DCs: E, immature DCs; F, mature DCs. (G) percentage 
of migrated DCs ± SD of both immature and mature DCs (*, Wilcoxon-rank-sum test, P<0.01). (H) speed of 
migrated DCs ± SD (Mann-Whitney U test, P<0.0001); datapoints, the speeds of individual cells; horizontal bars, 
the mean speed. Data are representatives of three experiments. 
 
 
Migratory capacity of DCs after injection into melanoma patients 
To examine whether the differences in migration between immature and mature DCs were 
similar in vivo as observed in vitro, cells were labeled with radionucleotide 111In (Eggert et 
al., 1999; De Vries  et al., 2002). Previously, we showed that both immature and mature 
monocyte-derived DCs can be labeled with equal efficiency (95%), while remaining viable 
(~80%) for 24-48 h (De Vries et al., 2002). Moreover, 111In-labeling did not affect surface 
receptor expression by DCs (data not shown). In vivo migration of DCs was studied in 
melanoma patients, who received tumor-peptide pulsed DCs either intradermally (n=8 
immature DCs; n=10 mature DCs) or intranodally (n=7 both immature and mature DCs), 24-
48 h before radical dissection of regional lymph nodes. A time point between 24 and 48 h 
was chosen because the half-life of DCs, either unlabeled or 111In-labeled, and of a MHC-
peptide complex that they express, is limited (Kukutsch et al., 2000). 
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Figure 3. Biodistribution of DCs after injection. In vivo localization of intradermally (A and B) and intranodally 
injected (C and D) 111In-labeled DCs by scintigraphic imaging with a gamma camera. Body contours are indicated. 
The four images are windowed differently to allow identification of the lymph nodes beyond the injection depot. 
(A) immature DCs 0.2%; mature DCs 0.8%. (B) mature DCs 1.5% and 1.1%. (C) 4%. (D) 23%. Dotted circles, 
injection depot of immature DCs. Closed circles, injection depot of mature DCs. 111In-labeled DCs injected 
intradermally were measured for their migratory capacity in vivo. (E) Wilcoxon-rank-sum test, P<0.01; each 
symbol, one individual patient. 
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In accordance with previous results (Morse et al., 1999), we observed that on intradermal 
injection, a significant percentage of both immature DCs and mature DCs remained at the 
site of injection (Fig. 3A and B). Nevertheless, a distinct amount of radioactivity was 
observed in the draining lymph nodes after injection of the DCs. Interestingly, a significantly 
higher percentage of mature DCs (mean ± SD, 1.8 ± 1.1%) migrated to lymph nodes and 
distributed over more lymph nodes (mean ± SD, 2.1 ± 1.6%) as compared to immature DCs 
(mean ± SD: 0.3 ± 0.1% migrated), which never migrated to more than one lymph node 
(Fig. 3A, B, and E). In addition, the migration of mature DCs, but not of immature, was 
somewhat enhanced after 48 h relative to 24 h. In one patient, we followed DC migration for 
up to 144 h, but no further increase in migration was observed. 
Injection of DCs directly into a lymph node resulted in a large variation in the migratory 
capacity within the immature as well as the mature DC population. There was no difference 
(Wilcoxon rank-sum test) in migratory capacity of mature DCs (mean 19.3%; range 0.4% – 
84%) versus immature DCs (mean 10.2%; range 0.5% – 30%) (Fig. 3C and D, and data not 
shown). 
 
 
Intranodal localization of DCs after injection into melanoma patients 
To investigate the capacity of DCs to migrate into lymph nodes, sections derived from 
resected lymph nodes distant from the node of injection were analyzed by 
microautoradiography. Explicit spots of radioactivity in the lymph node confirmed the 
migration of injected 111In-labeled DCs into these nodes (Fig. 4). Intriguingly, a major 
difference between immature and mature DCs was observed. Immature DCs resided at the 
periphery of the nodes, the marginal sinus, whereas mature DCs migrated deeply into the T-
cell areas further emphasizing their superior migratory properties (Fig. 4).  
 
 
Figure 4. Distribution of intranodally injected 111In-labeled DCs in distant lymph nodes in situ. After 
autoradiography, lymph node sections were stained with hematoxilin and eosin; black spots, the presence of 
111In-labeled DC (arrows). Overview of the lymph node section with immature DCs (A) and mature DCs (B). 
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DISCUSSION 
 
Clinical studies in which tumor-antigen loaded DCs are used to vaccinate cancer patients 
indicate that mature DCs are superior to immature DCs to induce antitumor responses 
(Jonuleit et al., 2001; Dhodapkar et al., 2001). This might be attributed to their unique 
antigen processing and presentation machinery, which in mature DCs results in extremely 
high expression of antigenic peptides on MHC molecules and high levels of costimulatory 
molecules (Mellman & Steinman, 2001). However, next to their superior antigen-presenting 
properties, it is of utmost importance that antigen-loaded DCs come in close proximity of T 
cells in the lymph nodes (Cyster, 1999). Therefore, DCs injected into patients must actively 
migrate into the T-cell areas of lymph nodes. Here, we unequivocally demonstrate that 
mature DCs are migratory both in vitro and in vivo, irrespective whether they are 
administered into the skin or intranodally. By contrast, in vitro-generated immature DCs are 
unable to leave the skin after intradermal injection. Moreover, when migrating to distinct 
lymph nodes after direct lymph node application, immature DCs do not invade the T-cell 
areas, which precludes effective interactions with naïve T cells.  
The low migratory capacity of immature DCs relates directly to their strong adhesive 
properties in vitro, which is mediated by highly expressed β1 integrins, in particular α5β1 
(D'Amico et al., 1998). Similar findings have been reported by Gunzer et al., who show, in a 
collagen matrix model, that the immature state of murine DCs is characterized by low 
migration, whereas mature murine DCs exhibit high migratory activity (Gunzer et al., 2000). 
Our observations extend their findings by demonstrating that mature DCs weakly bind to 
extracellular matrix (fibronectin) and use their dendrites to actively migrate, whereas 
immature DCs stretch and flatten, thus hampering translocation. 
Upon exposure to pathogens in peripheral tissues, resident DCs become activated through 
toll-like receptors (Kadowaki et al., 2001), take up and process antigen, while migrating to 
the draining lymph nodes to present their antigenic load (Hirao et al., 2000). To facilitate 
migration, CCR5 is down-regulated, while CCR7 is up-regulated, the latter being required for 
trafficking and entry into the T-cell areas of the lymph node (Dieu et al., 1998; Sallusto et 
al., 1998; Forster et al., 1999; Saeki et al., 1999; Gunn et al., 1999). As expected, we 
observed that CCR7-positive mature DCs migrate into the T-cell areas of the lymph nodes, 
whereas immature CCR7-negative DCs do not. The inability of immature DCs to migrate into 
the T-cell areas could explain why vaccination with KLH-loaded immature DCs in melanoma 
patients fails to induce both proliferative as well as DTH responses. Our observations that 
immature DCs fail to induce an immune response correlates with studies of others. Immature 
DCs, when used as a vaccine adjuvant, might give rise to T cells that display the typical 
properties of regulatory T cells; non-proliferative, IL-10-producing T cells that can dampen 
pre-existing antigen-specific effector T-cell function (Jonuleit et al., 2000; Dhodapkar et al., 
2001). 
Previously, we and others showed that the majority of injected DCs reside at the injection 
depot (Mackensen et al., 1999; Eggert et al., 1999; Morse et al., 1999; Barratt-Boyes et al., 
2000). Here, we demonstrate that monocyte-derived DCs that are matured in vitro, for the 
greater part, remain in the injection depot, although they express CCR7 and are highly 
motile in vitro. Gunzer et al. reasoned that the microenvironment largely influences 
emigration (Gunzer et al., 2000). In addition, the relative high local density of DCs at the site 
of injection may affect this microenvironment, thereby having a major impact on emigration. 
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A better understanding of this lack of emigration, which can be enhanced with matrix 
metalloproteinases, is of importance for future DC vaccine development (Ratzinger et al., 
2002). 
Although intradermally injected DCs migrate out of the skin very inefficiently, nevertheless, a 
10-fold higher number of mature DCs migrated to an adjacent lymph node when compared 
to their immature counterparts. In addition, mature, but not immature, DCs migrate to 
multiple lymph nodes after intradermal injection. Intranodal application of immature or 
mature DCs leads to a substantial migration to several distant lymph nodes, as soon as 1 h 
after vaccination. Although only the mature DCs reach the T-cell areas, after intranodal 
injection of immature and mature DCs, little or no difference is observed between the 
migration to lymph nodes. Intranodal injection resulted in a rather variable migration in both 
cell populations. This might be because injection of DCs directly into a lymph node leads to a 
partial destruction of the lymph node architecture, resulting in the migration to distant lymph 
nodes, of DCs that would otherwise reside in the injected node. Likewise, during intranodal 
administration, a significant proportion of DCs may be transported by the flow of lymphatic 
vessels to nearby lymph nodes. A major advantage of intranodal over intradermal 
vaccination is, therefore, that an increased number of DCs are getting to the lymph nodes, 
e.g., the site at which the initiation of the immune response occurs. Especially when peptide-
loaded DCs are used as a vaccine, the time required to reach the T-cell areas of the lymph 
nodes is of great importance, because the half-life of DCs and of a MHC-peptide complex 
that they express is limited (Kukutsch et al., 2000). In the first clinical study in melanoma 
patients, which reported on the efficacy of peptide-loaded DC vaccines, mature DCs were 
injected intranodally. Our results may provide a mechanistic explanation for the effectiveness 
of the protocol used in that study (Nestle et al., 1998). 
Given the previously described tolerizing capacity of immature DCs, the recent results from 
mature-DC vaccination studies, and the migration data presented in this study, we conclude 
that mature DCs are preferred over immature DCs in clinical vaccination studies in cancer 
patients. 
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ABSTRACT 
 
The capacity of DCs to activate naïve T cells depends on their maturation state and the 
migration to T-cell areas of the draining lymph nodes. Whereas mature DCs are highly 
migratory, immature DCs are strongly adherent. In the present study we investigated 
whether and how integrin expression contributes to these distinct adhesive capacities. 
Although both immature and mature DCs express comparable levels of the integrin subunit 
β1, the adhesion of mature DCs is clearly reduced. A β1-activating antibody could restore 
this decreased adhesion, suggesting that the β1 integrin is less active on mature DCs relative 
to immature DCs. Indeed, the expression of active β1, as measured by the 12G10 antibody, 
is reduced on mature DCs. Upon fibronectin adhesion immature DCs, but not mature DCs, 
formed podosome structures containing active β1. 
Together these findings imply that the adhesion of DCs to fibronectin is not regulated by 
expression levels, but rather by differential regulation of integrin activity during DC 
maturation. 
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INTRODUCTION 
 
Dendritic Cells (DCs) are highly motile, professional antigen presenting cells derived from 
hematopoietic bone marrow stem cells (Banchereau & Steinman, 1998; Liu, 2001). DC 
precursors migrate via the blood into peripheral tissues, where they reside as immature DCs 
patrolling for antigen. Antigen uptake results in a change in DC function from an immature, 
antigen uptake phenotype into a mature, migratory, antigen presenting phenotype 
(Steinman, 1991; Banchereau & Steinman, 1998). This maturation process is characterized 
by the upregulation of MHC molecules, costimulatory molecules, but also by a switch in 
chemokine receptor expression from CCR1 and CCR5 to CCR4, CXCR4, and CCR7 (Sallusto et 
al., 2000). CCR7 drives the migration of DCs from the skin into T cell areas of draining lymph 
nodes, where the mature DCs interact with naïve T cells to induce a primary immune 
response (Forster et al., 1999). 
During their migration from peripheral tissues to afferent lymphatics, DCs interact with 
extracellular matrix (ECM) molecules. Cell adhesion to ECM is regulated by special cellular 
adhesion structures, such as focal adhesions and podosomes. Focal adhesions are large 
adhesion contacts at the end of stress fibers (reviewed in Petit & Thiery, 2000). Podosomes, 
the most prominent adhesive organelles in DCs are short-lived structures that are formed 
upon cell-substrate contact (Marchisio et al., 1988; reviewed in Linder & Aepfelbacher, 
2003). Podosomes are related to focal adhesions and contain similar proteins, like actin, 
vinculin, talin, and integrins (Zamir et al., 2000). The importance of podosomes for adhesion 
is underscored by podosome-deficient WAS macrophages that exhibit a defective adhesion 
(Linder et al., 1999; Burns et al., 2001). 
β1 integrins are the main adhesion molecules implicated in cell-ECM interactions. Ligand 
binding depends on the activation state of the β1 integrin, which can be achieved via inside-
out signaling. This activation process can be induced by signaling via other surface 
receptors, such as G-protein-linked receptors, or via phorbol esters that activate PKC and 
results in regulated clustering of integrins and subsequent adhesion strengthening 
(Grabovsky et al., 2000; Stewart et al., 1998). Moreover, β1 integrin-mediated adhesion can 
be induced from the outside of the cell by divalent cations, like Ca2+, Mg2+, and Mn2+, or by 
activating antibodies (Gailit & Ruoslahti, 1988; van de Wiel-van Kemenade et al., 1992; 
Arroyo et al., 1992; Mould et al., 1995). 
Human epidermal Langerhans Cells (LCs) and human tonsillar follicular DCs adhere to 
fibronectin and laminin via α5β1 and α6β1 respectively (Le Varlet et al., 1992; Ogata et al., 
1996). Upon antigen stimulation LCs upregulate α4β1 expression, suggesting a role for this 
integrin in LC migration from the dermis into regional lymph nodes (Aiba et al., 1993). The 
adhesion of human monocyte-derived DCs to a natural ECM ligand derived by endothelium is 
mediated by the β1 integrins α4β1 and α5β1 (D'Amico et al., 1998; Bianchi et al., 2000). We 
and others have shown that DC adhesion to fibronectin is mediated by α5β1 (D'Amico et al., 
1998; Jancic et al., 1998; De Vries et al., 2003). 
The adhesive and migratory properties of DCs critically depend on their maturation state. In 
a collagen matrix model, murine mature DCs are fast migrating cells, whereas immature DCs 
have slow migration characteristics (Gunzer et al., 2000). Consistent with these observations 
human monocyte-derived mature DCs are highly migratory in comparison to their immature 
counterparts, both in vitro and in vivo (De Vries et al., 2003). 
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We have previously shown that immature DCs more strongly adhere to fibronectin when 
compared to mature DCs. This difference in adhesive capacity correlated with a higher 
migratory capacity of mature DCs on fibronectin. In order to determine the mechanism 
responsible for these differences in adhesive potential, we have compared both expression 
levels and activity of β1 in immature versus mature DCs. We demonstrate that the increased 
adhesive capacity of immature DCs can be attributed to a higher expression of active β1 on 
immature DCs than on mature DCs. Moreover immature DCs form podosomes containing 
active β1 integrins, whereas these structures are absent in mature DCs. We conclude that 
the presence of podosomes is inversely correlated with a migratory DC phenotype. 
 
 
MATERIALS AND METHODS 
 
Chemicals and antibodies 
The following mAbs were used: anti-HLA class I (W6/32), anti-HLA DR/DP (Q5/13), anti-CD80 (all 
Becton Dickinson, Mountain View, California), anti-CD14 and anti-CD83 (both Beckman Coulter, 
Mijdrecht, The Netherlands), anti-CD86 (Pharmingen, San Diego, California), AZN-D2 against DC-SIGN 
(Geijtenbeek et al., 2000a), TS2/16 against ß1 integrins (Hemler et al., 1984), AIIB2 against ß1 
integrins (Developmental Studies Hybridoma Bank, Iowa City), 12G10 against active ß1 integrins 
(Serotec, Oxford, United Kingdom), anti-vinculin (Sigma, St. Louis, MO), isotype controls mIgG1 
(Becton Dickinson, Mountain View, California), mIgG2a, mIgG2b, rIgG1 (all Pharmingen, San Diego, 
California), and the secondary antibodies goat anti-mouse Alexa-488 (Molecular Probes, Eugene, OR), 
goat anti-mouse-FITC (Zymed, San Francisco, CA), and goat anti-rat-PE (Becton Dickinson, Mountain 
View, CA). Rhodamin-conjugated phalloidin (Molecular Probes, Eugene, OR) was used to stain actin. 
 
Preparation of DCs 
DCs were generated from peripheral blood mononuclear cells (PBMCs) as described previously 
(Thurner et al., 1999; De Vries et al., 2002). Monocytes were derived from buffy coats or from a 
leukapheresis product. Plastic-adherent monocytes were cultured in X-VIVO 15 medium (BioWhittaker, 
Walkersville, Maryland) supplemented with 2% pooled human serum (PAA laboratories, Linz, Austria), 
IL-4 (500 U/ml) and granulocyte macrophage colony stimulating factor (GM-CSF, 800 U/ml) (both 
from Schering-Plough, International, Kenilworth, New Jersey)(Mackensen et al., 1999). Immature DCs 
were harvested on day 7. 
DCs were matured with monocyte-conditioned medium (MCM) with 10 ng/ml recombinant TNF-α 
(kindly provided by Dr. Adolf, Bender, Vienna, Austria) and prostaglandin E2 (PGE2, 10 µg/ml, 
Pharmacia & Upjohn, Puurs, Belgium) added on day 7 (30%, v/v). Mature DCs were harvested on day 
9. 
 
Immunofluorescence 
Cells (50x103) were incubated with 2-5 µg/ml mAb (25 µl/well) in PBA (PBS containing 0.5% bovine 
serum albumin and 0.01% NaN3) for 30 min at 4°C. After one wash step with cold PBA, cells were 
incubated with 25 ml FITC-labeled goat anti-mouse secondary antibody or goat anti-rat secondary 
antibody for 30 min at 4°C. Subsequently, cells were washed and diluted in 100 µl PBA. The 
fluorescence was measured using a FACScan® (Becton and Dickinson & Co., Oxnard, Ca). 
 
Fluorescence microscopy 
DCs were seeded on fibronectin coated glass coverslips (blocked with 0.01% gelatin) for 1 or 2 h and 
fixed in 3.7% formaldehyde/PBS for 10 min. Cells were permeabilized in 0.1% Triton X-100 and 
blocked with 2% bovine serum albumin in PBS. Cells were incubated with anti-vinculin antibody. 
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Subsequently, cells were stained with goat anti-mouse Alexa Fluor 488 and rhodamine-conjugated 
phalloidin. Images were collected by confocal laser scanning microscopy (Biorad) or fluorescence 
microscopy (Leica). 
 
Adhesion assay 
96-wells flat bottom plates (Costar, Corning, New York) were coated with 20 µg/ml fibronectin 
(Roche, Mannheim, Germany) for 60 min at 37°C, washed, and blocked with 0.01% gelatin (Sigma 
Chemical Co., St. Louis, Missouri) for 30 min at 37°C. DCs (1x107/ml) were labeled with Calcein-AM 
(25 µg/ml; Molecular probes, Eugene, OR) for 30 min at 37°C, either untreated or preincubated (10 
min, RT) with blocking mAb (10 µg/ml), and seeded on fibronectin-coated plates (20-40,000/well) for 
45 min at 37°C in the presence or absence of an activating antibody (1 µg/ml). Non-adherent cells 
were removed by gently washing steps with warm (37°C) 0.5% Bovine Serum Albumin (Boehringer 
Mannheim, Germany) in TSM (150 mM NaCl, 10 mM Tris/HCL, 2 mM MgCl2, 1 mM CaCl2, pH 8.0). 
Adherent cells were lysed with 100 µl lysisbuffer (50mM Tris, 0.1% SDS) and fluorescence was 
quantified using the cytofluorometer (PerSeptive Biosystems). Results are expressed as the mean 
percentage of adhesion of triplicate wells. 
 
Migration assay 
96-wells flat bottom plates (Costar, Corning, New York) were coated with 20 µg/ml fibronectin 
(Roche, Mannheim, Germany) and blocked with 0.01% gelatin (Sigma Chemical Co., St. Louis, 
Missouri) as described in the adhesion assay section. Per well, 3,000 cells (50 µl) were added resulting 
in approximately 100 cells per image. Mineral oil (30 µl, Sigma Chemical Co., St. Louis, MO) was 
pipetted on top of the medium to prevent pH changes and evaporation of the medium.  
DCs were monitored with our previously described migration system (Krooshoop et al., 2003). In brief, 
a Zeiss (Thornwood, NY) Axiovert 35M inverted microscope equipped with the 10x/0.3 Ph1 bright 
phase contrast objective is connected to a 512 x 512 video camera (HCS MX5, DIFA, Breda, The 
Netherlands). Signals were digitized with Scion CG-7 or Pixel Pipeline frame grabbers in a Macintosh 
workstation (G4 or Quadra 800)(Boezeman et al., 1997). The microscope was installed in a 37°C 
incubator to perform the experiments under physiologic temperatures. The wells of a 96 well plate 
were positioned in X, Y, and Z directions with an EK8b MTP scanning table (Marzhauser, Wetzlar, 
Germany) manually controlled by the operator or by the serial interface of the Mac during the 
experiment. The repetitive cycling table scans a series of wells and samples each well in parallel at a 
sample rate 1/30Hz. DCs were recorded for up to 60 min followed by analysis of individual DCs. The 
speed was defined as traversed path during the entire experiment divided by the imaging time. 
 
 
RESULTS 
 
Characterization of immature and mature DCs 
Human DCs were generated from monocytes and characterized by flow cytometry. Immature 
DCs expressed MHC class I and II, the costimulatory molecule CD86, the DC-specific marker 
DC-SIGN, expressed low levels of the costimulatory molecule CD80, and lacked the 
expression of the maturation marker CD83 (Fig. 1). Maturation of DCs by a combination of 
MCM, TNFα, and PGE2 resulted in the induction of CD80 and CD83, an upregulation of MHC 
class I, MHC class II, and CD86, and a downmodulation of DC-SIGN. 
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Figure 1. Characterization of immature and mature DCs. DCs were stained with monoclonal antibodies against 
antigen presentation molecules, costimulatory molecules, and DC-specific molecules, and measured by flow 
cytometry. Filled histograms represent isotype controls. 
 
 
Adhesion and migration of DCs on fibronectin 
We compared the adhesive and migratory capacity of immature versus mature DCs on 
fibronectin. When plated on fibronectin, immature DCs were subject to immediate and 
elaborate cell spreading, whereas mature DCs retained their veiled phenotype. Immature 
DCs seeded on fibronectin for 1 h began to form podosome-like structures recognizable as a 
dense core of actin surrounded by a ring of vinculin (Fig. 2A and B). These adhesive 
structures were not present in DCs with a “mature” phenotype (Fig. 2C and D). Prolonged 
incubation on fibronectin (2 h) resulted in more polarized immature DCs expressing 
podosomes, whereas mature DCs maintained their veiled phenotype and showed no 
podosome structures (Fig. 2E-H). 
 
    
 
    
 
Figure 2. Morphology of DCs on fibronectin. Immature DCs (A, B, E, and F) and mature DCs (C, D, G, and H) 
were plated on fibronectin-coated coverslips for 1 (A-D) and 2 h (E-H), and subsequently stained with phalloidin 
(stains actin; A, C, E, and G) and anti-vinculin antibody (B, D, F, and H). Arrows indicate the podosomes. Inserts 
represent enlargements of the podosome structures. 
E F G H 
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Likewise, a larger proportion of immature DCs (80%, Fig. 3A) than of mature DCs (20%, Fig. 
3B) bound to this ECM molecule. Consistent with the high adhesive properties of immature 
DCs, little or no migration was observed in this population (Fig. 3C). In contrast, mature DCs 
were highly motile and showed random migration at a mean speed of 5 µm/min (Fig. 3D and 
data not shown). 
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Figure 3. Adhesion and migration of DCs to fibronectin. Adhesion in the absence or presence of blocking 
antibodies against the α4, α5, and ß1 integrin chains (A, immature DCs; B, mature DCs). Results are expressed 
as the mean percentage of adhesion of triplicate wells. Data are representatives of three experiments. Migration 
of DCs on fibronectin (C and D). Plot of 50 individual immature (C) and mature (D) DC tracks (recording time 60 
min), which are aligned at their starting positions. 
 
 
Adhesion of mature DCs to fibronectin is enhanced by a β1-activating antibody 
Adhesion of mature DCs was clearly reduced compared to immature DCs although both DC 
populations expressed comparable levels of β1. To exclude the possibility that β1 on mature 
DCs was somehow deficient in mediating adhesion, we investigated whether the β1-
activating antibody TS2/16 could promote adhesion of mature DCs. Indeed adhesion of 
mature DCs to fibronectin was markedly enhanced by TS2/16. At the same time the adhesive 
capacity of immature DCs was not further induced, indicating that binding of immature DCs 
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to fibronectin was already maximal in medium conditions (Fig. 4). The TS2/16-induced 
adhesion of mature DCs was completely α5β1-mediated, since α5-blocking antibodies 
effectively blocked this interaction. These data indicate that α5β1 expressed on mature DCs 
is not defective in mediating adhesion. While cell-substrate adhesion not solely depends on 
integrin expression, but also on integrin distribution, and the activation state of the integrin 
(Huttenlocher et al., 1996; Palecek et al., 1997; van Kooyk & Figdor, 2000), these data 
suggest that β1 becomes either differentially distributed or less active upon DC maturation. 
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The activation state of β1 is reduced upon DC maturation 
To determine whether the reduced adhesion of mature DCs is due to decreased activation of 
β1, both immature and mature DCs were stained with the β1 antibodies AIIB2 (total β1) and 
12G10. It has previously been shown that the 12G10 antibody recognizes a unique cation-
regulated epitope on the β1 A-domain. The induction of this epitope correlates with the 
active conformation of the integrin (Mould et al., 1995). Flow cytometric analysis revealed 
comparable levels of total β1 between immature and mature DCs. In contrast, a decrease in 
expression of the activation epitope was observed on mature DCs relative to immature DCs. 
These differences in β1 activity on immature versus mature DCs most likely account for their 
distinct adhesive and migratory potency on fibronectin and demonstrate that the regulation 
of β1 integrin activity is a key determinant of DC behavior. 
 
fluorescence
co
un
ts
total β1
immature
mature
active β1
0
20
0
10 0 10 10 10 101 2 3 4 10 0 10 10 10 101 2 3 4
10 0 10 10 10 101 2 3 4
0
20
0
10 0 10 10 10 101 2 3 4
 
Figure 4. Adhesion of DCs after stimulation 
of the ß1 integrins. DC adhesion in the 
absence or presence of ß1-activating and α5-
blocking antibodies. Results are expressed as 
the mean percentage of adhesion of triplicate 
wells. Data are representatives of three 
experiments. 
Figure 5. Expression of 
the activation epitope 
12G10 on DCs. DCs were 
stained with the 
monoclonal antibodies 
against total β1 and the 
active conformation of the 
β1 A-domain and measured 
by flow cytometry. 
Representative expressions 
(1 out of 6) are shown. 
Filled histograms represent 
isotype controls.  
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Active β1 integrins localize to podosomes 
Since immature DCs express active β1 integrins and form podosomes we investigated 
whether active β1 localizes preferentially to these adhesion structures. Therefore immature 
DCs were seeded on fibronectin-coated surfaces, incubated for 2 h, and stained for actin, 
total β1, and active β1. Immature DCs formed actin-rich dots corresponding to podosome 
structures (Fig. 6A and C). Cell surface localization of total β1 exhibited a uniformly 
expression pattern (Fig. 6B). No enrichment of total β1 was observed in podosomes. Staining 
for active β1 by the 12G10 antibody showed that it was primarily localized around actin cores 
in podosomes (Fig. 6D). These findings indicate that adhesion of immature DCs to 
fibronectin is established via active β1 integrins present in podosome structures. 
 
   
 
   
 
Figure 6. Localization of the activation epitope 12G10 on DCs. DCs were seeded on fibronectin-coated coverslips 
for 2 h and double stained for actin (A) and total β1 (B), and for actin (C) and the active conformation of the β1 
A-domain (D). 
 
 
DISCUSSION 
 
The adhesion of immature DCs to fibronectin is considerably different from their mature 
counterparts; immature DCs adhere to fibronectin, whereas the adhesion of mature DCs is 
remarkably reduced. Here we have investigated to what extend either the expression level or 
the activation state of the β1 integrin contributes to these different adhesive capacities. 
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The expression level of the integrin β1 chain was comparable between immature and mature 
DCs, indicating that other factors than integrin expression modulate the difference in 
adhesion. Next to integrin expression levels, integrin activity and distribution can also be 
important modulators of adhesion (Huttenlocher et al., 1996; Palecek et al., 1997; van Kooyk 
& Figdor, 2000). For example, activation of αLβ2 results in a conformational change of the 
molecule and the expression of a Ca2+-dependent and a Mn2+-dependent epitope. Activation 
of αLβ2 and subsequent ligand binding result from conformational changes that increase 
both the affinity, but also the lateral multimerization of αLβ2 (avidity), and modulate 
adhesion (Binnerts & van Kooyk, 1999). Changes in integrin affinity and avidity vary with 
integrin type and the cellular context. While affinity and avidity changes play the most 
prominent role in the regulation of β2 integrins, the involvement of these changes in 
adhesion have also been shown for β1 integrins (Lobb et al., 1995; Stewart & Hogg, 1996). 
The integrin α4β1 can acquire multiple activation states with different affinities (Jakubowski 
et al., 1995). Likewise, α5β1 has at least two conformations, distinguished by the antibody 
12G10, which binds to a cation-regulated epitope on the β1 A-domain (Mould et al., 1995). 
High binding of 12G10 represents an "active" conformation, whereas an "inactive" state is 
recognized by low binding of 12G10 (Mould et al., 2002). By staining immature and mature 
DCs with this 12G10 antibody, we showed that mature DCs expressed lower levels of active 
β1 than immature DCs. Consistent with this notion, we showed in adhesion assays that the 
β1-activating antibody TS2/16 could enhance the adhesion of mature DCs up to levels of 
immature DCs. These findings imply that the activation state of β1, rather than expression 
per se, is regulated upon DC maturation and modulates DC adhesion and migration. 
Several studies have shown that cell surface distribution of integrins is also essential for their 
adhesive function. As example, reorganization of the spatial distribution of αLβ2 by a Rap1-
binding molecule regulates lymphocyte adhesion (Katagiri et al., 2003). Clustering of αLβ2 
on the cell surface not only strengthens cell-cell adhesion but is also essential for αLβ2 
activation and ligand binding. Expression of the Ca2+-dependent epitope of αLβ2 is 
associated with a clustered state of αLβ2, which is a prerequisite for ligand binding (van 
Kooyk et al., 1994; Binnerts & van Kooyk, 1999). Furthermore the distribution of αLβ2 is 
regulated upon DC differentiation (A. Cambi, personal communication). αLβ2 distribution 
changes from a clustered state in monocytes to a random distribution in immature DCs. The 
regulation of β1 activity during DC maturation might be induced by a difference in cell 
surface distribution. 
Adhesion of immature DCs to fibronectin results in the assembly (1 h) or presence (2 h) of 
podosomes, which were absent on DCs with a mature phenotype. These findings extended 
the study of Burns et al., who related podosome formation to cells with an immature 
phenotype (Burns et al., 2001). Podosomes consist of a core of actin filaments and actin 
associated proteins surrounded by a ring of vinculin and talin, and interact with the 
substratum via integrins (Marchisio et al., 1988; Linder & Aepfelbacher, 2003). We showed 
by fluorescence microscopy an enrichment of active β1 in these podosome structures, 
indicating that the activity as well as the distribution of β1 account for the opposite adhesive 
capacities of immature and mature DCs. Because transmission electron microscopy is a more 
sensitive technique to measure distribution patterns of cell surface molecules, we will use 
this technique to investigate whether β1 is differently distributed in immature and mature 
DCs. 
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Burns and colleagues have suggested that podosome structures play a role during the 
migratory phase of DCs (Burns et al., 2001). However, here we show that mature DCs, 
which lack podosomes, are highly migratory, whereas immature DCs containing this 
structure are strongly adherent. Since mature DCs use transient interactions with fibronectin 
to migrate, we speculate that podosomes regulate strong adhesion still allowing amoeboid 
crawling of cells (speed 0.5 µm/min, De Vries et al., 2003), but not the high speed migration 
seen in mature DCs (5 µm/min, De Vries et al., 2003). 
Activation of integrins and subsequent signal transduction is regulated by membrane 
recruitment of cytoplasmic proteins. One of such proteins is Cytohesin-1, which binds to 
αLβ2 and increases its avidity (Kolanus et al., 1996; Geiger et al., 2000; Weber et al., 2001). 
Another recently described protein is CYTIP, which is expressed in hematopoietic cells and 
only associates with the plasma membrane in cells that adhere to integrin ligands (Boehm et 
al., 2003). CYTIP interacts with cytohesin-1 and detachment of this complex from the plasma 
membrane abrogates β2 integrin adhesion, but has no effect on β1-dependent adhesion. 
The regulated expression of these molecules in DCs suggests a dynamic control of β2-
integrin-mediated adhesion. It would be interesting to investigate whether a comparable 
mechanism exists for β1 integrins. Cytoplasmic proteins that can bind the tail of β1 integrins 
and modulate their function are talin and paxillin (Schaller et al., 1995; Rock et al., 1997). 
Upon DC maturation, the actin-bundling protein fascin and the microfilament-associated 
protein palladin are upregulated (Mosialos et al., 1996; Mykkanen et al., 2001). Future 
investigations will demonstrate whether one of these proteins modulate integrin-mediated 
DC adhesion and migration. Recently, Cook et al. showed that the tetraspanin molecule CD9 
associates with α5β1 when transfected in CHO cells (Cook et al., 2002). Though no evidence 
is yet available on the effect of tetraspanins on integrin conformation, Cook and colleagues 
demonstrated that CD9 association modulates adhesion to fibronectin. We observed no 
colocalization of CD9 with α5β1 (data not shown) indicating that this tetraspanin molecule 
does not appear to be involved in immature and mature DC adhesion to fibronectin. 
In this report we demonstrate that the reduced adhesion of mature DCs versus immature 
DCs is predominantly determined by the activation state of the β1 integrin rather than by β1 
integrin expression levels. In addition we show that immature DCs, seeded on fibronectin 
exhibit podosomes that contain active β1 integrins. The migration of DCs upon maturation 
coincides with inactivation of the β1 integrin. Future experiments will be aimed at 
understanding the molecular mechanism responsible for this remarkable change in activation 
of the β1 integrin. 
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ABSTRACT 
 
Dendritic cells (DCs) are recruited from blood into tissues to patrol for foreign antigens. After 
antigen uptake and processing DCs migrate to the secondary lymphoid organs to initiate 
immune responses. We now show that DC-SIGN, a DC-specific C-type lectin, supports 
tethering and rolling of DC-SIGN-positive cells on the vascular ligand ICAM-2 under shear 
flow, a prerequisite for emigration from blood. The DC-SIGN/ICAM-2 interaction regulates 
chemokine-induced transmigration of DCs across both resting and activated endothelium. 
Thus, DC-SIGN is central to the unusual trafficking capacity of DCs, further supported by the 
expression of DC-SIGN on precursors in blood, and on immature as well as mature DCs in 
both peripheral and lymphoid tissues. 
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INTRODUCTION 
 
A fundamental aspect of dendritic cell (DC) function to control immunity is their capacity to 
migrate (Banchereau & Steinman, 1998). Immature DCs migrate from the blood into 
peripheral tissues to exert a continuous surveillance for incoming foreign antigens. This 
migration from blood is tightly regulated to provide a rapid response to inflammatory signals. 
Immature DCs in peripheral tissues are highly proficient in antigen capture and processing 
(Inaba et al., 1993; Svensson et al., 1997). Upon receiving an activation signal, immature 
DCs mature and specifically migrate from the periphery to secondary lymphoid organs for 
interaction with specific T cells and initiation of an immune response (Banchereau & 
Steinman, 1998). Little is known about the molecular basis of DC migration and whether DCs 
express specific molecules that regulate their adhesion and migratory capacity. We have 
recently identified the human DC-specific adhesion receptor DC-SIGN, a C-type lectin, 
through its high affinity interaction with ICAM-3 and which enables transient DC-T cell 
interactions, thus facilitating primary immune responses (Geijtenbeek et al., 2000a). 
Furthermore, DC-SIGN functions as a novel HIV-1 trans-receptor important in the 
dissemination of HIV-1 (Geijtenbeek et al., 2000b). HIV-1 is captured on DCs present in the 
periphery by DC-SIGN and thus transported by DCs that migrate into lymphoid tissues where 
DC-SIGN-associated HIV-1 efficiently infects target CD4+ T cells.  
Immature DCs express high levels of DC-SIGN (Geijtenbeek et al., 2000b), and since several 
lectins have also been reported to function as rolling receptors allowing leukocyte 
transendothelial migration (Vestweber & Blanks, 1999), we hypothesized that DC-SIGN might 
play a role in the specific migratory capacity of DCs. We investigated whether ICAM-2 
functions as a ligand for DC-SIGN, since ICAM-2 has a high homology with ICAM-3 (de 
Fougerolles et al., 1993) and, in contrast to ICAM-3, is abundantly expressed by vascular as 
well as lymphoid endothelium (Nortamo et al., 1991). Strikingly, DC-SIGN functions not only 
as the primary receptor for ICAM-2 on DCs, but also mediates DC rolling and transendothelial 
migration, thus demonstrating that DC-SIGN is crucial in the specific migratory processes of 
DCs. 
 
 
MATERIALS AND METHODS 
 
Adhesion  
Fluorescent bead adhesion assays were performed as described (Geijtenbeek et al., 1999; Geijtenbeek 
et al., 2000a). Briefly, carboxylate-modified Transfluospheres (488/645nm; Molecular Probes, Eugene, 
OR) were coated with ICAM-2-Fc. 50,000 cells were preincubated with mAb at 20 µg/ml for 10 min at 
room temperature. ICAM-2-Fc-coated fluorescent beads (20 beads/cell) were added, and the 
suspension was incubated for 30 min at 37ºC. Adhesion was determined by measuring the percentage 
of cells which had bound fluorescent beads by flow cytometry using the FACScan (Becton Dickinson, 
Oxnard, CA). Ca2+ affinity was determined by measuring the binding of DCs to ICAM-coated beads at 
different Ca2+ concentrations. Specificity is determined in the presence of antibodies to DC-SIGN 
(AZN-D1; 20 µg/ml). The resulting curves for both ICAM-2 and ICAM-3 were fitted to the equation for 
second order dependence to Ca2+ (fractional binding)=[Ca2+]2/((KCa)2+[Ca2+]2) (Mullin et al., 1997). 
Ligand affinity was determined by titrations of soluble ICAM-1, -2, -3-Fc and measuring the binding to 
either LFA-1- or DC-SIGN-transfectants. Binding was measured after 30 min at 37ºC by staining the 
ligand Fc chimeras with FITC-conjugated goat-anti-human Fc antibodies and determining the fraction 
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of labeled cells by flow cytometry. Specificity was determined by measuring in the presence of 
blocking antibodies to either LFA-1 (NKI-L15; 20 µg/ml) or DC-SIGN (AZN-D1; 20 µg/ml). 
 
Laminar flow assay 
The laminar flow assay was performed as previously described (Alon et al., 1995; Chen et al., 1999). 
Briefly, a polystyrene plate was coated with either ICAM-1-, ICAM-2-, or ICAM-3-Fc bound to 
immobilized protein A. The plate was assembled in a parallel-plate laminar flow chamber (260-µm 
gap) and mounted on the stage of an inverted phase contrast microscope (Diaphot 300; Nikon, 
Tokyo, Japan). K562-DC-SIGN transfectants (100 to 200 cells per field of view) were introduced into 
the flow chamber for 1 min at a constant low shear flow (0.25 dyn/cm2) before being subjected to an 
incremental increase in shear stress. Shear flow was generated and controlled with an automated 
syringe pump (Harvard Apparatus, Natick, MA) attached to the outlet side of the flow chamber. The 
wall shear stress was increased step-wise every 5 s until it reached 10 dyn/cm2. At the end of each 5-
s interval at a particular shear stress, the number of cells that remained bound (stationary or rolling) 
was determined relative to the number of cells that had accumulated at low shear flow on the ICAM-
coated field. Cellular interactions were determined on two representative fields of view (each typically 
0.34 mm2 of area). Displacement velocities were determined only for persistently-rolling cells which 
remained adherent throughout the entire shear stress assay. 
 
Adhesion and transendothelial migration 
Heterotypic cell clustering of DCs with the endothelial HMEC-1 cell-line was performed as described 
previously for DC-T cell clustering (Geijtenbeek et al., 2000a). Briefly, HMEC-1 cells, cultured in 
MCDB131 medium (supplemented with 10% FCS), were labeled with the fluorescent dye 
hydroethidine. DCs were labeled with the fluorescent dye sulfofluorescein. The cells were incubated 
with or without blocking antibodies (20 µg/ml) at 37ºC. Heterotypic cell clustering was measured by 
flow cytometry. Transwell 24 well plate (8 µm pore) were coated with fibronectin (20 µg/ml; 1 h at 
37ºC). 40,000 HMEC-1 cells were seeded on the inserts and after 24 h the cells were activated with 
TNF-α (5 ng/ml) for 16 h. 200,000 DCs were added to the monolayer of endothelial HMEC-1 cells. The 
lower chamber contained 10 ng/ml SDF-1. After 20 h at 37ºC, the number of transmigrated DCs 
(lower chamber) was determined by flow cytometry. The transendothelial migration was measured in 
the presence of blocking antibodies (40 µg/ml). 
 
Isolation of DC-SIGN-positive cells from blood 
PBMC obtained from a buffy coat were depleted for CD3-, CD20- and CD56-positive cells with 
magnetic beads (Dynal, Oslo, Norway) according to standard procedures. The depleted cell fraction 
was incubated with FITC-conjugated anti-DC-SIGN Ab (AZN-D1) and the DC-SIGN-positive cells were 
sorted by flow cytometry with the Coulter Epics Elite (Coulter, Hialeah, FL). The sorted cell fraction 
was analyzed for the expression of DC-SIGN (AZN-D1), CD14 and CD83 (Immunotech, Fullertone, 
CA), CD80 (Becton Dickinson, Oxnard, CA), CD86 (BD Pharmingen, San Diego, CA), CD83 
(Immunotech, Marseille, France) MHC class I (W6/32), MHC class II (Q5/13), CD11b (KIM225), and 
CD11c (SHCL3) by three-color fluorescence staining using FITC-, PE- and Cy5PE-conjugated directly 
labeled antibodies. 
 
Immunohistochemical staining 
Cryosections (8 µm) of tissues were fixed in 100% aceton for 10 min, washed with PBS and incubated 
with the primary antibody 10 µg/ml for 60 min at 37ºC. After washing, the final staining was 
performed with the ABC-PO/ABC-AP Vectastain kit (Vector Laboratories, Burlingame, CA) according to 
the manufacturer’s protocol. Nuclear counterstaining was performed using hematoxylin. 
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RESULTS 
 
ICAM-2, a novel counterstructure for DC-SIGN 
Monocyte-derived immature DCs (Romani et al., 1994; Sallusto & Lanzavecchia, 1994) 
express high levels of DC-SIGN and moderate levels of LFA-1, the primary ICAM-2 receptor 
on leukocytes (Fig. 1A). Immature DCs strongly bind ICAM-2 comparable to our results for 
ICAM-3 (Geijtenbeek et al., 2000a) (Fig. 1B), as determined by the novel ICAM-Fc-coated 
fluorescent bead adhesion assay (Geijtenbeek et al., 2000a). Adhesion of DCs to ICAM-2 is 
completely mediated by the DC-specific C-type lectin DC-SIGN and not by LFA-1 (Fig. 1B) 
since antibodies to DC-SIGN inhibit the adhesion in contrast to antibodies to the β2-integrin 
chain (Fig. 1B) or the LFA-1 α-chain (results not shown). The interaction with ICAM-2 is also 
inhibited by either EGTA or mannan (Fig. 1B), indicating that the adhesion is mediated by 
the C-type lectin domain of DC-SIGN. Even after activation of LFA-1 on DCs with the 
stimulatory anti-β2 antibody KIM185, adhesion to ICAM-2 remains completely DC-SIGN-
specific (Fig. 1C). 
In order to determine the relative affinity of DC-SIGN for ICAM-2 without any contribution 
from LFA-1, we generated a stable DC-SIGN-positive transfectant from the LFA-1-negative 
cell-line K562 (Fig. 1A). This DC-SIGN-positive transfectant strongly binds to both ICAM-2 
and ICAM-3, but not to ICAM-1, and the binding is inhibited by either EGTA or mannan as 
was observed for DCs (Fig. 1D). The relative binding affinity of DC-SIGN for soluble ICAM-2 
(IC50 of 1 µg/ml) is higher than that of LFA-1 on the HSB T cell-line (IC50 of 8 µg/ml) (Fig. 
2A and B) demonstrating that DC-SIGN is the primary receptor for ICAM-2. Until now the 
primary receptor for ICAM-2 has been thought to be the β2 integrin LFA-1. Moreover the 
affinity of DC-SIGN for ICAM-2 (IC50 of 1 µg/ml) is higher than that for ICAM-3 (IC50 of 6 
µg/ml) (Fig. 2A). Similar to the binding of ICAM-3, the ICAM-2 interaction with DC-SIGN 
requires two Ca2+-ions as demonstrated by the second order Ca2+ ion-dependency (Fig. 2C) 
that is characteristic for C-type lectins (Drickamer, 1995; Geijtenbeek et al., 2000a). Thus, 
we have identified ICAM-2 as a novel endothelial counter structure for DC-SIGN. 
 
 
 
 
 
Figure 1. ICAM-2 is a novel endothelial counter structure for the DC-specific C-type lectin DC-SIGN. (A) 
Immature DCs express high levels of DC-SIGN (AZN-D1) and intermediate levels of LFA-1 (NKI-L7). K562-DC-
SIGN transfectants express high levels of DC-SIGN but no LFA-1. Transfectants were generated as previously 
described (Geijtenbeek et al., 2000b). Dotted line represents isotype control and filled histogram indicates specific 
antibody staining of gated population. (B) Immature DCs bind both ICAM-2 and ICAM-3 through DC-SIGN. Cells 
were allowed to bind ICAM-Fc-coated fluorescent beads for 30 min at 37°C. Adhesion was measured by flow 
cytometry. The adhesion was determined in the presence of either mannan (5 mM), EGTA (5 mM) or blocking 
antibodies to DC-SIGN (AZN-D1, 20 µg/ml) or β2 integrins (AZN-L19, 20 µg/ml). One representative experiment 
out of three is shown. (C) DC-SIGN is the major ICAM-2 receptor on immature DCs even after LFA-1 activation. 
LFA-1 on DCs was activated by the stimulatory anti-β2 Ab KIM185 and adhesion to both ICAM-1 and ICAM-2 was 
determined in the presence of either anti-DC-SIGN (AZN-D1) or anti-LFA-1 (NKI-L15) Ab, as described in Fig. 1B. 
One representative experiment out of two is shown. (D) DC-SIGN expressed by K562 transfectants bind to ICAM-
2 as well as to ICAM-3. Adhesion was determined as described in Fig. 1B. One representative experiment out of 
three is shown. 
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DC-SIGN mediates rolling on ICAM-2 
A prerequisite for vascular migration of circulating immune cells from blood into tissues is 
establishment of shear-resistant contacts with blood vessel walls for transmigration through 
their endothelial lining (Springer, 1994). We investigated whether the DC-SIGN/ICAM-2 
interaction enables DCs to establish these shear-resistant contacts under physiological flow 
conditions by using the laminar flow chamber system, since ICAM-2 is abundantly expressed 
by vascular endothelium. This system has been extensively used to investigate leukocyte 
rolling mediated by receptors such as the selectins (Lawrence & Springer, 1991; Alon et al., 
1997; Smith et al., 1999). We analyzed the adhesive properties of DC-SIGN-expressing K562 
transfectants under shear flow to surfaces coated with similar densities of either the vascular 
endothelial ligands ICAM-1 or ICAM-2, or the resting T cell ligand ICAM-3. No contribution of 
the β2 integrin ICAM receptors, such as LFA-1 or Mac-1 is possible since K562 cells do not 
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endogenously express β2 integrins. DC-SIGN interacts only with ICAM-2 under shear flow 
(Fig. 3A), although DC-SIGN supports adhesion to both ICAM-2 and ICAM-3 equally under 
static conditions (Fig. 1D). Both the frequency of cell tethers as well as their resistance to 
detachment by incrementally increasing shear forces was augmented on ICAM-2 in contrast 
to ICAM-3 (Fig. 3A). Tethering and rolling on ICAM-2 is DC-SIGN-specific, since antibodies to 
DC-SIGN inhibited the observed interactions (data not shown). DC-SIGN binding to ICAM-2, 
but not to ICAM-3, supported continuous rolling of DC-SIGN-expressing transfectants, 
reminiscent of selectin-mediated leukocyte rolling (Fig. 3B and C). Average rolling velocity of 
DC-SIGN-positive cells at 1.5 and 2.0 dyn/cm2 is 17.9±1.4 and 19.8±1.4 µm/s, respectively. 
Furthermore, DC-SIGN-expressing cells are recruited to the ICAM-2-coated surface, since the 
cells bound to ICAM-2 when introduced into the flow chamber under shear flow. ICAM-2 
serves as a rolling ligand only for DC-SIGN and not for LFA-1, as the binding of LFA-1-
expressing cells to ICAM-2 is abolished when shear stress was applied (data not shown), 
demonstrating that the DC-SIGN/ICAM-2 rolling interaction is a characteristic of the C-type 
lectin DC-SIGN and not of the integrin LFA-1. Thus, DC-SIGN enables DCs to interact with 
vascular endothelium under shear flow, a prerequisite for extravasation from blood into 
tissues. 
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Figure 2. DC-SIGN has a higher affinity 
for both ICAM-2 and ICAM-3 than LFA-1. 
(A) DC-SIGN has the highest affinity for 
ICAM-2, intermediate for ICAM-3 and 
does not bind ICAM-1. Adhesion of 
soluble ICAM-2-Fc and ICAM-3-Fc to 
K562-DC-SIGN transfectants was 
measured. Binding was analyzed by flow 
cytometry after staining with FITC-
conjugated anti-human Fc antibody. The 
expression level of DC-SIGN on K562 
cells is similar to the level of LFA-1 on 
HSB cells (data not shown). One 
representative experiment out of three is 
shown (SD<5%). (B) LFA-1 has a low 
affinity for both ICAM-2 and ICAM-3 and 
high affinity for ICAM-1. LFA-1 on HSB 
cells was activated by the stimulatory 
anti-β2 integrin KIM185 antibody (10 
µg/ml). The binding assay was 
performed similar as in Fig. 2A. One 
representative experiment out of three is 
shown (SD<5%). (C) DC-SIGN-mediated 
binding to both ICAM-2 and ICAM-3 is 
Ca2+-dependent and DC-SIGN has a 
slightly higher KCa for ICAM-2 (0.28 mM) 
than for ICAM-3 (0.22 mM). Adhesion 
was determined by the fluorescent bead 
adhesion assay at different Ca2+ 
concentrations. One representative 
experiment out of three is shown. 
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Figure 3. DC-SIGN mediates tethering to and rolling on ICAM-2 but not on ICAM-3 under physiological shear 
flow. (A) DC-SIGN mediates tethering to ICAM-2 but not to ICAM-3. All adhesions were confirmed to be DC-SIGN-
specific by blocking with the anti-DC-SIGN antibody AZN-D1. DC-SIGN-mediated tethering to ICAM-2 was 5% 
when the shear flow was increased to 10 dyn/cm2 (data not shown). One representative experiment out of three 
is shown. (B) DC-SIGN mediates rolling on ICAM-2 coated surfaces. Fractions of adherent K562-DC-SIGN cells 
that maintained steady rolling or were arrested on the ICAM substrate at the indicated shear stresses are 
depicted. The fractions were determined in two representative fields at shear stresses of 1.5 and 2.0 dyn/cm2. 
One representative experiment out of three is shown. (C) Displacement with time of individual DC-SIGN-
transfected cells rolling on ICAM-2 and subjected to incremental shear stresses at the indicated time points. One 
representative experiment out of two is shown. 
 
 
DC-SIGN mediates transendothelial migration of DCs 
We next investigated whether DC-SIGN is necessary for the endothelial transmigration of 
DCs. Both resting and Tumor Necrosis Factor (TNF)-α–activated endothelial cells express 
intermediate levels of ICAM-1 and high levels of ICAM-2 but no ICAM-3, whereas TNFα-
activation strongly upregulates both ICAM-1 and VCAM-1 expression (Fig. 4A). DC bind to 
resting endothelial cells through DC-SIGN, whereas binding to TNFα-activated endothelium is 
both DC-SIGN- and β1/β2 integrin-dependent (Fig. 4B) due to upregulation of the β1 and β2 
integrin ligands VCAM-1 and ICAM-1, respectively. 
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Subsequently we investigated the involvement of DC-SIGN in the endothelial transmigration 
of DCs. Members of the chemokine family, such as SDF-1, have been shown to direct specific 
transendothelial migration of DCs (Sallusto & Lanzavecchia, 1994; Banchereau & Steinman, 
1998; D'Amico et al., 1998; Delgado et al., 1998). In a physiological system, SDF-1 induced 
migration of DCs across both resting and TNFα-activated endothelium (Fig. 4C). DC-SIGN 
also mediated transmigration to other chemokines such as MIP-1α and Rantes (data not 
shown). Both spontaneous and SDF-1-induced migration across resting endothelium was 
predominantly mediated by DC-SIGN, whereas the contribution of the β1/β2 integrins was 
minimal (Fig. 4C). SDF-1-induced migration of DCs across TNFα-activated endothelium was 
strongly dependent on DC-SIGN (Fig. 4C), despite the elevated levels of integrin ligands on 
the TNFα-activated endothelium (Fig. 4A). The discrepancy between the relatively minor 
contribution of DC-SIGN to the static adhesion of DCs to endothelium, compared to the 
major contribution of DC-SIGN to the transendothelial migration of DCs (Fig. 4B and C) 
demonstrates that the transient, more dynamic interactions, provided by DC-SIGN, are 
essential for transendothelial migration. 
 
A C
β1/β2 integrins-specific
DC-SIGN- and integrin-independent
DC-SIGN-specific
Tr
an
sm
ig
ra
tio
n 
D
C
 (%
) Resting TNF-α
0
5
10
15
20
25
Medium SDF-1 Medium SDF-1
B
Time (min)
0
4
6
8
10
12
15 30 45 60
S
pe
ci
fic
 a
dh
es
io
n 
(%
) 14 Resting
2
β1/β2 integrin-specific
DC-SIGN-specific
15 30 45 60
TNF-α-activated
VCAM-1
Resting
TNF-α
ICAM-1 ICAM-2 ICAM-3
 
 
Figure 4. DC-SIGN mediates SDF-1 induced transmigration of DCs across both resting and TNFα-activated 
endothelium. (A) Expression levels of ICAM-1 (Rek-1), ICAM-2 (CBR-IC2/2) and VCAM-1 (4B9) on both resting 
and TNFα-activated endothelial HMEC-1 cells. (B) Adhesion of DCs to both resting and TNFα-activated 
endothelium is mediated by DC-SIGN. Adhesion specificity was determined in the presence of blocking anti-DC-
SIGN (AZN-D1; 20 µg/ml) or anti-β1/β2 integrin (AIIB2 and AZN-L19; 20 µg/ml) Ab at 37°C. One representative 
experiment out of 2 experiments is shown. (C) DC-SIGN mediates transmigration of DCs across both resting and 
TNFα-activated endothelium in response to a SDF-1 gradient. The transendothelial migration was measured in 
the presence of antibodies to DC-SIGN (AZN-D1 and AZN-D2; 40 µg/ml), VLA-4 integrin (HP2/1; 40 µg/ml) and 
β2 integrins (AZN-L19; 40 µg/ml). One representative experiment out of three is shown. 
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DC-SIGN-positive precursors are present in blood 
We next assessed the in vivo relevance of these interactions by immunohistochemistry. 
ICAM-2 is abundantly expressed on the endothelial linings of both vascular and lymphatic 
vessels in vivo (Fig. 5A), suggesting that ICAM-2/DC-SIGN interactions might play a role in 
the migration of DC-SIGN-positive blood precursors into peripheral tissues as well as of 
immature and mature DCs into lymphoid tissues. Indeed we found that in blood two DC-
SIGN-positive subpopulations, CD14+ and CD14-, were present (Fig. 5B). Both cell 
populations express high levels of MHC class I, MHC class II, CD11b and CD11c, 
intermediate levels of CD83 and CD86, and no CD80 (Fig. 5C). This together with the 
expression of DC-SIGN on immature DCs in the periphery (Geijtenbeek et al., 2000a) (Fig. 
5D), and on mature DCs in the lymphoid organs (Geijtenbeek et al., 2000a) (Fig. 5E), 
indicate that DC-SIGN/ICAM-2 interactions may regulate DC migration from blood into 
peripheral tissues and subsequently into lymphoid tissues. 
 
 
DISCUSSION 
 
DC-SIGN, a DC-specific adhesion receptor, and a Type II transmembrane mannose binding 
C-type lectin, regulates primary immune responses by establishing transient DC-T cell 
interactions through binding of the leukocyte counter structure ICAM-3 (Geijtenbeek et al., 
2000a). We now show that this novel DC-specific adhesion molecule recognizes with high 
affinity the endothelial counter-structure ICAM-2, also a well-known ligand of the β2 integrin 
LFA-1. In contrast DC-SIGN does not bind ICAM-1, the major ligand of LFA-1. Thus, DC-SIGN 
is the primary DC-specific receptor for both ICAM-2 and ICAM-3, even though DCs express 
LFA-1. Although DC-SIGN binds to both ICAM-2 and ICAM-3 under static conditions, under 
physiological flow conditions, only the DC-SIGN/ICAM-2 interaction resists shear stresses, 
allowing DC-SIGN-positive cells to tether to and roll along ICAM-2-coated surfaces. ICAM-2 
serves as a rolling counter receptor for DC-SIGN but not for LFA-1 (data not shown) 
indicating that only DC-SIGN but not LFA-1 functions as a rolling receptor. ICAM-2 is 
abundantly expressed on endothelial blood vessels (Nortamo et al., 1991), which would 
enable DC-SIGN-positive DCs to tether to and roll along vascular endothelium, a prerequisite 
for transendothelial migration into the peripheral tissues. DC-SIGN-mediated rolling on ICAM-
2 was observed over the entire range of physiological shear stresses reported to occur in 
post-capillary venules that are known to support leukocyte emigration (Heisig, 1968). Thus, 
DC-SIGN is a DC-specific rolling receptor and apart from the P-, E- and L-selectins 
(Vestweber & Blanks, 1999), the only other known adhesion molecules involved in general 
leukocyte tethering and rolling on vascular endothelium were the α4-integrins VLA-4 (α4β1), 
and α4β7 (Springer, 1994; Alon et al., 1995; Berlin et al., 1995). DC-SIGN contains a C-type 
lectin domain, similar to the selectins, indicating that this particular class of lectin domains is 
well-suited to mediate rolling. The interaction of DC-SIGN with ICAM-2 resisted shear stress 
whereas binding of DC-SIGN to ICAM-3 was abolished under similar conditions. DC-SIGN-
mediated binding to ICAM-3 in vivo does not need to resist shear forces since ICAM-3 is 
absent on endothelial cells and the DC-SIGN/ICAM-3 interaction mediates DC-T cell 
clustering in secondary lymphoid tissues, which are not exposed to shear forces. 
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Figure 5. DC-SIGN is expressed by DCs precursors in blood, immature DCs in skin and mature DCs in lymphoid 
tissues. (A) ICAM-2 is abundantly expressed on endothelial vascular (HEV) cells as well as lymphatic vessels in 
tonsils. Tissue sections of tonsil were stained for the expression of ICAM-2 (CBR-IC2/2). (B) Blood contains two 
DC-SIGN-positive cell populations which are CD14-positive (90%) and –negative (5%), respectively (ratios 
between CD14-positive and CD14-negative varies between blood donors from 20:1 to 3:1). The DC-SIGN-positive 
fraction, representing 0.04% of total PBMC, was isolated from CD3/CD20/CD56-depleted PBMC by positive flow 
cytometric cell-sorting after staining with FITC-conjugated anti-DC-SIGN Ab (AZN-D2). One representative 
experiment out of three is shown. (C) DC-SIGN-positive blood precursors express both antigen-presenting and 
co-stimulatory molecules. DC-SIGN-positive blood cells (Fig. 5B) were stained for the expression of different 
markers. (D-E). DC-SIGN is abundantly expressed by immature dermal DCs in the skin (D=dermal, 
ED=epidermal) (D) and by mature DCs in tonsils (G=germinal center, T=T cell area) (E). Tissue sections of tonsil 
were stained for the expression of DC-SIGN (AZN-D1). 
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Monocytes have been demonstrated to be precursors of DCs (Randolph et al., 1998a) and 
we have demonstrated that DC-SIGN is rapidly upregulated on monocytes in the presence of 
IL-4 and GM-CSF (Geijtenbeek et al., 2000a). Thus, DC-SIGN-upregulation by cytokine 
mediators may induce migration of precursor DCs from blood into the periphery. The 
presence of DC-SIGN-positive cells in blood further supports our model that under 
physiological circumstances DC-SIGN/ICAM-2 interactions mediate rolling along endothelial 
linings and transmigration of DCs into the periphery. The ICAM-2/DC-SIGN-mediated 
tethering to and rolling interactions along the blood vessels enable these cells to react swiftly 
to inflammatory chemoattractants that direct extravasation of DCs into peripheral tissues as 
demonstrated by the abundant expression of DC-SIGN on DCs present in these tissues 
(Geijtenbeek et al., 2000a) (Fig. 5D). Upon antigen challenge these immature DCs will 
mature and migrate to the lymphoid tissues (Fig. 5E) where ICAM-2 is abundantly expressed 
on the endothelial linings in both vascular and lymphatic vessels (Fig. 5A). Therefore these 
results demonstrate a central role for ICAM-2 in DC-specific migration from blood into 
periphery, inflamed or not inflamed, and subsequently of immature DCs via lymph into 
lymphatic tissues. 
Our findings emphasize the importance of DC-SIGN in the unique function of DCs, both in 
mediating naïve T cell interactions through ICAM-3, and as a rolling receptor that mediates 
the DC-specific ICAM-2-dependent migration processes. The fact that DC-SIGN functions as 
a novel HIV-1 trans-receptor important in the initial capture of HIV-1 at the periphery and 
transport by DCs into lymphoid tissues, again demonstrates that the unique migratory 
capacity of DCs can be exploited for dissemination of viruses such as HIV (Geijtenbeek et al., 
2000b). We have found that DC-SIGN is involved in the migratory capacity of both blood-
borne DC precursors and tissue DCs; this suggests that clinical strategies which target DC-
SIGN will be successful both in restricting HIV-1 dissemination and pathogenesis, and in 
directing the migration of DCs to manipulate appropriate immune responses in autoimmunity 
and tumorigenic situations. 
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ABSTRACT 
 
CD83 is an immunoglobulin (Ig) superfamily member that is upregulated during the 
maturation of dendritic cells (DCs). It has been widely used as a marker for mature DCs, but 
its function is still unknown. To approach its potential functional role, we have expressed the 
extracellular Ig domain of human CD83 (hCD83ext) as a soluble protein. Using this tool we 
could show that immature as well as mature DCs bind to CD83. Since CD83 binds a ligand 
also expressed on immature DCs, which do not express CD83, indicates that binding is not a 
homophilic interaction. In addition, we demonstrate that hCD83ext interferes with DC 
maturation downmodulating the expression of CD80 and CD83, while no phenotypical effects 
were observed on T cells. Finally, we show that hCD83ext inhibits DC-dependent allogeneic 
and peptide-specific T cell proliferation in a concentration dependent manner in vitro. This is 
the first report regarding functional aspects of CD83 and the binding of CD83 to DCs. 
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INTRODUCTION 
 
Dendritic cells (DCs) are the most potent APCs of the immune system. DC maturation, with 
its associated functional and phenotypic changes is crucial to this role. In their immature 
state, DCs reside in peripheral tissues. Upon antigen uptake and inflammatory and microbial 
stimuli, they start to migrate to the T cell areas of the peripheral lymph nodes, where as 
mature DCs, they express additional molecules that will lead to binding and stimulation of T 
cells, while losing their ability for antigen-capturing (Steinman, 1991; Banchereau & 
Steinman, 1998; Dieu et al., 1998). In this respect, CD83 is the best known marker for 
mature DCs. Human CD83 (hCD83) is a 45-kD glycoprotein and member of the Ig 
superfamily (Zhou et al., 1992; Kozlow et al., 1993). Recently, also the cloning and 
biochemical characterization of the murine CD83 (mCD83) has been reported (Twist et al., 
1998; Berchtold et al., 1999). mCD83 shares an amino acid identity of 63% with hCD83 
suggesting a possibly conserved function. 
The selective expression and upregulation together with costimulatory molecules like CD80 
and CD86 suggests an important role of CD83 in the immune response (Zhou et al., 1992; 
Weissman et al., 1995; Zhou & Tedder, 1995; Zhou & Tedder, 1996). Although the precise 
function of CD83 is still unknown (no inhibitory antibody exists), we have recently shown 
that by interfering with the translocation of mRNA encoding CD83 and thus inhibiting CD83 
protein synthesis, the T cell stimulation capacity of DCs was significantly reduced (Kruse et 
al., 2000a). In addition, we demonstrated a selective downregulation of the surface 
expression of CD83 after the infection of mature DCs with Herpes simplex virus type 1 and a 
reduced ability to stimulate allogeneic T cells in mixed leukocyte reactions (MLRs; Kruse et 
al., 2000b). These observations indicated, but did not prove a critical role for CD83. 
Here we report the recombinant expression and purification of the extracellular domain of 
the hCD83 (hCD83ext). Interestingly, hCD83ext completely abrogates the DC-mediated 
primary allostimulation of T-cells in vitro. Furthermore, also the capacity to stimulate antigen 
specific T cells was inhibited by this soluble molecule. This is the first report describing a 
functional role for CD83 which will contribute to a better understanding of the DC biology in 
general and will hopefully lead to the development of new therapeutic strategies. Finally, we 
show that CD83 binds to immature as well as mature DCs. 
 
 
MATERIALS AND METHODS 
 
Cloning of hCD83ext 
The extracellular domain of human CD83 (amino acids 23-128) was PCR-amplified using the following 
primers: sense- pGEX2ThCD83: 5`-TCCCC-CGGGAACGCCGGAGGTGAAGGTGGCT-3` and antisense- 
CD83extra: 5`-AATTAGAA-TTCTCAAATCTCCGCTCTGTATT-3`. The amplified fragment was subcloned 
into the SmaI and EcoRI sites of the expression vector pGEX2T (Amersham Pharmacia Biotech, 
Freiburg, Germany) resulting in the plasmid pGEX2ThCD83ext and transformed into the E.coli strain 
TOP10F` (Invitrogen, Groningen, The Netherlands). The correct insert was verified by sequencing.  
 
Expression and purification of hCD83ext 
The expression of hCD83ext was induced in Escherichia coli as described previously (Berchtold et al., 
1999). Briefly, the cells were then pelleted and resuspended in 10ml native buffer (140 mM NaCl, 2.7 
mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 2.6 mM MnCl, 26 mM MgCl2, 1µg/ml leupeptin, 1µg/ml 
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aprotinin, 1µg/ml DNAseI, pH 7.6) per 500 ml culture. 50 µg/ml lysozyme was also added. After 15-
min incubation on ice the lysate was spun at 20,000 g. Protein purification: capture step: 40 ml 
supernatant were added to a GSTrap 5 ml column on an ÄKTA Explorer 10 system (Amersham 
Pharmacia Biotech). Binding buffer: PBS (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4, pH 7.6). Elution buffer: 50 mM Tris-HCl, pH 8.0, with 5 mM reduced glutathione. Flow rate: 5 
ml/min. Chromatographic procedure: 4CV (column volumes) binding buffer, 40 ml supernatant, 12CV 
binding buffer, 5CV elution buffer, 5CV 2N NaCl/PBS, pH 7.6, 5CV binding buffer. Intermediate 
purification steps: The GST-hCD83ext. containing elutions were dialysed against 50 mM 1-methyl-
piperazine, 50 mM Bis-Tris , 25 mM Tris pH 9.5 (buffer A), and loaded onto source 15Q PE 4.6/100 
anion exchange column on a ÄKTA Explorer 10 system. Proteins were separated by three different 
linear salt gradients: 16CV to target concentration 10% bufferB (buffer A/1N NaCl). 20CV to target 
concentration 50% buffer B. 10CV to target concentration 100% Buffer B. The GST-hCD83ext. 
containing elutions were dialysed against PBS pH 7.6. Then the GST-hCD83ext. fusion protein was 
incubated with Thrombin 20 U/ml at 22°C for 16h. To separate the hCD83ext protein from GST the 
elution was loaded onto prepacked glutathion sepharose 4B columns using the capture step buffer 
conditions. Under binding buffer conditions the flow through containing recombinant human CD83ext 
protein was collected. Polishing Step: finally a preparative gel filtration separation was performed 
loading the flow through onto a Superdex 75 (26/16) prep grade column on an ÄKTA Explorer 10 
system, running buffer PBS, pH 7.6, flow rate 3 ml/min. The GST protein was used as a negative 
control in functional analyses. 
 
Expression and purification of recombinant CD83-Fc-fusion protein 
CD83-Fc was constructed by fusing the extracellular domain of CD83 with the Fc part of human IgG1. 
A PCR product of the extracellular domain of CD83 was amplified using Pfu polymerase (Promega, 
Mannheim, Germany). The CD83 sense primer contains a XhoI restriction site (5’-
GCGGGGCTCGAGGCCACCATGTCGCGCGGCCTCCAGCTTCTGC) and the antisense primer a BglII 
restriction site (5’-CCCCGGAGATCTGCAGGGCATCCTGTCACTCTCA). PCR conditions were as follows: 
2min 94°C; 35x (1 min 94°C, 1 min 56°C, 1 min 72°C); 10 min 72°C. The PCR product was purified 
using a PCR purification kit (Qiagen, Hilden, Germany). After digestion with XhoI and BglII the PCR 
product was cloned into the XhoI and BamHI sites of the pCDM7 vector (a gift from Dr. Kolanus, 
Genecenter, Munich, Germany) containing the Fc part of IgG1 and transformed into MC1061P3 
bacteria. The construct was sequenced in order to exclude possible mutations (Sequiserve, 
Vaterstetten, Germany). 293-T cells, cultured in DMEM medium (Life Technologies, Karlsruhe, 
Germany) supplemented with 2 mM L-glutamine (Life Technologies), 100 U/ml penicillin/streptomycin 
(Life Technologies), 1 mM sodium-pyruvat (Life Technologies) and 10% FBS (Dynacyte, Heidelberg, 
Germany), were transiently transfected with CDM7/CD83-Fc using LipofectAMINE™ reagent and 
OPTIMEM 1 medium (Life Technologies). 293-T cells were cultured 10 days in serum free medium 
(293 SFMII; Life Technologies). Secretion of recombinant CD83-Fc protein into the supernatant was 
verified by Western Blot analysis. The CD83-Fc fusion protein was purified by protein A-Sepharose 
affinity chromatography (Amersham Pharmacia Biotech, Freiburg, Germany). 
 
Production of mAbs against human CD83 
~ 50 µg of the hCD83ext-GST fusion protein were injected intraperitoneally and subcutaneously into 
LOU/C rats. After a two month interval a final boost with the antigen was given intraperitoneally and 
subcutaneously three days before fusion. Fusion of the myeloma cell line P3X63-Ag8.653 with the rat 
immune spleen cells was performed according to standard procedure. Hybridoma supernatants were 
tested in a solid-phase immuno assay using the hCD83ext-GST protein adsorbed to polystyrene 
microtiter plates. After incubation with culture supernatants for 1 h, bound mAbs were detected with 
peroxidase-labelled goat anti-rat IgG plus IgM antibodies (Dianova, Hamburg, Germany) and O-
phenylenediamine as chromogen in the peroxidase reaction. An irrelevant GST-fusion protein served 
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as a negative control. Ig type of the monoclonal antibodies was determined using biotinylated anti-rat 
IgG subclass-specific monoclonal antibodies (American Type Culture Collection, Rockville, MA, USA). 
CD83-1G11 (rat IgG1) and CD83-4B5 (rat IgG2a) were used for Western blot analysis and FACS® 
analysis. Both detected specifically human CD83. Functional studies revealed that, like the 
commercially available anti-CD83 antibodies, these antibodies had no inhibitory activity. 
 
Immunoblotting analyses 
Western blot analyses of purified protein was performed as described previously (Kruse et al., 2000a) 
using monoclonal anti-CD83 antibodies (CD83-1G11; CD83-4B5 both described in this paper; and anti-
CD83 from Immunotech, Marseilles, France).  
 
1-D NMR studies 
1-D NMR studies were recorded with a sample of the hCD83ext using a Bruker AM 400 spectrometer 
at a temperature of 300K as described previously (Berchtold et al., 1999). 
 
Generation of Dendritic Cells 
DCs were generated from PBMCs in the presence of GM-CSF and IL-4 as described previously (Kruse 
et al., 2000a). For the final DC maturation the medium containing 1% human plasma, GM-CSF and IL-
4 was supplemented with IL-1β (1 ng/ml), TNFα (1.25 ng/ml), and prostaglandin E2 (0.5 mg/ml) 
(maturation mix). 
 
Plate adhesion assay 
A 96-well flat-bottom plat (Maxi Sorp, Nunc, Roskilde, Denmark) was precoated with 50 µl goat anti-
human Fc-specific F(ab`)2 (4 µg/ml, Jackson Immuno Research Laboratories, Inc, West Cove, PA, 
USA) or with 50 µl rat anti-human GST (1 µg/ml) for 1 h at 37°C and blocked with 1% BSA in Tris-
sodium buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM CaCl2, 2 mM MgCl2) for 30 min at 37°C. 
Subsequently, the plate was incubated with 500 ng/ml intercellular adhesion molecule (ICAM)-1-Fc 
(13), 500 ng/ml CD83-Fc. 40,000 cells/well were labeled in PBS with Calcein-AM (25 µg/107 cells per 
milliliter; Molecular Probes, Eugene, OR, USA) for 30 min at 37°C. Labeled cells were washed and 
preincubated for 10 min with different concentrations of recombinant hCD83ext or medium at RT. 
Cells were allowed to adhere for 45 min at 37°C. Adherent cells were lysed with 100 µl lysis buffer (50 
mM Tris, 0.1% SDS), and the fluorescence was quantified using a Cytofluor II (Perseptive Biosystems, 
Farmingham, MA, USA) or a Victor (Wallac, Turku, Finland) fluorometer. Results are expressed as the 
mean percentage of cells binding from triplicate wells. 
 
Coating of beads with CD83-Fc 
Streptavidin-coated TransFluoSpheres (488/645 nm; 1,8 µm; Molecular Probes, Leiden, The 
Netherlands) were generated as described previously (Geijtenbeek et al., 1999). The streptavidin-
coated beads (15 µl) were incubated with biotinylated goat anti-human anti-Fc F(ab`)2 fragments (33 
µg/ml) in 0.3 ml PBS, 0.5%BSA for 2 h at 37°C. The beads were washed once with PBS, 0.5% BSA, 
and incubated with CD83-Fc (500 ng/ml) in 500 µl PBS, 0.5% BSA overnight at 4°C. The binding 
efficiency was determined by FACS® analysis. 
 
Flow cytometric analysis 
Phenotypic analysis of cells or beads were performed by flow cytometry using saturating 
concentrations of the following mAbs: CD83 (CD83-1G11; CD83-4B5 both described in this paper and 
anti-CD83 from Immunotech, Marseille, France); CD80 (Immunotech); CD14 and CD86, MHC-I 
(Dianova, Hamburg, Germany); CD3 (Bio Research, Kaumberg, Austria), CD4, CD8, CD45RO, and 
CD45RA (Dako, Glostrup, Denmark). The isotype controls IgG1a, IgG2a, and IgG2b (Becton 
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Dickinson, Heidelberg, Germany) were run in parallel. Cells were analyzed on a FACScanTM (Becton 
Dickinson). Nonviable cells were gated out on the basis of their light scatter properties. 
 
Allogenic T cell proliferation 
Human PBMCs were isolated from buffy coats and the T cell fraction was purified by rosetting with 
neuramidase-treated sheep RBCs as described by Bender et al. (Bender et al., 1996). The CD4- and 
CD8-positive T cells were stimulated at different ratios with mature allogeneic DCs. DCs were treated 
with different concentrations of hCD83ext. GST or BSA was used as negative control (Bio-Rad 
Laboratories, Munich, Germany). CD83-Fc coated beads were also used for inhibitory studies. In these 
experiments uncoated beads were used as negative control. T cell proliferation was determined as 
described previously (Kruse et al., 2000a). 
 
Enzyme-linked immunospot assay 
Assessment of the IFN-γ production by the influenza matrix peptide M1 specific CTL clone (C9) was 
performed as described previously (Strobel et al., 2000). The HLA-A2.1 restricted M1 peptide 
(GILGFVFTL, amino acids 58-66) was used at a concentration of 10 µM. The number of spots forming 
cells was counted with a video imaging analysis system (Carl Zeiss Vision, Eching, Germany), using 
the KS enzyme-linked immunospot assay (ELISPOT) software version 4.1.143.  
 
 
RESULTS 
 
Recombinant protein expression 
The extracellular domain of hCD83 (hCD83ext) was expressed in E.coli as a glutathione S-
transferase (GST) fusion protein in sufficient quantities. For functional studies the fusion 
protein was cleaved by thrombin and only the hCD83ext was used, whereas GST served as a 
negative control. The correct expression of the protein was analyzed by silver staining and 
Western blot analysis (Fig. 1A and B). 
 
 
 
Figure 1. Biophysical analyses of recombinant hCD83ext. (A) hCD83ext was separated by SDS-PAGE and silver 
stained. (B) Western blot analysis of the blotted hCD83ext using monoclonal anti-CD83 antibodies and (C) one-
dimensional NMR spectrum, showing that hCD83ext is folded. 
 
A 
B 
C 
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Amino-terminal amino acid sequencing analyses further confirmed the correct identity of the 
purified protein (data not shown). To determine whether or not the recombinant protein was 
correctly folded, one-dimensional NMR studies were performed. The 1-D NMR spectrum of 
hCD83ext at 300K showed chemical dispersion typical of a structured protein (Fig. 1C). The 
presence of slowly exchanging amide resonances (~7-9 ppm) indicates that certain parts of 
the protein backbone are protected from solvent. Downfield-shifted a-CH resonances (~4.5-
5.7 ppm) are indicative of β-structures. Upfield-shifted methyl resonances (s < 0.9 ppm) 
provide further evidence of the protein being folded. These NMR data strongly support that 
the recombinant expressed hCD83ext is structurally folded and relevant functional studies 
can be performed using this protein. 
 
Human CD83 binds to immature and mature DCs 
To establish the cell surface binding of human CD83 a standard plate adhesion assay was 
employed. As shown in Fig. 2 immature day 4 DCs as well as mature day 7-8 DCs (Fig. 2A 
and B, respectively) bind to human CD83. This binding could be inhibited in a concentration-
dependent manner by the recombinant expressed extracellular domain of CD83 (hCD83ext). 
Binding to ICAM-1-Fc as a control could not be inhibited by hCD83ext. Uncoupled GST 
served as a negative control. The binding of ICAM-1 and GST was not specifically influenced 
by hCD83ext. In addition, as shown in Fig. 2C, binding of DCs to CD83 is concentration 
dependent. The specific binding was lost when decreasing amounts of CD83-Fc were used 
(Fig. 2C). 
Figure 2. Plate adhesion assay. ICAM-Fc and hCD83-Fc 
were bound to goat anti-human Fc-specific F(ab’)2 
precoated plates. Calcein-AM labeled DCs (40,000) were 
allowed to adhere for 45 min at 37°C. Fluorescence of 
adherent cells was quantified using fluorometric 
analyses. Clearly, immature (A) as well as mature (B) 
DCs bind to CD83. Preincubation of labeled DCs with 
recombinant hCD83ext inhibited the binding of the 
immature and mature DCs to plate-bound CD83-Fc. The 
binding could be inhibited in a concentration-dependent 
manner (5 and 20 mg/ml hCD83ext). Binding to ICAM-
1-Fc as a control could not be inhibited by hCD83ext, 
while GST  alone  was used as  a negative  control. Both 
were not specifically influenced by the addition of 
hCD83ext. In addition the binding of DCs to CD83 was 
concentration dependent (C). The binding was lost 
when decreasing amounts of CD83-Fc were used. In these experiments, Ig coated via goat anti-human-Fc, was 
used as negative control. The Ig binding was not influenced by hCD83ext. These experiments were performed 
five times using different donors for DC generation. This represents a typical experiment. 
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Interestingly, we could not demonstrate binding of naïve CD4+ or CD8+ T cells to CD83 (data 
not shown). From these data we conclude that immature and mature DCs bind specifically to 
CD83 and that the recombinant prokaryotic expressed hCD83ext could be used for further 
functional studies, indicating that glycosilation is not necessary. Furthermore, the fact that 
immature DC, which do not express CD83, also bind to CD83 implies that there is no 
homophilic interaction between CD83 molecules. Therefore, it is most likely a heterophilic 
binding reaction. 
 
hCD83ext induces downmodulation of specific molecules on DCs  
To analyze the influence of hCD83ext on the phenotype of DCs, FACS® analyses were 
performed on day 8 (Fig. 3). DCs can be fully matured with the use of a specific maturation 
cocktail composed of IL-1β, TNFα and PGE2. Interestingly, when this maturation cocktail was 
administered to immature DCs on day 5 together with hCD83ext (4 µg/ml) and left until the 
final FACS® analyses on day 8, these cells revealed a clear reduction in CD80 (from 96% to 
66%) and CD83 cell surface expression (96-30%), when compared with normally matured 
DCS (compare Fig. 3A with C). Thus, hCD83ext induces a reduction in DC maturation (see 
also increase of CD14-positive cells). In contrast, mature DCs, which where incubated with 
hCD83 for 24 h on day 7 and analyzed on day 8, showed only a minimal influence on CD80 
expression (96-92%), while CD83 expression was also reduced (96-66%) (compare Fig. 3A 
with B). Interestingly, CD86 expression was not influenced at any time point by the 
administration of hCD83ext. Also MHC class I and II expression was not affected, neither in 
immature nor in mature DCs. Noteworthy, no significant phenotypical changes could be 
observed within T cell populations by the addition of hCD83ext (data not shown), indicating 
that CD83 affects primarily DCs. 
 
Figure 3. FACS® analyses of DCs. (A) Immature DCs were matured in the presence of the maturation cocktail 
from day 5-8 (= mock control for mature DC). (B) Immature DCs were matured in the presence of the maturation 
cocktail (day 5-8) and on day 7 hCD83ext was added for 24 h. (C) Immature DCs were incubated in the presence 
of the maturation cocktail in combination with hCD83 from day 5-8. On day 8 cells were washed and stained with 
the indicated antibodies and analyzed by FACS®. 
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hCD83ext inhibits allogeneic T cell proliferation 
MLRs are a simple, yet very powerful tool to analyze the T cell stimulatory capacity of DCs. A 
typical feature of these MLR-assays is the formation of large DC-T cell clusters. Addition of 
hCD83ext at day 1 strongly inhibited the typical cell cluster formation of DCs and 
proliferating T cells, whereas GST had no influence (data not shown). As shown in Fig. 4A 
hCD83ext strongly inhibited [3H]thymidine incorporation in a dose-dependent manner. GST, 
which was expressed and purified in the same way as hCD83ext, was used as negative 
control and had, like BSA, no influence on T cell proliferation. Also the CD83-Fc molecule 
(expressed in a eukaryotic system) coupled to beads inhibited T-cell proliferation (Fig. 4B). 
These findings indicate again that CD83-glycosylation is not a prerequisite, since the 
prokaryotic expressed hCD83ext also inhibits T cell proliferation. 
 
 
 
To prove that the inhibitory effects of hCD83ext are not due to cytotoxic effects, day 5 DCs 
were incubated for 24 h with 5 µg/ml hCD83ext together with the final maturation mix. 
Then, hCD83ext was washed out, new maturation mix was added and the allostimulatory 
capacity of these cells was determined. Interestingly, T cell proliferation was not inhibited 
when hCD83ext has been washed out (data not shown). These data clearly show that 
hCD83ext is not cytotoxic and indicate that CD83ext must be present during the experiment 
to exhibit its inhibitory function. 
 
CA 
B Figure 4. hCD83ext inhibits allogeneic T cell proliferation. (A) MLR analyses: the prokaryotic 
expressed hCD83ext reduced T cell proliferation in a 
dose-dependent manner. GST, which was purified in 
the same way as hCD83ext and BSA (each 5 µg/ml) 
were used as controls. (B) Also the eukaryotic 
expressed CD83-Fc fusion protein coupled to beads 
inhibits T cell proliferation. Uncoupled beads alone 
were used as a negative control and hCD83ext as a 
positive control. (C) The inhibition is not due to a 
contamination: to prove that the purified hCD83ext 
protein was responsible for  the inhibitory  activity 
and   not  a  possible  contamination   present in  the
protein preparation, purified hCD83ext was filtered using a 10-kD Microcon system. Filtered and unfiltered 
hCD83ext exhibit comparable inhibitory effects, whereas cells which were treated with the filtrate alone showed 
no inhibition and the stimulation was comparable to mock treated cells. All experiments were performed at least 
three times. Data presented here represent a typical experiment. 
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To further demonstrate that the purified protein itself was responsible for the inhibitory 
activity and not a possible contamination present in the protein preparation, purified 
hCD83ext was filtered using a 10-kD Microcon system. Then, the filtered protein as well as 
the filtrate were tested (Fig. 4C). These experiments clearly show that the filtered hCD83ext 
protein was responsible for the inhibitory effects, while the filtrate had no influence on the T 
cell proliferation.  
To demonstrate that hCD83ext had no toxic effects on T cell level, cell viability was 
determined using the trypan blue exclusion method. T cells were incubated with hCD83ext (4 
µg/ml) for 4 days and compared with control cells (incubated with 4 µg/ml BSA). No 
significant decrease in T cell viability, after incubation with inhibitory concentrations of 
hCD83ext were detected (data not shown). Therefore, T cell death seems not responsible for 
the reduced proliferation. 
 
hCD83 inhibits proliferation of influenza virus specific CTL 
The ELISPOT assay is a very useful tool to analyze DC-mediated proliferation of specific 
CTLs, assessing the cytokine release at a single cell level. Furthermore, it can also be used 
for direct ex vivo quantification of peptide-reactive T cell responses. In this study we used 
the influenza matrix peptide M1 specific CTL clone C9 (Bednarek et al., 1991). HLA-A2.1 
positive DCs were incubated with the M1-peptide and then cocultivated with different 
numbers of CTLs. A computer-assisted video image analysis system was used for the 
evaluation of the experiments (Herr et al., 1997). Again, increasing amounts of hCD83ext 
resulted in a clear reduction of CTL specific responses (Fig. 5), indicating that the interaction 
between DCs and peptide specific T cells is inhibited. 
 
 
 
Figure 5. hCD83ext inhibits proliferation of influenza matrix peptide M1-specific CTL clone. DCs were loaded with 
influenza matrix peptide M1 and used to assess the stimulation (IFN-γ production) of the M1-specific CTL clone 
C9. Number of IFN-γ-producing spot are shown on the y-axis. Increasing concentrations of hCD83ext clearly 
reduced the number of spot forming cells. GST, which was purified in the same way as hCD83ext was used a 
negative control. Three independent experiments were performed. The data presented represent a typical 
experiment. 
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Secondary stimulation of hCD83ext treated T cells  
To investigate whether or not the proliferation arrest of hCD83ext treated T cells can be 
overcome, cells from the primary MLRs, which have been either incubated with or without 
hCD83ext, were stimulated for a second time period of 4 days without the addition of 
hCD83ext. For this, half of the medium was discharged and new medium containing IL-2 at a 
final concentration of 500 U/ml or without IL-2 was added to the cultures. After an additional 
incubation of 3 days, cells were pulsed and T cell proliferation was determined (Fig. 6A). 
Interestingly, T cells which were strongly inhibited by hCD83ext in the primary MLRs could 
be restimulated with IL-2. The proliferation was comparable to that obtained by untreated 
cells in the primary MLRs. These data clearly show that the proliferation arrest in T cells, 
caused by hCD83ext, is not due to an irreversible toxic effect. In fact proliferation can be 
restored using IL-2. Furthermore, to investigate this phenomenon in a more physiological 
setting, T cells which were inhibited with hCD83ext in the primary MLRs, were restimulated 
with allogeneic DCs,  instead of IL-2 (Fig. 6B). Again, arrested T cells could be restimulated 
with DCs, reaching stimulation levels comparable to those obtained with untreated cells in 
primary MLRs. Thus the inhibitory effect of hCD83ext is reversible and is not mediated via T 
cell anergy. 
 
 
 
 
 
A 
B 
Figure 6. Proliferation arrest of 
hCD83ext treated T cells can be 
restored. (A) hCD83ext-treated T 
cells derived from the primary MLRs, 
which have been either treated with 
or without hCD83ext, were stimulated 
for a second time period of 4 days 
without the addition of hCD83ext. 
Medium containing IL-2 or medium 
without IL-2 was added to the 
cultures. After a 3-days incubation 
period proliferation was determined. 
T cells which were strongly inhibited 
by hCD83ext in the primary MLRs 
could be restimulated with IL-2, 
clearly showing that the proliferation 
arrest, caused by hCD83ext in the 
primary MLRs, is not due to an 
irreversible toxic effect. (B) T cells 
which were inhibited with hCD83ext 
(4 µg/ml) in the primary MLRs (ratio 
DC:T cell = 1:20) , were restimulated 
with allogeneic DC (ratio 1:20). 
Arrested T cells could be restimulated 
with DCs, reaching stimulation levels 
comparable to those obtained with 
untreated cells in primary MLRs. 
Thus, the inhibitory function of 
hCD83ext is reversible. Experiments 
were performed at least three times. 
The data presented here represent a 
typical experiment. 
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DISCUSSION 
 
DCs act as nature’s adjuvant in inducing T cell-mediated immunity. To understand the 
biological properties of DCs it is vital to gain further knowledge regarding the role of DC-
specific proteins on a molecular level. Here, we provide for the first time evidence that CD83, 
the best known cell surface marker for mature DCs, has also a biological function. During DC 
maturation CD83 is rapidly upregulated together with the costimulatory molecules CD80 and 
CD86. These molecules provide the so-called second signal for the T cell activation 
(Schwartz, 1992). Multiple studies have shown that allostimulation can be prevented by 
blocking the CD28-mediated costimulatory signals using either anti-CD80/CD86 mAbs or the 
fusion protein CTLA4Ig (Boussiotis et al., 1994; Lenschow et al., 1995; Akalin et al., 1996; 
Larsen et al., 1996; Newell et al., 1999). As a result this blockage of signal two leads to T 
cell anergy.  
Although CD83 is strongly upregulated on mature DCs the function of this molecule has been 
unknown to date. To elucidate the mode of action of CD83 the extracellular Ig domain of 
human CD83 was expressed as a recombinant protein and used for functional studies in 
vitro. 1D-NMR data strongly support that the recombinant hCD83ext is correctly folded and 
therefore the suppressive effects observed in the T cell assays are due to a functionally 
active molecule. In addition, a CD83-Fc molecule, expressed in a eukaryotic system was 
used. 
Using plate adhesion analyses we could show for the first time that immature and mature 
DCs bind to CD83. The specificity of the CD83-binding to DCs could be demonstrated by the 
fact that the soluble extracellular hCD83ext domain inhibited the binding in a concentration-
dependent manner (Fig. 2 A-C). Furthermore, the binding of DCs to CD83 itself is also 
concentration dependent. The binding was lost when decreasing amounts of CD83 were 
used (Fig. 2C). These findings are highly relevant for several aspects: (i) since hCD83ext, 
which was expressed in a prokaryotic system, inhibits the binding of the eukaryotic 
expressed CD83-Fc underlines the fact that glycosilation is not necessary for CD83 binding to 
its ligand; (ii) the prokaryotic expressed hCD83ext protein is functionally active; (iii) the fact 
that CD83 binds also to immature DCs, which do not express CD83, indicates that there is no 
homophilic interaction between CD83 molecules. These findings rather suggest the existence 
of a heterophilic binding.  
Interestingly, immature DCs which were incubated with soluble hCD83ext could not be fully 
matured anymore. Even in the presence of the potent maturation cocktail composed of IL-
1β, TNFα, and PGE2 the maturation was blocked. hCD83ext treatment lead to the specific 
downmodulation of CD80, a crucial costimulatory molecule and of CD83 itself. This suggests 
that soluble hCD83ext induces a maturation block, which could be a regulatory mechanism in 
order to control immune responses. In this respect it is very interesting to know that a 
soluble form of CD83, like described for CD86 (Jeannin et al., 2000), has been characterized 
in vivo and is detectable in normal human sera and is released from activated DC and B-cells 
(Hock et al., 2001), underlying a possible important role in the regulation of immune 
responses. In addition, also mature DCs downmodulate CD83 from their cell surface when 
incubated with hCD83ext, indicating a regulatory mechanism also on mature DCs. The 
soluble molecule may either work by delivering a negative signal or blocking a positive signal 
that might be generated by interactions of maturing DCs. However, this hypothesis has to be 
proven in an experimental setting. 
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Furthermore, when mature DCs were incubated with soluble hCD83ext they completely lost 
their ability to stimulate allogeneic T cell responses. In addition, also CTL specific T cell 
responses were inhibited by hCD83ext. Again, the existence of a soluble form of CD83 in 
vivo (Hock et al., 2001) is an additional support of our data regarding the inhibitory effects 
of hCD83ext.  
Noteworthy, these effects are not due to cytotoxic effects on T cells. We demonstrate that T 
cells can be restimulated either with IL-2 or with allogeneic DC. This represents a novel 
mechanism which is not connected to T cell anergy, induced by the inhibition of the B7-CD28 
costimulatory pathway (Boussiotis et al., 1994). Since the inhibition mediated by hCD83ext is 
a competitive inhibition, hCD83ext has to be present throughout the experiment. Dilution of 
the hCD83ext concentration with medium alone allowed already the restimulation of T cells. 
Also the number of APCs is crucial. High numbers of DCs can only be blocked with 
correspondingly higher hCD83ext concentrations.  
Considering recent results, it becomes clear that CD83 plays an important role in DC biology. 
Previously, we could show that inhibition of CD83 expression, by interfering with a specific 
RNA export pathway, leads to a clear reduction of DC-mediated T cell stimulation (Kruse et 
al., 2000a). An additional indication, pointing towards the biological importance of CD83 is 
the fact that several viruses including herpes simplex virus type 1 and poxviruses 
downregulate CD83 (Kruse et al., 2000; Jenne et al., 2000b). Interestingly, these virus 
infected DCs are also inhibited in their allostimulatory capacity (Salio et al., 1999; 
Engelmayer et al., 1999; Kruse et al., 2000b; Jenne et al., 2000; Drillien et al., 2000). 
Nevertheless, regarding the biological function of CD83, these reports provided only 
circumstantial evidence. 
In contrast, here we report the identification of CD83 binding to DC and the characterization 
of a reversible inhibitor of DC mediated T cell stimulation, representing a new tool to explore 
DC biology and new therapeutic strategies. Future studies including the use of k.o. mice will 
help to elucidate the biological role of CD83 even in more detail. Further characterizations 
are also needed regarding the CD83 structure and the characterization of the ligand(s) 
present on DCs.  
 
 
ACKNOWLEDGMENTS 
 
We would like to thank Ralph Steinman and Manfred Lutz for suggestions and critical reading 
of the manuscript. We are grateful to Kristian Schweimer for performing the MNR analyses. 
This work was supported by the Deutsche Forschungsgemeinschaft (SFB466 - Grant B5). 
Matthias Lechmann is supported by the Else Kröner-Fresenius-Stiftung. Daniëlle 
J.E.B. Krooshoop is supported by The Netherlands Heart Foundation (NHS grant 96-150). 
  
  
 
  
 
 
Chapter 
 
 
 
Discussion 
 
 
 
 
 
 
 
 
 
 
 
  
 
Discussion 
105 
GENERAL DISCUSSION AND FUTURE DIRECTIONS 
 
Migration plays a crucial role in the lifespan of Dendritic Cells (DCs) and T cells. The 
migration of immature DCs and activated T cells into peripheral tissues and of mature DCs 
and naïve T cells into the lymph nodes is essential to elicit a proper immune response. The 
migration processes are very dynamic and modulated by chemokines. In addition, they 
require a continuous attachment and detachment of cells, tightly regulated by adhesion 
receptors and cytoskeletal constraints. In this chapter, the role of integrins and other 
adhesion receptors, like DC-SIGN and CD83 in DC adhesion and migration will be discussed. 
It will become clear that the regulated expression of DC-SIGN on DCs and integrins on DCs 
and T cells, the activation state of the adhesion molecules, the cytoskeletal constraint, and 
the maturation state of the cells determine the adhesive and migratory properties of the 
cells. 
 
 
INTEGRINS 
 
β1 integrins are involved in the interaction of immature as well as mature DCs with 
fibronectin. Whereas both DC-subtypes do express the α4 chain, they preferentially adhere 
to fibronectin through α5β1 (chapters 3 and 4). Most likely, the α5β1 molecule is more 
active than the α4β1 integrin on DCs and different cytoskeletal target molecules might be 
associated with the α5β1 than with the α4β1 integrin. The difference in receptor usage 
might be cell type dependent. Jancic and colleagues also show an α5β1-mediated adhesion 
of DCs to fibronectin. However, their human monocyte-derived DCs do not express α4 
(Jancic et al., 1998). Binding of DCs to a natural extracellular matrix produced by endothelial 
cells involves both α4β1 and α5β1 (Bianchi et al., 2000). Adhesion and migration studies on 
fibronectin performed with other leukocytes also show a cell type dependent usage of either 
α4β1, α5β1, or of both α4β1 and α5β1 (Gismondi et al., 1991; Hauzenberger et al., 1994; 
Hauzenberger et al., 1995; Crisa et al., 1996; Peled et al., 2000).  
I observed that a higher percentage of immature DCs versus mature DCs binds to 
fibronectin. Moreover, adhesion of mature DCs, but not of immature DCs to fibronectin can 
be induced by a β1-activating antibody (chapter 4). Since no difference in β1 expression was 
observed, either a change in activation state of the molecule or a change in cell surface 
distribution of β1 accounts for this difference. Interestingly, the expression of the β1 
activation epitope was reduced on mature DCs (chapter 4), indicating that the activation 
state of the α5β1 molecule determines the difference in adhesive and migratory behavior 
between both DC subtypes. The effect of the integrin activation state on adhesion and 
migration is also underscored in chapter 2, in which αLβ2 activation by the β2-activating 
antibody KIM185 resulted in an increased adhesion of HSB-2 T cells and as a result a 
decreased migration on ICAM-1 coatings. Moreover, I showed that ligand concentrations 
were critical in these processes; whereas adhesion increased with enhanced ligand 
concentration, only intermediate ligand concentrations did facilitate migration. Similar 
findings are observed by Palecek and colleagues, who showed that cells expressing α5β1 or 
αIIbβ3 have a biphasic migration pattern on fibronectin and fibrinogen respectively (Palecek 
et al., 1997). 
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Signaling is required to modulate integrin activity. Both the affinity and avidity changes of 
integrins required to bind ligand can be regulated by inside-out signaling (van Kooyk & 
Figdor, 2000). Many modulators are involved in this activation process, including phorbol 
esters, G protein coupled signaling, particular antibodies, or divalent cations (Rothlein & 
Springer, 1986; Gailit & Ruoslahti, 1988; Danilov & Juliano, 1989; Shimizu et al., 1990; van 
de Wiel-van Kemenade et al., 1992; Arroyo et al., 1992; Constantin et al., 2000; Alon & 
Feigelson, 2002). Binding and rolling studies of αLβ2 expressed in different cell types pointed 
at the importance of the cellular microenvironment in these processes; αL2 expressed in 
K562 does facilitate rolling on ICAM-1 coatings, whereas αLβ2-mediated rolling is not 
observed in PBL and Jurkat cells (Sigal et al., 2000). Likewise, the regulation of integrin 
activity might be different in immature DCs and mature DCs. Several proteins that may 
account for this difference are discussed below. DCs express β1 and β2 integrins, which can 
both associate with cytoskeletal proteins. Here, I will focus on cytoskeletal proteins which 
can bind to β1 integrins (Fig. 1), in particular α5β1, since I observed that this integrin 
mediates differences in adhesion to fibronectin for immature and mature DCs. 
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Figure 1. Overview of cytoskeletal and signaling proteins that link the α5β1 integrin to the actin cytoskeleton. 
The actin-binding proteins talin, α-actinin, and filamin link integrins to the cytoskeleton, either direct or indirect 
via vinculin. The enzyme calpain cleaves these actin-bindings proteins from the integrin, resulting in freely mobile 
integrins. Integrins can stimulate Rho-GTPases via the signaling molecules FAK and ILK, but also via ICAP-1. Rho-
GTPases are signal transducers that orchestrate cytoskeletal functions. PKC inhibits actin polymerization. In 
addition it phosphorylates proteins, like Rack1 and paxillin, and increases intracellular calcium levels. Calcium can 
subsequently activate proteases like calpain. The complex formed by these cytoskeletal proteins and integrin 
regulates adhesion and migration. The actin-bundling protein fascin and the microfilament-associated protein 
palladin are both upregulated upon DC maturation. The role of these proteins in DC adhesion and migration is 
currently unknown. 
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Role of actin cytoskeleton on β1 integrin activation 
The actin cytoskeleton plays a pivotal role in cell adhesion and migration, as high 
concentrations of actin-disrupting agents completely abolish these processes. Filamentous 
actin and actin-associated proteins can form complex structures inducing membrane 
remodeling, such as filopodia, microspikes, lamellipodia, and stress fibers, which are involved 
in adhesion and migration (reviewed in Mitchison & Cramer, 1996). Interestingly, maturation 
of DCs results in rearrangement of the cytoskeletal organization. For instance, DC maturation 
results in a lack of podosome formation, resulting in a loss of organized vinculin and F-actin 
structures (chapter 4; Burns et al., 2001). In podosomes, tyrosine-phosphorylated proteins 
and actin-related proteins (Arp) colocalize with F-actin as do WASp proteins (Burns et al., 
2001). In contrast to Burns and colleagues, who suggested a relation between podosome 
formation and cell adhesion, we showed a highly migratory behavior of mature DCs, which 
lack podosomes. Since mature DC migration was mediated by transient interactions with the 
matrix molecule fibronectin, we tentatively suggest that podosome formation is related to 
more amoeboid crawling.  
An additional cytoskeletal protein, which is upregulated during DC maturation, is the actin-
bundling protein fascin. Fascin plays an important role in dendrite formation, hinting to a role 
for fascin in DC migration (Mosialos et al., 1996; Ross et al., 1998; Ross et al., 2000). 
Another example of a protein, which is induced upon DC maturation, is the microfilament-
associated protein palladin. In immature DCs, palladin is expressed in actin-containing 
podosomes, whereas in mature DCs it is localized along actin filaments (Mykkanen et al., 
2001). 
This maturation-induced rearrangement might regulate the binding of these cytoskeletal 
proteins to the β1 integrins. Actin-binding proteins that link β1 integrins to the cytoskeleton 
are talin (Horwitz et al., 1986), α-actinin (Otey & Burridge, 1990), and filamin (Loo et al., 
1998). The β1 chain binds talin and α-actinin either direct or via other proteins, such as 
vinculin (reviewed in Geiger et al., 2001). Point mutations in the β1 cytoplasmic chain lead to 
disruption of talin binding to the β1 integrin resulting in a decreased cell spreading (Kaapa et 
al., 1999). Although the interaction between talin and the β1 integrin is necessary, it is not 
sufficient for integrin-mediated cell spreading and targeting of integrins to focal adhesions 
(Kaapa et al., 1999). Both talin and α-actinin colocalize with integrins in focal adhesions, 
whereas filamin localizes to the cortical actin cytoskeleton and along stress fibers. Filamin 
also functions as an adapter protein for several signaling proteins that regulate cytoskeletal 
dynamics. 
Other proteins that regulate β1 integrin activity are paxillin (Schaller et al., 1995) and calpain 
(Rock et al., 1997). Paxillin mediates bridges between α4β1 and the actin cytoskeleton, but 
does not link α5 to the cytoskeletal constraint (Liu et al., 1999). However, loss of α5β1-
mediated monocyte adhesion to fibronectin induced by interferon-β and interferon-γ is 
correlated with changes in actin and paxillin cytoskeleton (Surin et al., 2000). Calpain 
regulates the β1 integrin-mediated T cell adhesion and spreading (Rock et al., 1997). Talin, 
filamin, and α-actinin are identified as potential proteolysis targets for calpain, resulting in 
freely mobile integrin. Deactivation of calpain inhibits adhesion and cell spreading of T cells 
on fibronectin. In addition, calpain regulates cell migration by supporting the dissociation of 
integrins from the cytoskeleton at the end of the cell reducing the retraction of the cell’s rear 
(Huttenlocher et al., 1997). As immature DCs spread on fibronectin and have more active β1, 
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it is very likely that calpain is active in these cells. Inhibition experiments blocking calpain 
activity should confirm this hypothesis. 
Since all those cytoskeletal proteins bind the cytoplasmic tail of β1, it would be very 
interesting to study the colocalization of the discussed proteins with the α5β1 integrin in our 
DC culture setting. 
It is important to note that under physiological circumstances cells display 3D-matrix 
adhesions resulting in a distinct cytoskeletal organization of proteins than on 2D coatings. 
For example α5 in fibroblasts placed on tissue- or cell-derived 3D matrices colocalizes with 
paxillin, vinculin, focal adhesion kinase (FAK), phosphotyrosine, α-actinin, and activated β1 
integrin, whereas this is not demonstrated on 2D substrates (Cukierman et al., 2001). 
Another difference observed between 2D and 3D matrix interactions are the integrins used 
for migration. For instance, the migration of T cells in collagen matrices is reduced by an 
activating β1 antibody, whereas it is not inhibited by a combination of β1, β2, β3, and αv 
blocking antibodies, suggesting that the migration is β1 integrin independent, which 
contrasts with 2D systems (Friedl et al., 1998). 3D matrix interactions in vivo may also be 
distinct from 3D interactions in vitro. In vivo imaging of T cells in lymph nodes indicates 
different migration speeds compared with in vitro studies in collagen matrix models (Friedl et 
al., 1994; Miller et al., 2002). 
 
Role of signaling molecules on β1 integrin activation 
Next to a distinct organized actin cytoskeleton, a difference in signaling proteins that bind to 
the β1 integrin cytoplasmic domains might be responsible for the distinct adhesive properties 
of immature versus mature DCs. These proteins are focal adhesion kinase (FAK) (Schaller et 
al.. 1995), integrin-linked kinase (ILK) (Hannigan et al., 1996), and receptor for activated 
protein kinase C (Rack1) (Liliental & Chang, 1998). ILK localizes to focal adhesions and has 
been implicated in the regulation of cell adhesion and cell migration. The interaction between 
Rack1 and integrins requires stimulation of the cell with phorbol esters, indicating that this 
interaction is regulated. FAK is an adapter protein with kinase activity, which localizes to 
integrins at the cell substratum contact sites and its activation state is regulated by cell-ECM 
interactions (reviewed by Schlaepfer & Hunter, 1998). In an in vitro DC differentiation model, 
transformation of DC progenitor cells from chicken bone marrow with a v-Rel estrogen 
receptor (ER) fusion protein v-RelER can result in highly motile v-relER DCs (Boehmelt et al., 
1995). In addition, this differentiation reduces cell-extracellular matrix interactions (Madruga 
et al., 1999). These v-relER DCs exhibit a polarized pattern of actin and vimentin, which is 
also observed in human DCs derived from CD34+ cells. Moreover, the expression of FAK was 
reduced upon differentiation. However, downregulation of FAK is apparently not essential in 
motility mechanisms since ectopic FAK expression in vRelER DCs does not affect their 
adhesion and migration. This suggests that FAK is most probably not responsible for the 
difference in adhesion between immature and mature DCs. 
Another protein, which binds the β1 tail of integrins but is not directly involved in signaling, 
is ICAP-1 (integrin-cytoplasmic-domain-associated protein 1) (Chang et al., 1997). ICAP-1 
overexpressing COS cells display an enhanced β1-mediated migration. Upon cell-fibronectin 
interactions, ICAP-1 becomes phosphorylated. This may imply that immature DCs have more 
phosphorylated ICAP-1 than mature DCs. The role of ILK, FAK, Rack-1, and ICAP-1 in β1 
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integrin-mediated adhesion in immature versus mature DCs needs to be studied in future 
experiments. 
 
Role Rho-GTPases and PKC on β1 integrin activation 
Rho-GTPases are signal transducers orchestrating cytoskeletal functions (reviewed in 
Etienne-Manneville & Hall, 2002; Keenan & Kelleher, 1998). The regulation of actin 
polymerization is orchestrated by Rho/Rac/Cdc42 proteins. Rho proteins are involved in the 
formation of stress fibers, while Rac proteins mediate ruffling and lamellipodia formation, 
and Cdc42 regulates filopodium formation (reviewed in Takai et al., 2001). Rho-family 
proteins also control podosome assembly and localization in immature DCs (Burns et al., 
2001). Rho activation leads to tail detachment of migrating monocytes, neutrophils, and 
eosinophils by stimulation of actomyosin filament contraction through negative regulation of 
integrin-mediated adhesion at the rear of the cell (Worthylake et al., 2001; Alblas et al., 
2001). Worthylake and colleagues propose a model in which RhoA is required to 
downregulate integrin adhesions at the rear of the cells to allow tail retraction. Recently, 
Nischarin a novel intracellular protein that binds α5 has been described which affects Rho-
family GTPases signaling resulting in inhibition of cell motility and alterations in actin filament 
organization (Alahari, et al., 2000). In mice, Nischarin is expressed in brain and kidney; 
lower levels were observed in heart, liver, lung, and skeletal muscle, whereas no expression 
was seen in spleen and testis. So far, no data exist for Nischarin expression in DCs. 
PKCs are involved in the activation of integrins, and subsequently in adhesion and migration 
(Rigot et al., 1998; Ng et al., 1999; Sun & Rotenberg, 1999). PKCε regulates β1 integrin-
mediated migration through internal trafficking of these receptors through motile cells 
(Ivaska et al., 2002). Upon PKC inhibition, PKCε and β1 are accumulated in tetraspanin 
CD81-positive intracellular vesicles, resulting in reduced cell migration. 
 
Role of integrin-associated molecules on integrin activation 
Next to the regulation of this internal traffic step of integrins, the association of tetraspanins 
with integrins is predicted to influence cell migration by controlling spatial organization of 
membrane complexes or modulating integrin signaling (Berditchevski, 2001). However, no 
data are available showing the influence on integrin conformation. α5β1 can associate with 
CD9, CD81, CD82, and CD151 (reviewed in Berditchevski, 2001) in different cell types. 
Transfection of CD9 into CHO cells resulted in association with α5β1 and F-actin, α-actinin, 
FAK, and subsequent affected adhesion to fibronectin (Cook et al., 2002). We observed no 
colocalization of CD9 and α5β1 in DCs (unpublished results), indicating that CD9 may not be 
involved in DC adhesion to fibronectin. 
A transmembrane proteoglycan which binds to α5β1 is syndecan-4. α5β1 requires the cell 
surface proteoglycan syndecan-4 for focal adhesion formation and migration (Woods & 
Couchman, 2001; Bass & Humphries, 2002). The α5β1/syndecan-4 complex directly 
activates PKCα, which in turn might stimulate Rho GTPases (Mostafavi-Pour et al., 2003). 
It remains to be determined if tetraspanins or syndecan-4 are expressed in cultured DCs, 
and if so, colocalize with α5β1 in immature and mature DCs and whether such associations 
might regulate adhesion in DCs. 
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Role of chemokine and lipid receptor signaling and integrin cross-talk on integrin 
activation 
Integrin activation can also be accomplished by signaling via chemokine receptors. 
Immobilized chemokines on endothelium can induce arrest, but also earlier integrin-
mediated capture of lymphocytes (Campbell et al., 1998; Grabovsky et al., 2000; Constantin 
et al., 2000). In addition, chemokines also induce integrin-mediated T cell adhesion to ECM 
molecules, like fibronectin (Clissi et al., 2000). Increasing evidence supports leukocyte 
migration by ligation of lipids, like lysophosphatidic acid (LPA) with their respective 
receptors, ligation of hormones, like prostaglandin E2 (PGE2) with their receptors coupled to 
the Gs proteins (EP receptors), or ligation of nucleotides, such as adenosine triphosphate 
(ATP) with purinergic receptors on DCs. Maturation of DCs via a maturation cocktail including 
PGE2 induces DC migration (Luft et al., 2002; Scandella et al., 2002). Engagement of ATP 
with their receptors results in a migratory DC phenotype (la Sala et al., 2002). Future studies 
should reveal whether lipid mediators and nucleotides are able to signal to integrins. 
Signaling via other integrins can also regulate integrin-mediated adhesion. For example, 
adhesion of human T cells to ICAM-1 via αLβ2 decreases the adhesion mediated via α4β1 to 
VCAM-1 and fibronectin, but has less effect on α5β1-mediated binding (van Kooyk et al., 
1993; Porter & Hogg, 1997). This latter cross talk may be important for the transition of 
adherent to a more migratory state of the cells. 
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Figure 2. Overview of possible cross talk or associations between transmembrane receptors and the α5β1 
integrin. Upon chemokine binding chemokine receptors (CKR) activate α5β1 resulting in enhanced adhesion to 
fibronectin. The activation of α5β1 by cross talk via other integrins, the PGE2 receptor (EP) or purinergic receptors 
is unknown as far. Tetraspanins and syndecan-4 can associate with α5β1. Whether these molecules can modulate 
integrin conformation has to be investigated. Both tetraspanins and syndecans can bind extracellular matrix 
molecules. The association of the tetraspanin CD9 with α5β1 results in decreased adhesion to the ECM, whereas 
the association between syndecan-4 and α5β1 is required for focal adhesion formation. 
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Fig. 2 gives an overview of receptors, which might affect integrin activity. Future 
investigations should shed light on the possible existence of such signaling routes. From this 
summary of proteins that regulate β1 integrin activity it becomes clear that many factors 
orchestrate integrin-mediated adhesion and migration. Not much is known about the role of 
these proteins in DCs. It would be very interesting to investigate cytoskeletal 
rearrangements and α5β1 integrin-linked associations in immature versus mature DCs to 
unravel the distinct adhesive and migratory properties between those subtypes. 
 
 
DC-SIGN 
 
DC-SIGN was originally identified from a placental cDNA library as a C-type lectin binding the 
HIV-1 envelope glycoprotein gp120 (Curtis et al., 1992). Later, it was found to be a DC-
specific adhesion receptor (Geijtenbeek et al., 2000a; Geijtenbeek et al., 2000b). DC-SIGN 
binds to the Ig-superfamily members ICAM-2 and ICAM-3 under static, and in case of ICAM-
2 also under flow conditions (chapter 5). Interestingly, DC-SIGN also supports tethering and 
rolling interactions on ICAM-2. I want to stress that the rolling capacity of DC-SIGN is 
investigated in transfected K562 cells and not in a DC environment. As discussed above, 
αLβ2 transfected in K562 also mediates rolling interactions, whereas wild-type αLβ2 in 
peripheral blood lymphocytes and Jurkat cells does not mediate rolling (Sigal et al., 2000). 
Sigal and colleagues hypothesized that the difference in rolling capacity of αLβ2 depends on 
the restriction in αLβ2-mediated adhesion strengthening, which is cell type dependent. 
Therefore, it would be interesting to test the involvement of DC-SIGN expressed on DCs in 
rolling, in vitro on ICAM-2 coatings and endothelium, or in vivo by intravital microscopy, both 
in combination with DC-SIGN blocking antibodies or using DCs treated with RNAi of DC-SIGN 
to knock out DC-SIGN expression. 
DC-SIGN is also involved in binding and transendothelial migration of DCs, to resting as well 
as activated endothelium (chapter 5). In contrast to Geijtenbeek and colleagues who found 
DC-SIGN expression on CD34+-derived DCs, Nguyen and colleagues showed that their 
CD34+-derived DCs lack DC-SIGN and adhere to resting dermal microvascular endothelium 
via αLβ2, αMβ2, and CD36 (Geijtenbeek et al., 2000a; Nguyen et al., 2002). Activation of the 
endothelium results in an upregulation of ICAM-1 and VCAM-1. Consistently, other adhesion 
receptors for transmigration of DCs are involved, like β2 and most probably the β1 integrins 
(chapter 5 and D'Amico et al., 1998). A recent study showed defective migration of 
monocyte-derived DCs in LAD-1 immunodeficiency (Leukocyte Adhesion Deficiency) (Fiorini 
et al., 2002). Patients suffering from LAD have a lost expression of β2 molecules (Anderson 
& Springer, 1987). Chemokine-induced migration as well as spontaneous migration through 
activated endothelium are impaired in LAD-1 patients, despite the fact that their DCs do 
express DC-SIGN (Fiorini et al., 2002). This again indicates that β2 integrins are also 
important players in transmigration of DCs through activated endothelium. Since DC-SIGN 
binding to different types of endothelium seems to depend on the glycosylation of ICAM-2 on 
the distinct origins of endothelium (unpublished results van Kooyk & Geijtenbeek, 2002), 
rolling, adhesion and transmigration experiments of DCs through endothelium derived from 
different tissues will provide more insight into DC-SIGN-mediated migration to distinct sites 
in the body. 
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Though we found a major involvement of DC-SIGN in DC adhesion to endothelium, other 
studies showed that αLβ2 is equally important (D'Amico et al., 1998; Nguyen et al., 2002). 
Since αLβ2 requires activation to interact with its ligands (van Kooyk et al., 1989; Dustin & 
Springer, 1989), these DC migration studies suggest that αLβ2 is in an active conformation 
on DCs. Staining of our DCs with an antibody which recognizes the activation epitope of 
αLβ2 showed that αLβ2 is not in an active state on DCs (unpublished results). Since 
activation of αLβ2 can be achieved by signaling via other adhesion molecules (Chan et al., 
2000; May et al., 2000; Rose et al., 2001), it would be interesting to study whether DC-SIGN 
could play a role in this activation process. 
DC-SIGN is expressed on monocyte-derived and CD34+-derived DCs upon culture with IL-4 
and GM-CSF (Geijtenbeek et al., 2000a). In vivo, DC-SIGN is present on DCs in many 
different tissues. Intriguingly, two DC-SIGN-positive cell populations are found in blood, a 
CD14- as well as a CD14+ population (chapter 5). This latter population is of myeloid origin, 
since these cells express CD14, CD16, and CD33, in addition to CD1c, CD11b, CD11c, CD86, 
and high levels of MHC class I and II molecules (Engering et al., 2002a). In addition, a 
subpopulation of BDCA-2+ plasmacytoid DC (PDC) precursors expresses DC-SIGN (Soilleux et 
al., 2002). In mouse, five homologues of DC-SIGN are cloned, one of which is highly 
expressed on DCs (Park et al., 2001). The occurrence of DC-SIGN-positive cells in the 
periphery implies a role for DC-SIGN/ICAM-2 interactions in migration of these cells from 
blood into peripheral tissues and subsequently via lymph into lymph nodes. This hypothesis 
remains to be validated by in vivo experiments. The very low percentage of DC-SIGN-
positive cells in blood, i.e. 0.04% of total PBMC (Chapter 5), makes these experiments 
difficult to perform. 
DC-SIGN not only functions as an adhesion receptor, but also as an antigen receptor. DC-
SIGN binds both viral and nonviral pathogens, including HIV, SIV, Mycobacterium 
tuberculosis, and Candida Albicans (Geijtenbeek et al., 2000b; Pohlmann et al., 2001; 
Appelmelk et al., 2003; Cambi et al., 2003; Tailleux et al., 2003). Upon antigen binding, the 
DC-SIGN-antigen complex is internalized and targeted to endosomal compartments 
(Engering et al., 2002b; Cambi et al., 2003; Tailleux et al., 2003). The dual function of DC-
SIGN as an adhesion and antigen receptor raises the question whether pathogen uptake by 
DCs via DC-SIGN interferes with its adhesion and migration capacity. Previous studies done 
by Engering and colleagues indicate that antigen internalization mimicked by binding of DC-
SIGN antibodies to DC-SIGN does not hinder ICAM-3 binding or T cell proliferation (Engering 
et al., 2002b). Upon internalization of these anti-DC-SIGN/DC-SIGN complexes the surface 
expression of DC-SIGN is restored. However, HIV-1 infection results in the expression of HIV 
Nef protein, which affects the intracellular trafficking of DC-SIGN and enhances its cell 
surface expression (Sol-Foulon et al., 2002). This enhanced expression results in increased 
adhesion to ICAM-3 expressed on T cells or ICAM-3-coated beads. Since the affinity of DC-
SIGN for ICAM-2 is higher than for ICAM-3 (chapter 5), it is very likely that Nef also 
enhances DC-SIGN/ICAM-2 interactions. This increased adhesion might affect migration of 
DCs to lymphoid organs resulting in an impaired immune response. The findings of Engering 
and Sol-Foulon and colleagues suggest that each pathogen might activate different signaling 
pathways upon DC-SIGN binding. More experiments will be required to unravel the effects of 
DC-SIGN-mediated antigen uptake on DC adhesion and transendothelial migration.  
After pathogen uptake DCs mature and migrate to lymph nodes. In vitro, maturation of 
immature DCs with TNFα slightly reduced DC-SIGN expression. A functional role for this 
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downmodulation of DC-SIGN has not been described. Future experiments will have to reveal 
whether the reduced expression of DC-SIGN on mature DCs affects DC-SIGN-mediated 
migration. 
A recent study unraveling the carbohydrate specificity of DC-SIGN showed that Lex-
neoglycoconjugates, such as Lex, Lea, Ley, Leb, and sulfo-Lea, all bind with high affinity to DC-
SIGN (Appelmelk et al., 2003). Lea is present on mucin-expressing tumors (reviewed in 
Appelmelk et al., 2003), whereas Ley is overexpressed on many carcinomas, including ovary, 
pancreas, prostate, breast, colon, and non-small cell lung cancers (Hellstrom et al., 1990). 
This indicates that DC-SIGN may mediate adhesion between DCs and tumor cells. The 
binding of DC-SIGN to tumor peptides might be of great relevance in anti-tumor therapy, in 
particular for non-immunogenic tumors. DC-SIGN could be relevant for tumor antigen 
capture and internalization, which is followed by processing and subsequent peptide 
presentation in MHC molecules. In this way, tumor antigen uptake via DC-SIGN might induce 
antitumor responses. DC-SIGN positive cells are found in the peritumoral area of melanomas 
(Vermi et al., 2003). This suggests a role for DC-SIGN in tumor antigen uptake. Hence, it 
would be very interesting to test the direct interaction of tumor cells or tumor antigens with 
DCs via DC-SIGN. It is important to realize that solid malignancies overexpress TGF-β1. TGF-
β1 suppresses the immune system by restraining in vitro activation and upregulation of 
costimulatory molecules, resulting in an arrest in DC maturation and reduction in antigen 
presentation (Strobl & Knapp, 1999). Whereas human DCs derived from CD34+ progenitors 
are blocked in their maturation upon TGF-β1 exposure, epithelial Langerhans Cells are 
positively regulated by TGF-β1. For example, BL6 murine melanoma metastasized animals 
have high plasma levels of TGF-β1, and TGF-β1 and TGF-β2 plasma levels are significantly 
higher in colon cancer patients compared with unaffected individuals (La Porta & Comolli, 
2000; Bellone et al., 2001). TGFβ is able to reduce DC-SIGN expression (Relloso et al., 
2002). This suggests that TGFβ might affect DC adhesion to tumors and tumor endothelium 
and subsequent migration into malignant tissue via downregulation of DC-SIGN expression.  
 
 
CD83 
 
The maturation process of DCs is characterized by an upregulation of costimulatory 
molecules, MHC molecules, and of the maturation marker CD83. The selective expression of 
CD83 on mature DCs suggests a functional role of CD83 in immune responses. Indeed, 
inhibition of CD83 protein synthesis results in reduced T cell stimulation by DCs (Kruse et al., 
2000a). Circumstantial evidence for a biological role of CD83 came from studies in which DCs 
were infected with viruses (Kruse et al., 2000b; Jenne et al., 2000). For instance, HSV-1 
infection of DCs results in degradation of CD83 resulting in a reduced capacity to initiate T 
cell proliferation in an allogeneic mixed leukocyte reaction setting (Kruse et al., 2000b). The 
importance of CD83 in immune responses is also underscored in CD83-/- mice, which 
showed a block in CD4+ single positive thymocyte generation (Fujimoto et al., 2002). 
Normal human sera contain low levels (121 ± 3.6 pg/ml) of a circulating soluble form of 
CD83, which is released from activated DCs and B lymphocytes (Hock et al., 2001). We 
demonstrated that both immature and mature DCs bind to hCD83-Fc fusion protein (chapter 
6). Immature DCs lack CD83 suggesting that the interaction of CD83 with DCs is 
heterophilic. Scholler and colleagues showed that CD83-Ig binds to monocytes and a subset 
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of activated CD8+ T cells (Scholler et al., 2002). This again indicates a heterophilic 
interaction of CD83. Because monocytes, a subset of activated CD8+ T cells, immature and 
mature DCs all bind CD83 a CD83 receptor shared by those cells might be involved in this 
interaction. Another possibility is that those cells use different receptors. Future experiments 
using blocking antibodies or biochemical reagents have to reveal which receptor or kind of 
receptor is involved. 
Addition of the soluble recombinant extracellular domain of CD83 (hCD83ext) to immature 
DCs resulted in a block in DC maturation, as indicated by a reduction in CD80 and CD83 
surface expression (chapter 6). The expression of MHC class I and II as well as CD86 were 
not affected by hCD83ext. Since DC maturation is a prerequisite for DC migration into T cell 
areas of lymph nodes (chapter 3), it would be interesting to investigate whether DCs treated 
with soluble CD83 also lack expression of the chemokine receptor CCR7 and if the random 
and chemotactic migratory behavior of these DCs is impaired. The migration of partially 
matured DCs into lymph nodes might result in a non-effective, suppressive immune 
response.  
Next to the block on DC maturation, hCD83ext inhibits mature DC-induced allogeneic and 
peptide-specific T cell proliferation in a concentration-dependent manner (chapter 6). 
Scholler and colleagues showed that soluble CD83-Ig fusion protein is costimulatory when 
coimmobilized with anti-CD3 (Scholler et al., 2002). As described above, human sera contain 
low amounts of soluble CD83. We used 10,000 fold higher concentrations than those 
observed in human sera to demonstrate the block in DC maturation and inhibition of T cell 
stimulation. It would therefore be very interesting to investigate soluble CD83 concentrations 
in serum in pathological situations to validate the (patho)physiological relevance of this 
circulating factor. Intraperitoneal injection of soluble CD83-Ig in tumor-bearing mice results 
in larger tumors than in the control group (Scholler et al., 2002). This suggests that if high 
concentrations of soluble CD83 are present, this may lead to immunosuppression. The 
measurement of soluble CD83 concentrations in the environment of activated DCs may also 
provide clues to the physiological function of CD83. High local CD83 concentrations might 
control the immune response by inducing an arrest in DC maturation. Future studies 
unraveling the receptor for CD83 on DCs might clarify the signaling mechanisms underlying 
this inhibitory effect. In addition, these investigations will reveal whether distinct or the same 
CD83/receptor interactions are used for DC adhesion, inhibition of DC maturation and T cell 
proliferation. 
Arrode and colleagues described an indirect effect of virus on CD83 expression. Cross-
presentation of human cytomegalovirus (HCMV) late-stage infected fibroblasts results in 
inhibition of DC maturation (Arrode et al., 2002). Soluble factors secreted by HMCV-infected 
fibroblasts modulate CD83 expression on DCs, resulting in a reduced capacity to induce an 
antiviral CD8+-T cell response. Transforming Growth Factor-β1 (TGF-β1) is one of the 
modulators involved, though the authors cannot exclude IL-10 as an interfering cytokine in 
DC maturation. 
As described above cancer patients have higher plasma levels of TGFβ than unaffected 
individuals. This aspect together with the downmodulating effect of TGFβ on CD83 
expression and subsequent inhibition of DC maturation might reduce anti-tumor responses 
by suppressing the costimulatory effect of CD83. Mouse melanoma cells transfected with 
CD83 induce an anti-tumor response against wild-type melanoma cells, whose 
immunogenicity is very low (Scholler et al., 2002). Scholler and colleagues tentatively 
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conclude that interaction between CD83 and its ligand(s) may be involved in regulation of 
immune response to tumors by activation of CD8+ T cells. The transfection of CD83 into 
tumor cells might be an interesting way to increase the anti-tumor response. A more 
profound knowledge of the binding partners and the costimulatory function of CD83 could 
lead to new insights in tumor immunology and new therapeutic strategies. 
 
 
OTHER RECEPTORS 
 
DC migration is directed by chemokines and their receptors. Upon maturation, DCs switch 
their chemokine receptor repertoire and express CCR7. CCR7 is required for the mobilization 
of mature DCs into lymphatic vessels and their subsequent entrance in secondary lymphoid 
organs. In chapter 3, we demonstrated that mature DCs, which do express CCR7, indeed 
migrate into T cell areas of lymph nodes. Immature DCs labeled with 111In, which do not 
express CCR7 were also able to reach the lymph nodes, but did not enter the T cell areas. 
Unfortunately, we were not able to stain the 111In-labeled DCs in situ with CD83 or CCR7 
antibodies, since the 111In-staining was too prominent. The fact that immature DCs did reach 
the lymph nodes could not be contributed to an in vivo maturation process, since these DCs 
were not able to induce a “de novo” immune response in vivo. The localization of injected 
immature DCs at marginal sinuses in lymph nodes after intranodal injection suggests that 
those DCs, which lack CCR7, do emigrate from the injection depot. This might be due to the 
disruption of the microenvironment after injection or to passive trafficking via the flow of 
lymph vessels. 
Other receptors, which are indirectly involved in DC migration, are EP2 and EP4. These 
receptors bind PGE2, which is a cofactor in DC differentiation, induces the expression of 
CCR7 on DCs, and is an important modulator of their migratory function (Jonuleit et al., 
1997; Kalinski et al., 1998; Luft et al., 2002; Scandella et al., 2002). Interestingly, we and 
others observed a reduced random migration of DCs when matured in the presence of MCM, 
TNFα, but in the absence of PGE2 (unpublished data; Jonuleit et al., 1997). This must be an 
effect of maturation because PGE2 by itself does not induce random migration (K. Broers 
unpublished data). Serum contains many chemokines and lipids, like ATP, sphingosine-1-
phosphate (S1P) and lysophosphatidic acid (LPA), which can induce cell migration (Idzko et 
al., 2002; Panther et al., 2002; Idzko et al., 2002). Since we performed our experiments in 
the presence of serum, it is tempting to speculate that these components induce DC 
migration in our system. Preliminary migration experiments using overnight serum-starved 
mature DCs in medium containing albumin, showed migration, indicating migration as an 
intrinsic property of the cells. However, other preliminary experiments showed that culturing 
of DCs in the absence of serum abrogates DC migration. These data suggest that presence 
of serum factors during DC culture and a maturation cocktail including PGE2 are prerequisite 
for random DC migration. 
 
 
LINK OF DC MIGRATION TO ANTI-TUMOR THERAPY AND FUTURE PERSPECTIVES 
 
Nowadays DCs are used as cell-based vaccines in immunotherapy against cancer. 
Irrespective of the place of injection (subcutaneously, intradermally, intraveneously, or 
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intranodally), these DCs must come in close proximity of T cells in the lymph nodes. Mature 
DCs are preferred over immature  DCs since they have higher migratory capacities and do 
reach the T cell areas of the lymph nodes, where they can efficiently stimulate naïve T cells 
(Hollender et al., 2002; Gunzer et al., 2003; de Vries et al., 2003). In contrast, immature 
DCs can silence T cells either by deletion or by inducing regulatory T cells, which exert 
suppressive immune functions (reviewed in Steinman et al., 2003). The presence of 
regulatory T cells downmodulates the anti-tumor response. 
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Figure 3. DC migration model. The migration of DC precursors and blood DC into peripheral tissues is 
presumably mediated via DC-SIGN-ICAM-2 interactions. When the tissue is inflamed other receptors, like β1 and 
β2 integrins are also involved. Subsequently, these DCs reside in an immature state expressing low MHC 
molecules, low costimulatory molecules, DC-SIGN and active β1 integrins, and patrol for antigen. Upon sensing 
chemokine gradients, but also LPA, S1P, and ATP, they migrate to the center of these gradients and pick up 
pathogens either via DC-SIGN, toll-like receptors or via endocytotic pathways. In case of tumors, they might 
migrate into malignant tissue via DC-SIGN-tumor endothelium interactions and/or adhere to tumor cells via DC-
SIGN-Ley or sulfo-Lea interactions. Danger signals, such as PGE2, TNFα, IL-1β, but also ATP induce maturation of 
immature DCs; MHC molecules and costimulatory molecules are upregulated, CCR7 and CD83 are induced, the 
cytoskeleton will rearrange and active β1 integrins are downmodulated, as is DC-SIGN. Mature DCs migrate via 
lymph vessels (DC-SIGN-ICAM-2 interactions) into T cell areas of lymph nodes via CCR7. They interact with naïve 
T cells via DC-SIGN-ICAM-3 interactions and activate these T cells via costimulatory molecules and CD83. 
 
 
Although injected mature DCs do express CCR7, a major proportion remains in the injection 
depot. Enhanced migration of DCs out of this depot by the induction of matrix 
metalloproteinases might induce more effective T cell priming (Ratzinger et al., 2002). In 
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addition, the application of inflammatory cytokines at the place of injection might induce the 
migration of those DCs. Interestingly, more data becomes available that the injection site is 
also very important for T cell priming and homing. It becomes clear that T cells stimulated in 
a lymph node gain local homing receptors to exert their effect in the environment of that 
particular lymph node (Dudda, 2003; Mora et al., 2003). This suggests that local 
administration of DCs results in local homing receptors on T cells. This finding is of 
importance for DC-based anti-tumor therapy, in which activated T cells should specifically 
migrate to and attack tumor cells. 
In conclusion, many factors determine whether DC-based vaccines are able to migrate and 
are effective in anti-tumor therapy. We demonstrated that DC migration is most prominent in 
mature DCs. In addition, we showed that the distinct adhesive behavior between immature 
and mature DCs is regulated by the activation state of the β1 integrin chain. In this respect 
immature DCs have higher expression levels of active β1 and likewise adhere better to 
fibronectin than mature DCs. Future studies should reveal which cytoskeletal component or 
transmembrane protein causes this difference in activation state of β1 integrin. We also 
showed that DC adhesion and migration through endothelium are mediated by DC-SIGN. 
However, in vivo data are still lacking. Another molecule studied in this thesis is CD83. By 
using CD83-Fc, we demonstrated that DCs adhere to this chimera and that binding results in 
a block in DC maturation and T cell proliferation. Although soluble CD83 was measured in 
serum, its in vivo role remains to be determined. A schematic overview of the role of β1-
integrins, CCR7, DC-SIGN, and CD83 in DC biology is depicted in Fig. 3. I want to stress that 
this figure only focuses on the molecules presented in this thesis and that many more 
molecules and proteins are involved. In vivo, DC adhesion and migration depend on 
numerous environmental factors that until now cannot be replicated by in vitro studies. The 
introduction of two-photon imaging allowed the discrimination of individual cells in their 
natural environment, e.g. in the lymph nodes. This technique is very promising to study DC 
behavior in physiological cellular compartments and might expand our knowledge of 
individual migration capacities of cells. 
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SUMMARY 
 
The immune system is a very complex system, which controls the body for invading 
microorganisms, like bacteria and viruses (pathogens). This defense system comprises many 
different white blood cells, also called leukocytes that orchestrate to fight against pathogens. 
Dendritic cells (DCs) and T cells are important players in the defense system. DC precursors 
are produced in the bone marrow, circulate in the blood and pass the blood vessel wall 
(endothelium) to enter tissues (transendothelial migration). Once in the tissues, these 
precursors develop into immature DCs, which patrol for invading pathogens. Upon pathogen 
encounter, DCs take up the pathogen, degrade the proteins into small pieces, called peptides 
and present these peptides in specialized molecules (MHC molecules) on their surface. This 
process is accompanied by a change in DC phenotype; they transit from an immature into a 
mature state. Upon maturation DCs migrate from the infection site via lymph vessels into the 
lymph nodes. Here they interact and present the MHC-peptide complexes to naïve T cells. 
Recognition of the complex by T cells with the appropriate receptor results in T cell 
activation. Activated T cells proliferate and subsequently leave the lymph nodes and migrate 
via the blood into the infected tissue, where they can directly kill the infected cells. 
During their migration DCs and T cells continuously interact with endothelium and tissues. 
These interactions are mediated by cell adhesion molecules. Many cell adhesion molecules 
are present on the surface of leukocytes. They can be divided in several groups, including 
lectins and integrins. Integrins mediate a broad range of interactions between cells (β1 and 
β2 integrins) or between cells and tissue structures (β1 integrins). Cell adhesion via integrins 
is tightly regulated. The cell can either change the affinity of the integrin (binding force of 
the integrin) or the avidity of the integrin (lateral mobility of integrins induced by changes in 
the skeleton of the cell (cytoskeleton)) to bind its specific counterpart molecules (ligands). In 
this thesis the role of integrins in DC and T cell adhesion and migration is investigated. In 
addition, the function of an adhesion molecule of the lectin group, specifically expressed on 
DCs, called DC-SIGN in adhesion and migration is studied. Finally, the cell surface molecule 
CD83 and its role in DC adhesion and the immune response is studied. 
Chapter 1 provides an overview of the adhesion molecules that are involved in adhesion 
and migration of DCs and T cells through endothelium and within tissues. This chapter 
describes the state of the art on the role of integrins and lectins (like DC-SIGN) in these 
processes and the scope of this thesis. 
Many techniques are available to study leukocyte migration in the lab. Some of them only 
provide information on the total cell population, whereas more sophisticated migration 
assays coupled to time-lapse video systems monitor the migratory behavior of individual 
cells. The cell recognition in these latter systems is based on contrast differences between 
cells and the contact surface or on a priori cell shape (morphology) criteria. As migrating 
cells continuously change their shape during their movement, the algorithm should be robust 
to the changing morphology. In chapter 2, an Automated Cell Track System (ACTS) to 
quantify and track migration of multiple cells is described, which fulfils the specifications of 
such an algorithm. Automatic tracking of these cells highly correlated with manual analysis. 
This novel system also allows simultaneous monitoring of multiple experimental conditions. 
The migration of T cells (HSB-2 T cells) on the InterCellular Adhesion Molecule-1 (ICAM-1) 
was used to validate the system. ICAM-1 is a cell surface molecule expressed on various cell 
types, including endothelium and functions as a ligand for integrins. HSB-2 T cells bind 
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ICAM-1 via the β2 integrin αLβ2. We show that activation of αLβ2 resulted in an enhanced 
binding and a decreased migration of HSB-2 T cells on ICAM-1. In addition, both the 
adhesion and migration of HSB-2 T cells depended on the ICAM-1 concentration. 
DCs, as professional antigen presenting cells are nowadays explored for their capacity to 
present tumor antigens to the immune system and raise anti-tumor responses in patients. 
They are cultured in the laboratory from their precursors circulating in the blood, loaded with 
tumor peptides or proteins, and subsequently re-injected into the patient. To elicit a proper 
immune reaction against tumors, DCs have to migrate from the injection site to draining 
lymph nodes to interact and stimulate naïve T cells. In chapter 3, the adhesive and 
migratory behaviors of immature and mature DCs are compared. Immature DCs strongly 
adhered to the tissue protein fibronectin via the β1 integrin α5β1, whereas mature DCs were 
highly motile as measured by the ACTS. Interestingly, this difference in DC migration was 
also observed in our in vivo studies in melanoma patients, in which only mature DCs reached 
the T cell areas of lymph nodes. This highly migratory capacity together with the T cell-
interacting properties favors mature DCs over immature DCs in immunotherapy against 
cancer. 
The distinct adhesive characteristics of immature and mature DCs were further studied in 
chapter 4. As described DC adhesion to fibronectin is mediated by α5β1. Although 
immature and mature DCs expressed comparable levels of the integrin chain α5, mature DCs 
adhered considerably less to fibronectin than immature DCs. The reduced adhesion of 
mature DCs could be restored by activation of α5β1. Thus during DC maturation α5β1 
becomes inactive and/or differentially distributed at the cell surface. The lower expression of 
the activation epitope 12G10 on mature DCs (presence of 12G10 indicates an active 
conformation of β1 integrins) confirmed this finding. Incubation of immature, but not mature 
DCs on fibronectin resulted in the formation of special adhesion structures (podosomes). 
These structures contained active β1 integrins and regulate the adhesion of immature DCs to 
fibronectin. 
The extravasation of leukocytes from the blood into tissues is a multi-step process. First, 
leukocytes are slowed down and roll along the endothelium. Second, their integrins will be 
activated resulting in leukocyte arrest and adhesion to the endothelium. The adhesion is 
followed by transmigration, in which leukocytes pass the endothelium and enter the 
underlying tissue. In chapter 5, the role of DC-SIGN in DC adhesion and migration through 
endothelium is explored. DC-SIGN is specifically expressed on DCs and binds next to several 
pathogens like HIV, Candida Albicans, and Mycobacteria tuberculosis to ICAM-3. ICAM-3 has 
a high homology with ICAM-2, which is constitutively expressed on (lymph vessel) 
endothelium. We showed that DC-SIGN binds ICAM-2 and facilitates DC-endothelium 
interactions. To study the role of DC-SIGN in rolling on ICAM-2, we artificially induced 
expression of DC-SIGN in K562 cells (K-DC-SIGN), which normally do not have DC-SIGN on 
their surface. These K-DC-SIGN cells rolled on ICAM-2, indicating that DC-SIGN mediates 
rolling-interactions. In addition, we show that DC-SIGN regulated DC adhesion to 
endothelium and was involved in their transendothelial migration. These findings imply a role 
for DC-SIGN in DC extravasation. 
Maturation of DCs is characterized by an upregulation of costimulatory and MHC molecules, 
molecules that form the complex structure for specific interaction with the T cells. In 
addition, mature DCs express the maturation marker CD83. In chapter 6, we assessed the 
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functional role of CD83. Immature as well as mature DCs, which do express CD83, bound to 
CD83. Since immature DCs lack CD83, the interaction should be heterophilic (mediated by a 
distinct adhesion receptor). Binding of CD83 by DCs resulted in a maturation block as 
indicated by a reduced expression of the costimulatory molecule CD80 and the maturation 
marker CD83. In addition, a reduction in T cell activation was found after treatment of DCs 
with CD83. Interestingly, CD83 had no effect on the phenotype of the T cells. 
The activation state of integrins determines cell adhesion and migration, as illustrated in this 
thesis. It has become apparent that several cytoskeletal proteins and membrane proteins 
regulate integrin activation. In chapter 7 the role of the cytoskeleton, but also of membrane 
proteins on integrin activation is discussed. Future investigations will have to shed light 
whether these proteins are differentially regulated in immature versus mature DCs and cause 
their distinct adhesive capacities. In addition, the function of DC-SIGN as an adhesion and 
antigen receptor, and the functional role of CD83 are discussed in this chapter. 
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Het immuunsysteem is een erg complex systeem dat op zoek gaat naar allerlei micro-
organismen die het lichaam binnengedrongen zijn, zoals bacteriën en virussen (pathogenen). 
Dit verdedigingssysteem bestaat uit veel verschillende witte bloedcellen, ook wel leukocyten 
genoemd die samenwerken om tegen pathogenen te vechten. Dendritische Cellen (DCs) en 
T cellen zijn belangrijke spelers van het afweersysteem. Voorlopers van DCs worden 
geproduceerd in het beenmerg. Ze circuleren in het bloed en moeten de bloedvatwand 
(endotheel) passeren alvorens ze het onderliggende weefsel binnen kunnen treden 
(transendotheliale migratie). Eenmaal in het weefsel, ontwikkelen voorloper DCs zich tot 
onrijpe DCs, die op zoek gaan naar binnengedrongen pathogenen. Wanneer ze een 
pathogeen gevonden hebben, nemen ze deze op, verwerken het tot kleine deeltjes (peptiden 
genoemd) en presenteren deze peptide in gespecialiseerde moleculen (MHC moleculen) op 
hun celoppervlak. Dit proces gaat gepaard met een verandering in DC fenotype; ze gaan van 
een onrijpe naar een rijpe vorm. Vervolgens migreren de rijpe DCs via lymfevaten naar de 
lymfeklieren. Hier gaan ze een interactie aan met naïve T cellen en presenteren ze de MHC-
peptide complexen. Herkenning van het complex door de T cel resulteert in T cel activatie. 
Geactiveerde T cellen vermenigvuldigen zich, verlaten vervolgens de lymfeklieren en 
migreren via het bloed naar het geïnfecteerde weefsel, waar ze de geïnfecteerde cellen 
direct kunnen doden. 
Tijdens hun migratie gaan DCs en T cellen interacties aan met endotheel en weefsels. Deze 
interacties worden verzorgd door adhesiemoleculen. Het oppervlak van leukocyten bevat 
veel adhesiemoleculen. Ze kunnen verdeeld worden in verschillende groepen, waaronder 
lectines en integrines. Integrines reguleren verschillende interacties tussen cellen (β1 en β2 
integrines) of tussen cellen en weefselstructuren (β1 integrines). Celadhesie door integrines 
is strikt gecontroleerd. De cel kan de affiniteit van het integrine veranderen (bindingskracht 
van het integrine) of de aviditeit van het integrine (verschuiving van integrines over de 
celmembraan door veranderingen in het skelet van de cel (cytoskelet)) om zijn 
tegenstructuur (liganden) te binden. In dit proefschrift is de rol van integrines in DC en T cel 
adhesie (binding) en migratie bestudeerd. Tevens is de functie van een adhesiemolecuul van 
de lectinegroep, genaamd DC-SIGN, bestudeerd in adhesie en migratie. Tot slot is de rol van 
het oppervlakte-eiwit CD83 in DC adhesie en de immuunrespons onderzocht. 
Hoofdstuk 1 geeft een overzicht van de adhesiemoleculen die betrokken zijn bij de adhesie 
en migratie van DCs en T cellen door endotheel en in weefsels. Dit hoofdstuk beschrijft de 
rol van integrines en lectines (zoals DC-SIGN) in deze processen en het doel van dit 
proefschrift. 
Er zijn veel technieken waarmee leukocytmigratie in het lab bestudeerd kan worden. 
Sommige van deze technieken geven slechts informatie over de totale celpopulatie, terwijl 
meer geavanceerde migratiesystemen, die gekoppeld zijn aan time-lapse video’s, het 
migratiegedrag van individuele cellen vastleggen. In deze laatst genoemde systemen wordt 
de cel herkend op basis van contrastverschillen tussen de cel en zijn contactoppervlak of op 
a priori celvorm (morfologie) criteria. Het algoritme wat gebruikt wordt moet echter robuust 
zijn voor deze morfologieveranderingen aangezien bewegende cellen continu van vorm 
veranderen. In hoofdstuk 2 wordt een automatisch celtrack systeem (ACTS) beschreven 
dat voldoet aan de specificaties voor dit algoritme en waarmee meerdere cellen 
gekwantificeerd en gevolgd kunnen worden tijdens hun migratie. Het automatisch traceren 
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van de cellen correleerde erg goed met manuele analyses. Daarnaast kunnen met dit nieuwe 
systeem verschillende experimentele condities simultaan gevolgd worden. De migratie van T 
cellen (HSB-2 T cellen) op het InterCellulair AdhesieMolecuul-1 (ICAM-1) is gebruikt om het 
systeem te valideren. ICAM-1 is een celoppervlaktemolecuul dat in verschillende cellen tot 
expressie wordt gebracht, inclusief endotheel, en is een ligand voor integrines. HSB-2 T 
cellen binden aan ICAM-1 via het β2 integrine αLβ2. Wij laten zien dat activatie van αLβ2 
resulteerde in een verhoogde adhesie en een verminderde migratie van HSB-2 T cellen op 
ICAM-1. Tevens was de adhesie en migratie van HSB-2 T cellen afhankelijk van de ICAM-1 
concentratie. 
DCs worden als professioneel antigen-presenterende cellen gebruikt vanwege hun capaciteit 
om tumorantigenen te presenteren aan het immuunsysteem en wekken antitumorresponsen 
op in patiënten. Ze worden in het laboratorium gekweekt van de DC-precursors die in het 
bloed circuleren, beladen met tumorpeptiden of eiwitten, en vervolgens weer geïnjecteerd in 
de patiënt. Om een goede immuunreactie tegen tumoren te bewerkstelligen moeten de 
geïnjecteerde DCs van de injectieplaats naar de lymfeklieren migreren om naïve T cellen te 
ontmoeten en te stimuleren. In hoofdstuk 3 worden het adhesie- en migratiegedrag van 
onrijpe en rijpe DCs vergeleken. Onrijpe DCs binden aan het weefseleiwit fibronectine via het 
β1 integrine α5β1, terwijl rijpe DCs juist migreren op fibronectine (gemeten met het ACTS). 
Dit verschil in DC migratie werd ook bevestigd door in vivo studies in melanoompatiënten, 
waarin alleen rijpe DCs de T celgebieden van de lymfeklieren bereikten. Hun goede 
migratiegedrag en hun capaciteit om interacties aan te gaan met T cellen maken rijpe DCs 
favoriet in immunotherapie tegen kanker. 
Het verschil in adhesiegedrag tussen onrijpe en rijpe DCs is verder uitgediept in hoofdstuk 
4. Zoals zojuist beschreven wordt de adhesie van DCs aan fibronectine gereguleerd door 
α5β1. Ondanks dat onrijpe en rijpe DCs vergelijkbare hoeveelheden β1 tot expressie brengen 
hechten rijpe DCs aanzienlijk minder aan fibronectine dan onrijpe DCs. Deze lage adhesie 
kon hersteld worden door β1 te activeren. Dit impliceert dat β1 minder actief is en/of anders 
verdeeld is over het celoppervlak van rijpe DCs vergeleken met onrijpe DCs. De lage 
expressie van de activatie-epitoop 12G10 op rijpe DCs (aanwezigheid van 12G10 indiceert 
een actieve vorm van β1 integrines) bevestigde dit. Incubatie van onrijpe, maar niet van 
rijpe DCs op fibronectine resulteerde in de vorming van speciale adhesiestructuren 
(podosomen). Deze structuren bevatten actieve β1 integrines en reguleren de adhesie van 
onrijpe DCs aan fibronectine. 
De migratie van leukocyten vanuit het bloed naar het onderliggende weefsel is een proces 
dat uit verschillende stappen bestaat. Eerst worden de leukocyten afgeremd en rollen ze 
over het endotheel. Vervolgens worden hun integrines geactiveerd wat resulteert in een 
stopsignaal en adhesie aan het endotheel. De adhesie wordt gevolgd door de 
transmigratiestap, waarbij leukocyten het endotheel passeren en het onderliggende weefsel 
binnentreden. In hoofdstuk 5 wordt de rol van DC-SIGN in DC adhesie en migratie door 
endotheel beschreven. DC-SIGN komt specifiek tot expressie op DCs en bindt naast allerlei 
pathogenen, zoals HIV, Candida Albicans en Mycobacterium Tuberculosis, aan ICAM-3. 
ICAM-3 heeft grote overeenkomsten met ICAM-2 dat zich op endotheel in bloed- en 
lymfevaten bevindt. Wij laten zien dat DC-SIGN aan ICAM-2 bindt en zo DC-
endotheelinteracties kan reguleren. Om de functie van DC-SIGN in het rollen over endotheel 
te bestuderen, hebben we artificieel DC-SIGN tot expressie gebracht in K562 cellen (K-DC-
SIGN), die normaal geen DC-SIGN op hun oppervlak hebben. Deze K-DC-SIGN cellen rollen 
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op ICAM-2 wat betekent dat DC-SIGN rolinteracties kan reguleren. Tevens reguleerde DC-
SIGN de adhesie van DCs aan endotheel en was het betrokken bij de transendotheliale 
migratie van DCs. Deze bevindingen impliceren een rol voor DC-SIGN in de uittreding van 
DCs uit bloed- en lymfevaten. 
De rijping van DCs wordt gekarakteriseerd door een verhoogde expressie van costimulatoire 
en MHC moleculen, moleculen die een complexe structuur vormen voor specifieke interacties 
met T cellen. Daarnaast brengen rijpe DCs ook het eiwit CD83 tot expressie. In hoofdstuk 
6, hebben we de functionele rol van CD83 bestudeerd. Zowel onrijpe DCs, die geen CD83 tot 
expressie brengen, als rijpe DCs bonden aan CD83. Omdat onrijpe DCs geen CD83 op hun 
oppervlak hebben, moet de interactie wel heterofiel zijn (verzorgd door een andere 
adhesiereceptor). De binding van CD83 aan DCs resulteerde in een blokkade in het 
rijpingsproces. Dit werd gekenmerkt door een gereduceerde expressie van het costimulatoire 
molecuul CD80 en de rijpingsmarker CD83. Eveneens werd een verminderde T cel stimulatie 
waargenomen na behandeling van de DCs met CD83. CD83Fc had echter geen effect op het 
fenotype van T cellen. 
Zoals geïllustreerd wordt in dit proefschrift bepaalt de mate van integrine-activatie 
celadhesie- en migratie. Het is bekend dat verschillende cytoskeletaire eiwitten en 
membraaneiwitten integrine activatie reguleren. In hoofdstuk 7 wordt de rol van 
cytoskeletaire eiwitten, maar ook membraaneiwitten op integrine activatie bediscussieerd. In 
de toekomst zullen studies moeten bepalen of deze eiwitten verschillend gereguleerd zijn in 
onrijpe versus rijpe DCs en of ze het verschil in adhesie veroorzaken. Daarnaast worden in 
dit hoofdstuk de functie van DC-SIGN als een adhesie- en antigenreceptor en de functionele 
rol van CD83 bediscussieerd. 
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ACTS   automated cell track system 
APC   antigen-presenting cell 
Arp   actin-related protein 
ATP   adenosine triphosphate 
BDCA   blood dendritic cell antigen 
CD   cluster of differentiation 
CLA   cutaneous lymphocyte-associated antigen 
CLSM   confocal laser scanning microscopy 
CTL   cytotoxic T lymphocyte 
CYTIP   cytohesin-1 interacting protein 
DC   dendritic cell 
DC-SIGN  dendritic cell specific ICAM-grabbing non-integrin 
DTH   delayed type hypersensitivity 
ECM   extracellular matrix 
ELC   EBI1-ligand chemokine 
ELISPOT  enzyme linked immunospot assay 
ESL-1   E-selectin ligand-1 
FACS   fluorescence activated cell sorter 
FAK   focal adhesion kinase 
FCS   foetal calf serum 
FITC   fluorescein isothiocyanate 
GlyCAM-1  glycosylation-dependent cell adhesion molecule-1 
GM-CSF  granulocyte/macrophage colony stimulating factor 
gp   glycoprotein 
GST   glutathion S transferase 
HCMV   human cytomegalovirus 
HEV   high endothelial venule 
HIV   human immunodeficiency virus 
HLA   human leukocyte antigen 
HMEC   human microvascular endothelial cell 
HSV   herpes simplex virus 
ICAM   intercellular adhesion molecule 
ICAP-1   integrin cytoplasmic domain-associated protein-1 
ILK   integrin-linked kinase 
IFN   interferon 
Ig   immunoglobulin 
111In   111-Indium 
IL   interleukin 
JAM   junctional adhesion molecule 
KLH   keyhole limpet hemocyanin 
LAD   leukocyte adhesion deficiency 
LARC   liver- and activation-regulated chemokine 
LC   Langerhans cell 
Le   Lewis neoglycoconjugate 
LFA-1   leukocyte function-associated antigen-1 
LPA   lysophosphatidic acid 
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LTC4   leukotriene C4 
mAb   monoclonal antibody 
Mac-1   macrophage receptor 
MAdCAM-1  mucosal addressin cell adhesion molecule-1 
MCM   monocyte conditioned medium 
MDC   myeloid dendritic cell 
MDR   multidrug resistance protein 
MHC   major histocompatibility complex 
MIP   macrophage inflammatory protein 
MLR   mixed lymphocyte reaction 
MMR   macrophage mannose receptor 
MRP   multidrug resistance-associated protein  
NK   natural killer cell 
NMR   nuclear magnetic resonance 
PBMC   peripheral blood mononuclear cell 
PBL   peripheral blood lymphocyte 
PCR   polymerase chain reaction 
PDC   plasmacytoid dendritic cell 
PE   (R-)phycoerythrin 
PGE2   prostaglandin E2 
PKC   protein kinase C 
PLC   phospholipase C 
PSGL-1  P-selectin glycoprotein ligand-1 
Rack1   receptors for activated C-kinase 
RANTES  regulated upon activation, normal T expressed, and secreted 
RNA   ribonucleic acid 
S1P   sphingosine-1 phosphate 
SDF-1   stromal cell-derived factor-1 
SDS   sodium dodecyl sulphate 
SIV   simian immunodeficiency virus 
SLC   secondary lymphoid tissue chemokine 
Tcm   central memory T cell 
Tem   effector memory T cell 
TGF   transforming growth factor 
Th cell   T helper cell 
TLR   Toll-like receptor 
TNF   tumor necrosis factor 
VCAM-1  vascular cell adhesion molecule-1 
VLA   very late antigen 
WASp   Wiskott-Aldrich syndrome protein 
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DANKWOORD 
 
De hoofdstukken voor dit proefschrift zijn af! Na al het wetenschappelijke schrijfwerk ben ik 
nu aangekomen bij het misschien wel meest gelezen deel van dit boekje, het dankwoord. 
Zonder de bijdrage van velen zou dit proefschrift er niet zo hebben uitgezien. Een aantal van 
hen wil ik daarom graag met naam noemen. 
Allereerst wil ik mijn promotor Carl Figdor bedanken. Beste Carl, jouw optimisme als mede je 
vertrouwen werkten erg stimulerend. Gedurende de afgelopen jaren heb je mij getoond dat 
uit elk resultaat wel iets positiefs te halen is. Besprekingen met jou hebben veel nieuwe 
inzichten en vaak ontelbare (soms “onuitvoerbare”) ideeën opgeleverd. In de loop der jaren 
heb ik geleerd hier een selectie uit te maken. Dat je me in een vroeg stadium al betrokken 
hebt bij het verzorgen van het onderwijs heb ik erg gewaardeerd. 
Reinier Raymakers, als co-promotor heb je een belangrijk aandeel gehad in mijn promotie-
onderzoek, met name in het opzetten van het migratiesysteem. Ik wil je bedanken voor je 
nooit aflatende enthousiasme en interesse voor mijn onderzoek. 
De collega’s van de universiteit Twente, Jan Feijen, André Poot en Ype van der Zijpp. 
Bedaankt veur ut saamwerk’n! Helaas waren de verschillen tussen de ondergrondjes niet 
dusdanig dat er een gezamenlijke paper uit is gekomen. 
Alessandra, door de verhuizing naar de toren werd jij mijn U-genoot. Wat hebben we veel 
leuke (en soms minder leuke) momenten samen gedeeld! De “rustige hoekjes” van het lab 
wisten we toch maar altijd te vinden. Bedankt voor je luisterend oor en al je (al dan niet 
wetenschappelijke) adviezen. Dat kinderdrankje blijft toch altijd lekker! Heel erg veel succes 
met het afronden van jouw promotieonderzoek! Ik ben erg blij dat je mijn paranimf wilt zijn. 
Jolanda, als andere “vaste” bewoner van “het hok” ben je nu mijn paranimf. Jouw adviezen 
en inzichten van (DC)wetenschap tot schaatstechniek (bedankt voor het slijpen) waren erg 
nuttig. Tijdens het schrijven van ons gezamenlijk artikel heb ik, naast de betekenis van alle 
functietoetsen, veel van je geleerd. De ontspanning op maandagavond werd altijd een stuk 
plezieriger als jij ook van de partij was. Ik vind het fijn dat je mijn nimf wilt zijn. 
Karin Broers, jouw hulp tijdens de laatste paar maanden van mijn AiO-bestaan was erg 
welkom. Bedankt voor je inzet! Heel erg veel succes met je studie. En die 8.00 uur taxi was 
erg luxe. 
Jeroen van den Beucken en Marjolein Keizer, bedankt voor jullie bijdragen. Het was voor mij 
een erg prettige ervaring om jullie te mogen begeleiden tijdens jullie stage. Ik heb er veel 
van opgestoken. Jeroen, succes met je promotieonderzoek, en Marjolein, succes met het 
afronden van je studie. 
Reinier, Jan, Peter, Gerty, Arie, Leonie, Marc, Bart en Gerard van het CHL wil ik bedanken 
voor alle input die ik gekregen heb tijdens de wekelijkse “lunchbespreking” op vrijdag. Jan, 
bedankt voor het ontwikkelen van de trackprogramma’s, die het analyseren van migrerende 
cellen een stuk aangenamer hebben gemaakt. Dat je altijd tijd voor me vrijmaakte als ik 
weer “even een vraagje had” (als er filmpjes omgezet moesten worden naar een bepaald 
formaat of wanneer er statistiek bedreven moest worden) heb ik erg gewaardeerd. Peter en 
Gerard, jullie hulp en ideeën bij het opzetten van het migratie- en rolsysteem waren erg 
nuttig. En Peter, jouw aanwezigheid was vaak al voldoende om de apparatuur aan de praat 
te krijgen. Alle overige medewerkers van het CHL, hartelijk bedankt voor de gastvrijheid en 
gezelligheid op jullie lab. 
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De “Amsterdamgangers” wil ik bedanken voor het meedenken over experimenten tijdens de 
eerste helft van mijn AiO-periode. Bedankt voor het mooie DC-SIGN artikel (Sandra, bedankt 
voor je hulp bij het vullen van al die transwells)! Yvette, jouw deur stond altijd open, 
bedankt voor je begeleiding. 
Next, I would like to thank our collaborating colleagues from Germany, Prof. dr. Alexander 
Steinkasserer, dr. Matthias Lechmann, and Prof. dr. Peter Friedl. Dear Alexander and 
Matthias it was a great pleasure to perform experiments with you. And Matthias, in one week 
time, you learned me a lot about “your molecule”. Your enthusiasm for CD83 was very 
catching. Peter, unfortunately the data did not support our hypothesis, resulting in a 
cancellation of my visit to your lab. 
Lucy van de bloedbank en alle medewerkers van verloskunde wil ik bedanken voor al die 
keren dat ze navelstrengen voor me verzameld hebben. 
Mijn collega’s van de adhesiegroep wil ik graag bedanken voor alle ideeën die ze 
aangedragen hebben tijdens de wekelijkse werkbespreking. Frank van Leeuwen, die 
podosomen “multi bene” doen het goed! 
Frank de Lange, bedankt dat je wat tijd voor mij vrijgemaakt hebt om mooie plaatjes te 
schieten voor de kaft. Met het volleyen op de donderdagavond had ik veel eerder moeten 
beginnen (dat ik je ooit nog een keer zal afblokken zal wel een illusie blijven). 
Jolanda, Nicole en Mary-lène, fijn dat ik altijd wel wat DCs van jullie kon krijgen als ik een 
migratie-assay wilde doen. De Catan-collega’s wil ik bedanken voor de gezellige 
kolonistenavondjes. Nu heb ik meer tijd om mee te spelen (en misschien wat vaker te 
winnen???). Alle overige (ex)-Tillers: bedankt voor de fijne tijd die ik op het lab heb gehad! 
Mijn kamergenoten van de AiO-kamer op de tweede verdieping, Judith, Rik (de sleutel is 
gereviseerd) en Franca, wat was ik blij dat ik op 2.76 mocht blijven zitten. Jullie begrip, 
adviezen en al de gezelligheid ook na jullie promoties waren erg stimulerend. Jullie zijn alle 
drie het goede voorbeeld voor me geweest en nu is het dus mijn beurt. 
Ale en Judith, de etentjes die ontstaan zijn bij de “voorbereiding” van Judith's promotie 
ervaar ik altijd als erg lekker en gezellig (nee, we hebben nog geen keuze gemaakt uit het 
menu). Ik hoop dat we ook na de komende twee promoties nog veel “nieuwe” 
eetgelegenheden zullen ontdekken. 
Franca, Sandra, Alessandra en Maaike, bedankt voor al die leuke jaarlijkse weekendjes weg. 
Hopelijk volgen er nog vele en durven jullie nog eens bij me in de boot te stappen. 
Mijn huisgenoten van de Minervaplaats, Guus, Evelyn, Caroline en Leonie bedankt dat ik mijn 
ei bij jullie kwijt kon. 
Al mijn familie, vrienden en vriendinnen wil ik bedanken voor alle ontspannende 
(telefoon)gesprekken, stapavonden, etentjes, weekendjes en vakanties. Hopelijk heb ik nu 
meer tijd om eens wat vaker iets van me te laten horen. 
Lieve Herbert, Christiaan en Kirsten, misschien dat jullie na het “lezen” van dit proefschrift je 
een idee kunnen vormen van waar ik me de afgelopen jaren mee bezig heb gehouden. 
Bedankt voor alle gezelligheid als ik thuis kwam. Zou een “echte” baan er nog een keer 
inzitten? Herbert, de kaft is echt heel erg mooi geworden, bedankt! 
Lieve pap en mam, heel hartelijk bedankt voor jullie onvoorwaardelijke steun en het 
vertrouwen dat jullie in mij hebben. Bedankt voor alle opbeurende telefoongesprekken als 
het weer eens tegen zat. De weekendjes naar Goor zijn altijd een erg fijne, gezellige 
ontspanning. 
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Lieve Jeroen, jou heb ik in het laatste jaar van mijn promotie ontmoet. Met jouw 
relativerende vermogen heb je mij veel zaken van een andere kant laten zien. Dat het surfen 
op internet unieke hits op kan leveren heb jij me wel bewezen. Bedankt voor alle liefde en 
steun die ik van je mag ontvangen.      
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CURRICULUM VITAE 
 
Daniëlle Krooshoop werd geboren op 11 oktober 1973 te Goor. In 1992 behaalde zij haar 
VWO diploma aan het R.K. Lyceum de Grundel te Hengelo (o). In datzelfde jaar begon zij 
aan de studie biomedische gezondheidswetenschappen aan de Katholieke Universiteit 
Nijmegen. Tijdens haar studie heeft zij als stagiaire bij de afdeling Cytogenetica van het UMC 
St. Radboud onder begeleiding van F. Stellink, dr. J. Tuerlings en Prof. dr. A. Geurts van 
Kessel onderzoek gedaan naar de detectie van microdeleties van 9p21 van MTS1 en MTS2 
genen bij lymfomen. Daarna heeft zij stage gelopen op de afdeling immunologie van het 
Nederlands Kanker Instituut onder supervisie van dr. M.A. Oosterwegel en Prof. dr. A.M. 
Kruisbeek. Hier heeft ze met behulp van de phage-display techniek onderzoek uitgevoerd 
naar de identificatie van antigenen op stromale cellen die mogelijk betrokken zijn bij T cel 
ontwikkeling. Als extra stage is zij in 1997 voor 7 maanden naar Cambridge in Engeland 
geweest. Op de afdeling Protein and Nucleic Acid Chemistry van het Medical Research 
Council heeft zij onder begeleiding van dr. A.E. Corcoran en dr. A.R. Venkitaraman de rol van 
de transcriptiefactor pax5 tijdens de regulatie van de B cel ontwikkeling door de interleukine 
7 receptor bestudeerd. Tijdens haar studie heeft ze in 1994 de aantekening 
proefdierdeskundige (ex. Art. 9 van de Wet op Dierproeven) behaald. Na het afstuderen 
begon zij in september 1997 als Assistent in Opleiding aan de afdeling tumorimmunologie 
van het UMC Nijmegen onder leiding van Prof. dr. C.G. Figdor aan het in dit proefschrift 
beschreven onderzoek. 
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